|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/4/2 ¤W¤È 09:36:27
|
¯E¹©°O¡G 1¡n¯E¹©2015¦~3¤ë¥¿¦¡±q¿³ÂdÂà¤WÂd,«o±q400¤¸¶^¨ì250¤¸ 2¡nÀHµÛ¸Ñª¼®É¶¡±µªñ,¥«³õ¤W°ª«×ªºÃöª`»P°l±·,¿v©³Ãk¤É¨ì750¤¸ªº¤Ñ»ù 3¡n2016/2/21¸Ñª¼«á, ¥Ñ©ó¸Ñª¼¥¼¹F¹w¥ý³]©wªº¥Ø¼Ð, ¦A¥[¤W¦W¼L¥ß©e´CÅé½Ñ¦h¥H³_¶Ç³_,¥H°¾·§¥þ, ¥B¥¼¸gÃҹꪺ«ü±± ÁöµM¤½¥q»¡¯à°÷²£¥Í§ÜÅ骺±Ú¸s´N¯à°÷²£¥ÍÁ{§É¤WªºÀø®Ä,©ó¬O¦³©Ò¿×ªº"¤@ӸѪ¼,¨âºØ¸ÑŪ,¦U¦Ûªíz" ¤@¸ô¤U¶^¨ì350¤¸¥ª¥k 4¡n¦ý¦b2016/3/31²×©óªï¨ÓÀò±oASCO Oral presentationªº®¶¾Ä®ø®§,4¤ë1¤é·M¤H¸`·í¤Ñ,ªï¨Ó¤F¤[¹Hªº¤@¸ôº¦°±ªO 5¡n6¤ëªìªºASCO, ÁÞ¤k§Y±N´¦¶}¦oªº¯«¯µ±¯½ ¨Ì¾Ú²Î¤@§ëÅU±i¥ß¸s¤ÀªR®v¬ã¨s¡G https://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwins9egnPzLAhVikIMKHcc1DN8QFgggMAE&url=http%3A%2F%2Fpcmc.uni-psg.com%2Fvip%2F20160226-01.pdf&usg=AFQjCNHCCWDKl493HzcquFVIcJoolRPgnQ »PµL±¡¤jªº¤ÀªR¡G http://tsjh301.blogspot.tw/2014/08/obipharma.html ¥»µÛªø´Á§ë¸ê, °l®Ú¨s©³ªººë¯«¨Ó±´¯Á¯E¹©ªº§ë¸ê»ùÈ, ¤£¦]µu´ÁªÑ»ùªi°Ê°_¥ñ¦Ó¼vÅT¹ï "¥þ²y²Ä¤@ÁûFirst in class, Best in classªº§ÜÀùÁÞ¤À¤l¥þ·sÃĪ«"§ë¸êªº¼ö±¡ ¨ÃÅé²{¤½¥qÄ@´º: "³Ð³y¥xÆW¥Í§Þ«~µP,¦¨¬°Àù¯gÀøªkªº¥þ²y»â¯èªÌ" "2025¦~¦¨¬°¥xÆW¥Í§Þ²Ä¤@«~µP, 2035¦~¦¨¬°¥þ²yÀù¯gªvÀø»â¾É¤½¥q" Åwªï¤À¨É¥ô¦ó¹ï¯E¹©Ä@´º»P»ùȵû¦ôªº¬Ýªk»P°ª¨£~~ |
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/21 ¤U¤È 04:28:48²Ä 2700 ½g¦^À³
|
¡u¥¼§e²{²Îp¾Ç¤WÅãµÛ·N¸q¡vªº·N«ä´N¬O¤£ª¾¹DµL´c¤Æ¦s¬¡´ÁPFS¡A¦]¬°°Ñ¥[¤HÅé¹ê²{ªº¯f±w¡A¤j³¡¤À¸g¹L¦h¦~³£ÁÙ¬¡µÛ¦n¦nªº¡A®Ú¥»´N¤£ª¾¹D¦s¬¡´Á¬O¦h¤[ ´N¹³§AÁÙ¬¡µÛ¦n¦nªº¡A«ç»òª¾¹D§Aªº¦s¬¡´Á¬O¦h¤[??? ¨Ò¦p§A³Q¤H¬r¥´¤@¹y¤§«á¡A¸g¹L«Ü¦h¦~¡A§AÁÙ¬¡µÛ¦n¦nªº¡A¦]¦¹¦b¶i¦æ§A³Q¬r¥´¤@¹y¯à¬¡¦h¤[ªº¹êÅ礤¡u¥¼§e²{²Îp¾Ç¤WÅãµÛ·N¸q¡v §Ú²{¦b©ú¥Õ¬°¤°»òn¿ï¦b¬P´Á¤é¤½¥¬¸Ñª¼µ²ªG¤F¡A¥Dn¬O¯E¹©·sÃĪºÀø®Ä¡A¦n¨ì¶W¶Vªk³W¡A¦]¬°¤@¯ëÀù¯g·sÃĦA«ç»ò¼F®`¡A¯S§O¬O¨ÅÀù¥½´Á¡A¤j³¡¤À³»¦h¥u¬O©ìÓ´X¦~¡A¦]¦¹³£¯à§e²{²Îp¾Ç¤WÅãµÛ·N¸q¡A¤]´N¬O¥§¡¯à©µªø¹Ø©R´X¦~ ¦ý¡A°ÝÃD¬O¯E¹©·sÃijºµM§â¨ÅÀù¥½´Áµ¹ªv¡¡A®Ú¥»µL©Ò¿×¦s¬¡´Á¥i¥H²Îp!!! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/21 ¤U¤È 04:25:38²Ä 2699 ½g¦^À³
|
¶^¯}²´Ãè ¯uªº¦n¥Èªº»¡ªk ¤£ª¾¹D±i¸³»¡¸Ü®Éªºªí±¡¬°¦ó? ¦³¤H¥i¥H¤À¨É¶Ü? |
|
|
·|û¡GBenjamin10139027 µoªí®É¶¡:2016/2/21 ¤U¤È 04:11:41²Ä 2698 ½g¦^À³
|
http://udn.com/news/story/6/1515419-%E5%BC%B5%E5%BF%B5%E6%85%88%EF%BC%9A%E5%9C%8B%E9%9A%9B%E8%97%A5%E5%BB%A0%E5%B0%87%E3%80%8C%E8%B7%8C%E7%A0%B4%E7%9C%BC%E9%8F%A1%E3%80%8D ¯E¹©¸Ñª¼¡A¥þ²y³£¦b¬Ý¡C¦b¤µ¤é¯E¹©¤½¥¬¸Ñª¼µ²ªG²{³õ¤¤¡A´CÅé´£°Ý¦³Ãö°ê»ÚÃļt¬Ý¨ì¯E¹©¸Ñª¼µ²ªG«áªº¤ÏÀ³¡A¸³¨Æªø±i©À·O¹w´ú¡A³o¨Ç¼ç¦b¦X§@¹Ù¦ñ±N¡u¶^¯}²´Ãè¡v¡A¦Ü©ó¸Ó§Î®e¬°¥¿±ÁÙ¬Ot±¡A±i©À·O«h¥¼°µ¸ÑŪ¡AÅý¥~¬É¯d¤U·Q¹³ªÅ¶¡¡C ¯E¹©OBI-822¬°¥þ²yº³Ð¬ð¯}¦¡§K¬ÌÀøªk¡A¬ãµo´Á¶¡°ê»Ú¦U¤jÃļt°ª«×Æf¥Ø¡A¨ä¤¤¹O40®a°ê»ÚÃļt¬°¯E¹©¼ç¦b¦X§@¹Ù¦ñ¡C±i©À·Oªí¥Ü¡A¦b³o¦¸¸Ñª¼µ²ªG¤½¥¬«á¡A¯E¹©±N©µÄò©M¼ç¦b¦X§@¹Ù¦ñ¦X§@ªº¥i¯à©Ê¤¤¥]¬AOBI-822»P¨ä¥LÀøªk¦X¨Ö¨Ï¥Î¡A¥H¤Î¨ÅÀù¥H¥~¨ä¥L¤Q¾lºØ¾AÀ³¯gªº¬ãµoµ¥¡A§¡¤£±Æ°£¥H§ë¸ê¤H³Ì¤j§Q¯q«e´£¤U±Ò°Ê°ê»Ú±ÂÅv¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/21 ¤U¤È 03:46:20²Ä 2697 ½g¦^À³
|
¯E¹©¨ÅÀù·sÃÄOBI-822¸Ñª¼¥¼¹LÃö ¦ý¨ã¦³Á{§É·N¸q ¹d¦ëºô°OªÌ§õ©y¾§ ¥x¥_¡@¡@2016-02-21 15:12¡@ ¯E¹©(4174-TW)¤½¥¬¨ÅÀù·sÃÄOBI-822¸Ñª¼µ²ªG¡A²Ä¥|´ÁÂಾ©Ê¨ÅÀù¯f¤H¬°¹ï¶Hªº²Ä¤G¡B¤T´ÁÂùª¼Á{§É¸ÕÅç¡A¥ÎÃIJջP¹ï·Ó²Õ¬Û¤ñ¡A¨ä¥DnÀø®Ä«ü¼Ð¥¼§e²{²Îp¾Ç¤WªºÅãµÛ·N¸q¡A¦ý¨ä¤¤³\¦h¦³·N¸qªº¬ì¾Ç¤ÎÁ{§É¸ê°T¡A¤w¬°¥¼¨Ó²£«~µo®i´£¨Ñ¤F©ú½Tªº¤è¦V¡C ¯E¹©¸³¨Æªø±i©À·Oªí¥Ü¡AOBI-822³o¦¸ªº¸Ñª¼¬O¥X¥G·N®Æªº¸Ñª¼¡A¤£¬O¥¢±Ñ¡B®À±Ñªº¸Ñª¼¡A¥Dn¬O¦b§K¬Ì§ÜÅé¡A¦³Á{§É·N¸q¡A¦ý¬O¤½¥q·íªì¨S¦³§â³oÓ³]©w¬°µ²ªG¡A¦]¦¹¦bÁ{§É¤W¬O¦¨¥\ªº¸Ñª¼¡A¦ý¬Oªk³W¤WÁÙn¦A°Q½×¡A¸ò¶Ç²Î¤W³]©wªº¼Ð·Ç¤£¦P¡C ¯E¹©Á`¸g²z¶À¨q¬üªí¥Ü¡A¥»¦¸¸Ñª¼³Ì¤jªº»ùȬݨì©ú½Tªº¤è¦V¡A¤£n¤Ó¦b·N¸Ñª¼ªºÀø®Ä¡A¤½¥q¦b¸Ñª¼¤§«e쥻ÁÙ¦b·Q¡AnÄ~Äò°µ¦h¤Öªº¯f¤H¡A¬O1000¤HÁÙ¬O700¤H¡A¦ý¬OÁ{§É¦¨¥»«Ü°ª¡A¹ï§ë¸ê¤Hªº²ü¥]¬O¤@Ó¦ÒÅç¡A¤£¹L³Ì«áªº¸Ñª¼¼Æ¾ÚÃÒ¹ê¤F·íªì¹Î¶¤ªº·Qªk¬O¥¿½Tªº¡C ¹ï©ó¹ê»Ú¸Ñª¼ªº¼Æ¾Ú¡A¯E¹©ªí¥Ü¡A±N¦b°ê»Úª¾¦WÂå¾Ç·|¤Î«nÂå¾Ç´Á¥Z½×¤å¤Wµoªí¡C °w¹ï¥»¦¸¸Ñª¼ªºµ²ªG¡A±i©À·Oªí¥Ü¡A·|¸ò¬ÛÃö¥DºÞ¾÷Ãö·¾³q¡A¬O§_¦bªk³W¤W»Ýn°µþ¨Çªº×¥¿¡C ~~~~~~~~ ª`·N 1.¹ï©ó¹ê»Ú¸Ñª¼ªº¼Æ¾Ú¡A¯E¹©ªí¥Ü¡A±N¦b°ê»Úª¾¦WÂå¾Ç·|¤Î«nÂå¾Ç´Á¥Z½×¤å¤Wµoªí¡C***¤½¥q±N·|¦bASCOµoªí¡AÅã¥Ü¤@©w«H¤ß 2.¸Ñª¼¼Æ¾ÚÃÒ¹ê¤F·íªì¹Î¶¤ªº·Qªk¬O¥¿½Tªº¡C***822¤Þµo§ÜÅé§K¬Ì¤ÏÀ³¡A¥]¬AÅé²G§K¬Ì»P²ÓM§K¬Ì¤ÏÀ³¡A¥¼¨Ó¬ã¨s¡A¥H§K¬Ì¤ÏÀ³¬°«ü¼Ð¡AÁ{§É¹êÅç¼Ë¥»¥i¥HÅܤ֡Aªá¶OÅܤ֡CY¨Æ«e¿z¿ï¦³GLOBO Hªº¨ü¸ÕªÌ §ó®e©ö¹êÅç²ÎpÅãµÛ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/21 ¤U¤È 03:15:23²Ä 2696 ½g¦^À³
|
¯E¹©±NÅܧó³]p ÂX¤j¤T´ÁÁ{§É¸ÕÅç °w¹ï¯E¹©§Ü¨ÅÀù·sÃÄOBI-822«áÄòµo®i¡A¸³¨Æªø±i©À·Oªí¥Ü¡A¦¹¦¸¸Ñª¼¾¨ºÞ¥¼¹F¼Ð¡A¦ý«áÄò¤´±N©M¥xÆW¹½Ã¸p°Q½×¥Ó½ÐÃÄÃÒªº«áÄò¨Æ©y¡A¥B¦³Å²©ó¦¹¦¸¸Ñª¼¬ÛÃö¼Æ¾Ú¤wÃÒ©úIgG¡BIgM§K¬Ì§ÜÅé¤ÏÀ³¾÷¨î®ÄÀ³¡A²{¥¿´Â²Ä¤T´ÁÁ{§É¸ÕÅç³]p¡A¥Dn¦b¬ü¡B¼Ú¶i¦æ¡A±NÂX¤j¥þ²yÁ{§É¸ÕÅç¤H¼Æ¡C ¡@ OBI-822¦h°êÁ{§É¸ÕÅçpµeÁ`¥D«ù¤H¶À«T¤É«ü¥X¡A¸Ñª¼ªì¨Bµ²ªGÅã¥Ü¡AOBI-822¯àÅý²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌÀò±o«D±`ÅãµÛªº¯q³B¡A¬ã¨s¹Î¶¤¬Û·í®¶¾Ä¡A±N¶i¤@¨B¥H«e´Á¹êÅçµ²ªG¬°¨Ì¾Ú¡A«·s³]p²Ä¤T´ÁÁ{§É¸ÕÅç¡A¥H¦³µL²£¥Í§K¬Ì¤ÏÀ³¬°¥Dn¼Ð·Ç¡A¦³®Ä°§C²Ä¤T´ÁÁ{§É¸ÕÅ窺·ÀI¡C ¡@ ¶À«T¤É«ü¥X¡A¦pªG«ö·Ó¥Ø«e²Ä¤T´ÁÁ{§É³]p³Wµe¡A¥H¦³µL§K¬Ì¤ÏÀ³§@¬°·s³]p«ü¼Ð¡AY®M¦b³o¦¸¸Ñª¼µ²ªGÀ³¸Ó¤w¡u¹LÃö¡v¡A¥Bªk³W³æ¦ì¹ï·s«ü¼Ðªº±µ¨ü«×¤]°ª¡A¥[¤W¸ÕÅçµ²ªGªº¥ÎÃĦw¥þ©Ê¤£¿ù¡A¹ï«áÄò²Ä¤T´ÁÁ{§É¸ÕÅ窺µ²ªG¤´©ê«ù¼ÖÆ[¡C ~~~~~~~~~~~~ ª`·N 1.±NÄ~Äò°Q½×¥Ó½Ð¥xÆWÃÄÃÒ?Áö²ÎpµL®Ä ¡A¦ý¬O¹ï¦¸±Ú¸s¦³GLOBO Hªº¨ü¸ÕªÌÁ{§É¦³®Ä ¦w¥þ©Ê¨Î ©Ò¥H¥i¥H¦³±ø¥ó³q¹L 2.OBI-822¯àÅý²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌÀò±o«D±`ÅãµÛªº¯q³B¡A¬ã¨s¹Î¶¤¬Û·í®¶¾Ä¡CÃÒ©úÃIJz§K¬Ì¾÷Âà¬O¹ïªº ¡A¦³®Äªº 2.ÂX¤j¥þ²yÁ{§É¸ÕÅç¤H¼Æ¡C¥H¦³µL§K¬Ì¤ÏÀ³§@¬°·s³]p«ü¼Ð¡C§ó¦³®Ä´ú¶q¥H§K¬Ì¤ÏÀ³¨Ó·í®ÄªG«ü¼Ð ¡A «D¦´ÁªºPFS¡AOS¡C¥¼¨Ó»ÝnGLOBO H¿z¿ï´¹¤ùªº¨ó§U¡A ´£¨Ñ¯E¹©¥¼¨Ó¤@±øÀsªºÂåÀøªA°È¤§¾÷·| |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/21 ¤U¤È 02:35:12²Ä 2695 ½g¦^À³
|
¯uªº¬OÁp¦X³¾³ø¡A·s»D³ø¾É¥u³ø¾É¤@³¡¤À? ©ú©ú´N¬O¡u¶W¥G¹w´Áªºµ²ªG¡A¬O«Ü¦¨¥\ªºÁ{§É¸ÕÅç¡v¡AÁp¦X³¾³øªº·s»D¼ÐÃD«o¼g¡u³ø¼~¡v¡u¥¼¹LÃö¡v??? «ç¼Ë¡AÁpX³øªº°OªÌ¬O·Q«K©y¶R¡A¬G·N©ñ°²®ø®§¶Ü?¯u¬O¼F®`¼F®`! Ãø©Ç¯E¹©¨è·N¿ï¦b¬P´Á¤é¤~¤½¥¬¡A´N¬OnÅý¤j®a¦³¾÷·|¥¿½T±µ¨ü¨ì¸ê°T¡A¤£·|³Q³¡¤À°¾»áªº´CÅéµ¹»~¾É ¡e°OªÌ³¯¥Ã¦N¡þ¥x¥_³ø¾É¡f²³©ÒÆf¥Øªº¯E¹©¡]4174¡^¨ÅÀù¬Ì]OBI-822Á{§É¸ÕÅçµ²ªG¡A¤µ¤Ñ¤U¤È¤½¥¬¡A¯E¹©¸³¨Æªø±i©À·Oªí¥Ü¡A®Ú¾Ú¸Ñª¼ªì¨B¼Æ¾ÚÅã¥Ü¡AÁöµMµL´c¤Æ¦s¬¡´ÁPFS¡u¥¼§e²{²Îp¾Ç¤WÅãµÛ·N¸q¡v¡A¦ý¦b¨ä¥L³¡¤À«o¥X²{¶W¥G¹w´Áªºµ²ªG¡A¬O«Ü¦¨¥\ªºÁ{§É¸ÕÅç¡A¨ä¤¤³\¦h¦³·N¸qªº¬ì¾Ç¤ÎÁ{§É¸ê°T¡A¤w¬°¥¼¨Ó²£«~µo®i´£¨Ñ©ú½Tªº¤è¦V¡C http://news.ltn.com.tw/news/business/breakingnews/1608919 ²³æÁ¿¡A´N¬O¦]¬°Àø®Ä¤ÓÅå¤H¡A©~µM»·»·¶W¶V¤F¥H©¹³\¦h¨ÅÀùÃĪ«ªºÀø®Ä¡A¥H¦Ü©ó¤@°ï¤H¦Y¤F¯E¹©ªºÃĪ«¤§«á¡A¦h¦~¤U¨Ó³£¨S¦³´_µo©Î¦º¤`¡A³o¤~µLªk´£¨ÑµL´c¤Æ¦s¬¡´ÁPFS ( ®Ú¥»´N¨S´c¤Æ¡A«ç»òª¾¹D¨ì©³¥i¥H¦s¬¡´X¦~??? ) ¦]¬°¹ê»Ú¤WªºµL´c¤Æ¦s¬¡´ÁPFS¡A·d¤£¦n¬O10¦~©Î20¦~¡A·sÃĪº¤HÅé¹êÅç¨S¿ìªkµ¥³o»ò¤[ ¦AªÌ¡A¯f±w¤]¦³¥i¯à¦]¬°¨ä¥L¯e¯f©Î¦]¯À¡A¬¡¤£¨ì10¦~¡A¬Æ¦Ü20¦~¡AÁ{§É¤W§ó¬OµLªk´£¨ÑµL´c¤Æ¦s¬¡´ÁPFS ¥u¤£¹L¬O¦]¬°Àø®Ä»·»·¶W¶V¹w´Á¡AµLªk´£¨ÑµL´c¤Æ¦s¬¡´ÁPFSªº¼Æ¾Ú¡AÁp¦X³¾³ø«o¼ÐÃD¼gµÛ¡u³ø¼~¡v¡u¥¼¹LÃö¡v ¥O¤HÃhºÃ¡Aµo³o·s»Dªº°OªÌ¬O¤£¬O·N¹Ï¤£¥¿·í¼vÅTªÑ»ù??? ÁÙ¦n²{¦b¸ê°T¬y³q«Ü§Ö¡A¤£·|¦A³Q¤Ö¼Æ´CÅéÃbÂ_ |
|
|
·|û¡G¥ú¼v10031538 µoªí®É¶¡:2016/2/20 ¤U¤È 10:55:57²Ä 2694 ½g¦^À³
|
³o¸Ì¦³«Ü¦h¬ÝÄw½Xªº°ª¤â Ó¤H ±q¬Y®a XX-X´ò ¨é°Óªº¶i¥X¡AÁÙ¦³¼í®õX-ÅvÃÒªº§G§½¨Ó¬Ý ©ú¤Ñ©M¶g¤@³o¨â¤Ñ¡A§Æ±æ³£¯à±aµ¹¯E¤Í̦nªºµ²ªG~ ¯¬¤j®a¥¦w³ß¼Ö... |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/19 ¤U¤È 09:32:15²Ä 2693 ½g¦^À³
|
´µ¤å¤j ±zªº·Qªk ¤p§Ì¤]´¿³o¼Ë·Q¹L ¦ý¬O §Ú¤Ï¦V«ä¦Ò »{¬° ¦h¤è¤w¸g¦h¼Æ¶i³õ ¶g¤@¶i³õ¤Ö ªÅ¤è¦ü¥G¤£©È¸Ñª¼¶¶§Q§Q¦h ¦]¬°°£«DpÈ·¥¤p ¾_¾Ù¹w´Á¤ß²z ©ÎªÌ»{¬°§Q¦h¥XºÉ ¤]´N¤£·|¿E¯P¦^¸É ©Ò¥H §Ú¤~»¡¤£·|º¦°± ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G´µ¤p¤å10139040 µoªí®É¶¡:2016/2/19 ¤U¤È 08:27:06²Ä 2692 ½g¦^À³
|
¯E§J¤j §Úı±oÀ³¸Ó·|¦³«Ü¦h¤H¬°¤FÁקK°ò¨È21¤ä¦A«×µo¥Í ©Ò¥H¸Ñª¼«e½æ¥X µM«á½LºâµÛµ¥½T©w¹L¤F«á ¦A±¾º¦°±°l¦^§Y¥i ³»¦h®t10% ¦ý¬O¯uªº¦³³o»ò¦nªº¨Æ·|µo¥Í¶Ü ©êªÑµ¥¶}µP·ÀIªºÃB¥~³ø¹S À³¸Ó¤£¥u10% ©Ò¥H§Úı±o¬P´Á¤@¥i¯à·|¸õªÅº¦°± |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/19 ¤U¤È 07:00:50²Ä 2691 ½g¦^À³
|
Åó±ø±ø¤j ¤p§Ìı±o¶g¤@¤£·|º¦°± À³¸Ó¬O¤¤ªø¬õ µM«á©P½uªø¦h ª½¨ìASCO |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/2/19 ¤U¤È 05:41:58²Ä 2690 ½g¦^À³
|
¤@¦~¦h«e¡A§Ú¨ì¬Y¤j¾ÇÅ¥¤@¦ìÁ{§É¸ÕÅ礽¥qt³d¤HºtÁ¿¡A¥L»¡¥xÆW³Ìªñ´X¦~¤£·|¦³·sÃÄÁ{§É¦¨¥\ §Ú·í®É´N«Ü¤£¥H¬°µM ÁöµM«á¨ÓÂûÀnºbÀtÅý§ë¸ê¤H±¼¤J«Ë§|(¥x»y:¯ä¤Ä¤Ä) ¦ý«OÄÖ²y¥i¥´¤FÓ¤õÂû¡A¥i·í®³¨ìÃÄÃÒ«o¤]¥u¯à¬O¯¸¦b°ª±^¤W¡A°ª³B¤£³Ó´H¡A±q¦¹·È·Æ±è ¤¤¸Î¬Ý°_¨Ó®³¨ìÃÄÃÒ¤]¤£·|¦³¤Ó¤j°ÝÃD ¯E¹©¬Ý°_¨Ó¦ÛµM¨ì®É¤]·|¤ô¨ì´ë¦¨§a 822¸Ñª¼«á¥¢±Ñ·|¤£·|¹³ÂûÀn¤@¼Ë¡A·íµM·|¡A¦ý¬O´X¥G¤£¥i¯àµo¥Í¡ALR 187/229...¤w¸g¯}¸Ñ¤Ñ®Ñªº¤@¤j¥b ¦ý¦¨¥\·|¤£·|¹³«OÄÖ²y¤@¼Ë¡A¤@Âm¤d¨½¡A§Ú»{¬°¤]´X¥G¤£·|µo¥Í¡A¦]¬°«OÄÖ²y°^ÄmªºEPS³Q¯}¸Ñ«á»ùÈ´N¥u¦³XXX ¯E¹©ªº»ùÈ¥i´N¤j±o¦h¡A³s¤¤¸Î³£n±æ¨ä¶µI... ©Ò¥H²z©Ê§PÂ_¸Ñª¼«áÀ³¸Ó¤~¬O¤jªi¬qªº°_º¦ÂI¡A·íµM¥«³õ¤£¬O§Ú»¡¤Fºâ¡A ¦pªG¦³¿ú¤Hn¥ô©Ê¶Ã½æªÑ²¼¦V¤W¦¸¨ì250,¨º¥u¯à¥Ñ±o¥L¥h¡A¦ý¬O¥Ø«e680¬O¤£¬O»¡©ú·í®É¥L̽æ¤Ó¦¤Ó§C¤FÂI¶Ü? »ùȲרs¯B²{¡A¬Û«H¥xÁÞ¤j¡AFaith¤jµ¥¹w´ú»¡ªº³£·|¦¨¯u~~ http://udn.com/news/story/7254/1511117-300%E5%85%83%E4%BF%B1%E6%A8%82%E9%83%A8-%E7%94%9F%E6%8A%80%E5%8D%A0%E4%B8%89%E6%88%90 ®Ú¾Ú²Îp¡A¦Ü¬Q¡]18¡^¤é¬°¤î¡A¥xªÑ¤W¥«Âd¥ø·~¤¤¡AªÑ»ù¹O300¤¸¥H¤W¤½¥q¦³22®a¡A¥Í§ÞªÑ´N¥e¤F¤»®a¡A¤ñ«ª½¹G¤T¦¨¡A·N¨ý¥Í§Þ±Ú¸s¤wÀò±o§ë¸ê¥«³õ¤@©w»{¦P¡C¤ÀªR®v«ü¥X¡A¥Í§Þ±Ú¸s·f¤W·s¬F©²¬Fµ¦§ß´ÓÃD§÷¡Aªñ´Á®ð¶Õ±j¡A¥¼¨ÓªÑ»ùÄò¯è¤O¡AÃöÁä¦bªk¤HºA«×¡C ¥~¸ê°é¹ï¥xªÑ¥Í§Þ±Ú¸s¿³½ì·U¨Ó·U°ª¡A±©¬ã¨s½d³ò»EµJ¦b¥«È¸û¤j¡B°ò¥»±¤w¸g¦³Àò§QªºÓªÑ¡C Á|¨Ò¨Ó»¡¡A¯«¶©³sÄò¼Æ¦~Àò§QѬ°¥¿¼Æ¡BªÑ¥»¤]¹F70»õ¤¸¥H¤W¡A¬Q¤Ñ¸Ó¤½¥q¦bÃÒ¥æ©ÒÁ|¿ìªk»¡·|¡A§Y§l¤ÞªáºXÀô²yÃÒ¨é¥xÆW°Ï¬ã¨s³¡¥DºÞ¨¦¤ë²[¡]Peter Kurz¡^¡A¥H¤Î¦h¦W¥~¸ê¾÷ºc¤ÀªR®v¿ËÁ{¡F¬Û¹ï¦a¡A°w¹ïÀò§Qª¬ªpÁÙ©|¥¼©ú®Ôªº¥Í§Þ»sÃÄ·~ªÌ¡A¥~¸ê°é¦h¥b¥ý«ùÄòÃöª`¡A©|¥¼¯Ç¤J¬ã¨s½d³ò¡C ¸ê²`ÃÒ¨é¤ÀªR®v¤è¼}À©»¡©ú¡A¥Í§Þ·sÃıڸs¦V¨Ó¨ã¦³¬ãµo´Áªø¯S©Ê¡A¦bÃÄ«~¨ú±oÃÄÃҩαM§Q¶}ªáµ²ªG«e¡A¦h³B©óÁ«·l¡AµM¤@¥¹¨ú±o¦¨¥\¡A«áÄòÀò§Q¤]¦³¤@¸½Ä¤Ñªº®×¨Ò¡C¤ÀªR®v´£¿ô¡A¯S§On¯d·Nªº¬O¡A·sÃĸѪ¼µ²ªG¤@½¨âÀü²´¡A¥«³õ·|§óª`·N«áÄò·ÀI¡C ¤»Àɥͧްª»ùªÑ¤¤¡A¶È¯E¹©¥Dn·~°È¬°·sÃĬãµo¡A¨ä¾l¹³ºëµØ¡BF-ª÷¥i¡BF-±d¤Í¡B¨Õ¬ã¡BF-ÄRÂ×µ¥¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/2/19 ¤U¤È 05:41:58²Ä 2689 ½g¦^À³
|
¤@¦~¦h«e¡A§Ú¨ì¬Y¤j¾ÇÅ¥¤@¦ìÁ{§É¸ÕÅ礽¥qt³d¤HºtÁ¿¡A¥L»¡¥xÆW³Ìªñ´X¦~¤£·|¦³·sÃÄÁ{§É¦¨¥\ §Ú·í®É´N«Ü¤£¥H¬°µM ÁöµM«á¨ÓÂûÀnºbÀtÅý§ë¸ê¤H±¼¤J«Ë§|(¥x»y:¯ä¤Ä¤Ä) ¦ý«OÄÖ²y¥i¥´¤FÓ¤õÂû¡A¥i·í®³¨ìÃÄÃÒ«o¤]¥u¯à¬O¯¸¦b°ª±^¤W¡A°ª³B¤£³Ó´H¡A±q¦¹·È·Æ±è ¤¤¸Î¬Ý°_¨Ó®³¨ìÃÄÃÒ¤]¤£·|¦³¤Ó¤j°ÝÃD ¯E¹©¬Ý°_¨Ó¦ÛµM¨ì®É¤]·|¤ô¨ì´ë¦¨§a 822¸Ñª¼«á¥¢±Ñ·|¤£·|¹³ÂûÀn¤@¼Ë¡A·íµM·|¡A¦ý¬O´X¥G¤£¥i¯àµo¥Í¡ALR 187/229...¤w¸g¯}¸Ñ¤Ñ®Ñªº¤@¤j¥b ¦ý¦¨¥\·|¤£·|¹³«OÄÖ²y¤@¼Ë¡A¤@Âm¤d¨½¡A§Ú»{¬°¤]´X¥G¤£·|µo¥Í¡A¦]¬°«OÄÖ²y°^ÄmªºEPS³Q¯}¸Ñ«á»ùÈ´N¥u¦³XXX ¯E¹©ªº»ùÈ¥i´N¤j±o¦h¡A³s¤¤¸Î³£n±æ¨ä¶µI... ©Ò¥H²z©Ê§PÂ_¸Ñª¼«áÀ³¸Ó¤~¬O¤jªi¬qªº°_º¦ÂI¡A·íµM¥«³õ¤£¬O§Ú»¡¤Fºâ¡A ¦pªG¦³¿ú¤Hn¥ô©Ê¶Ã½æªÑ²¼¦V¤W¦¸¨ì250,¨º¥u¯à¥Ñ±o¥L¥h¡A¦ý¬O¥Ø«e680¬O¤£¬O»¡©ú·í®É¥L̽æ¤Ó¦¤Ó§C¤FÂI¶Ü? »ùȲרs¯B²{¡A¬Û«H¥xÁÞ¤j¡AFaith¤jµ¥¹w´ú»¡ªº³£·|¦¨¯u~~ http://udn.com/news/story/7254/1511117-300%E5%85%83%E4%BF%B1%E6%A8%82%E9%83%A8-%E7%94%9F%E6%8A%80%E5%8D%A0%E4%B8%89%E6%88%90 ®Ú¾Ú²Îp¡A¦Ü¬Q¡]18¡^¤é¬°¤î¡A¥xªÑ¤W¥«Âd¥ø·~¤¤¡AªÑ»ù¹O300¤¸¥H¤W¤½¥q¦³22®a¡A¥Í§ÞªÑ´N¥e¤F¤»®a¡A¤ñ«ª½¹G¤T¦¨¡A·N¨ý¥Í§Þ±Ú¸s¤wÀò±o§ë¸ê¥«³õ¤@©w»{¦P¡C¤ÀªR®v«ü¥X¡A¥Í§Þ±Ú¸s·f¤W·s¬F©²¬Fµ¦§ß´ÓÃD§÷¡Aªñ´Á®ð¶Õ±j¡A¥¼¨ÓªÑ»ùÄò¯è¤O¡AÃöÁä¦bªk¤HºA«×¡C ¥~¸ê°é¹ï¥xªÑ¥Í§Þ±Ú¸s¿³½ì·U¨Ó·U°ª¡A±©¬ã¨s½d³ò»EµJ¦b¥«È¸û¤j¡B°ò¥»±¤w¸g¦³Àò§QªºÓªÑ¡C Á|¨Ò¨Ó»¡¡A¯«¶©³sÄò¼Æ¦~Àò§QѬ°¥¿¼Æ¡BªÑ¥»¤]¹F70»õ¤¸¥H¤W¡A¬Q¤Ñ¸Ó¤½¥q¦bÃÒ¥æ©ÒÁ|¿ìªk»¡·|¡A§Y§l¤ÞªáºXÀô²yÃÒ¨é¥xÆW°Ï¬ã¨s³¡¥DºÞ¨¦¤ë²[¡]Peter Kurz¡^¡A¥H¤Î¦h¦W¥~¸ê¾÷ºc¤ÀªR®v¿ËÁ{¡F¬Û¹ï¦a¡A°w¹ïÀò§Qª¬ªpÁÙ©|¥¼©ú®Ôªº¥Í§Þ»sÃÄ·~ªÌ¡A¥~¸ê°é¦h¥b¥ý«ùÄòÃöª`¡A©|¥¼¯Ç¤J¬ã¨s½d³ò¡C ¸ê²`ÃÒ¨é¤ÀªR®v¤è¼}À©»¡©ú¡A¥Í§Þ·sÃıڸs¦V¨Ó¨ã¦³¬ãµo´Áªø¯S©Ê¡A¦bÃÄ«~¨ú±oÃÄÃҩαM§Q¶}ªáµ²ªG«e¡A¦h³B©óÁ«·l¡AµM¤@¥¹¨ú±o¦¨¥\¡A«áÄòÀò§Q¤]¦³¤@¸½Ä¤Ñªº®×¨Ò¡C¤ÀªR®v´£¿ô¡A¯S§On¯d·Nªº¬O¡A·sÃĸѪ¼µ²ªG¤@½¨âÀü²´¡A¥«³õ·|§óª`·N«áÄò·ÀI¡C ¤»Àɥͧްª»ùªÑ¤¤¡A¶È¯E¹©¥Dn·~°È¬°·sÃĬãµo¡A¨ä¾l¹³ºëµØ¡BF-ª÷¥i¡BF-±d¤Í¡B¨Õ¬ã¡BF-ÄRÂ×µ¥¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/19 ¤W¤È 08:35:29²Ä 2688 ½g¦^À³
|
Walden¤j¡A ·P«_¤]¬Oªv¤£¦nªº¡C·P«_ÃÄ¥u¯à®ø°£¯gª¬¡AÅý§K¬Ì¨t²Î¦³®É¶¡®ø·À¤J«I¯f¬r¡C ±o·R´þ¯fªº¤H¦pªG¤£¥ÎÃı±¨î¡A§K¬Ì¨t²Î¨¾½u±Y¼ì¡A«h¤@Ó·P«_¤]¥i¯àn¥Lªº©R¡C B¨x¦Ü¤µªv¤£¦n¡A¦ý¬OC¨xªv±o¦n¡C¨ä¹êµ¹¤Fªø´Á¤W±o¥Hªv¡¯f¬r©Ê¯e¯fªº¤è¦V¡C·R´þ¯f©Î³\¤]¦³¥i¥H®Úªvªº¤@¤Ñ¡A¦b¨º¤§«e¡A¥ý¥u¯à¾aÀ£§í¯f¬r¬¡°ÊªºÃĪ«¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/2/19 ¤W¤È 08:31:30²Ä 2687 ½g¦^À³
|
YunYunHome¤j ¤p§Ì·Q¸ò±z¤À¨É¤@¤U¡AÁٽбz¤£§[«ü±Ð ¦pªG¦³¤@¤Ñ¡A¼w°êÁ|¿ì¤F°ê»Ú¨®®i¡A¤p§Ì«e¥h°Ñ¥[¤F¡A¤p§Ìµ´¤£·|¥u·Q¬Ý³Ì«G²´¡B³Ì¶Qªº¨º¥x¨®¡I ¦Ó¦pªG¡A¦b°Ñ®iªºÅu¦ì¤W¡A¦³¤@¤jÅu¬O»OÆWªºÅu¦ì¡A¨º»ò¤p§Ì·|«D±`ªº°ª¿³»Pź¶Æ¡I ¨ä¹ê¡A´Nºâ¬O°ò¨È¤]¦n¡A¤p§Ì³£§Æ±æ¥L¯à¦¨¥\¡I ¦]¬°¡A©ñ¤j²´¥ú¨Ó¬Ý¡A¥ô¦ó·sÃÄ¡A¤£¶ÈÀ°¦£ªº¬O¯f¤H¡A ¹ï¥Í§ÞènµÞªÞªº¥xÆW¦Ó¨¥¡A§Ú̳£¬O¡u¥Í©R¦@¦PÅé¡v¡A±N¨Ó³£¥²»Ý¬Û¤¬§ß«ùªº¡I ¥t¡A³o¨Ç¦~¡AÆ[¬Ý¦³¨Çª©¡A¥]¬A¿³Âdª©¡A·Pı¤j®a¯uªº«Ü¦³¤ô·Ç ¦³¨Ç«äºû¡A¤@»y¹DºÉºëÅè¡A ¦³¨Ç¥y¤l¡A¨ã¦³ÆF»î¤§¬ü¡I¯uªº«Ü´Î¡I ¦@«j¤§ |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/2/18 ¤U¤È 11:43:09²Ä 2686 ½g¦^À³
|
¹x¥Û¤j~ »¡±o¦n~ ©Ò¥H¨Ì·Ó³oÓÅÞ¿è¡AÀ³¸Ó¥Í²£·P«_ÃĪº¤½¥q¥«È¥²¶·³Ì¤j! ¦]¬°´X¥G³£ªv¡¤F~ «¢«¢ |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/18 ¤U¤È 10:04:17²Ä 2685 ½g¦^À³
|
YunYunHome¤j¡A ¦UºØ·R´þ¯fÃĪ«°Ý¥@¦Ü¤µ¡A¥þ²y¥u¦³¤@Ó³Qªv¡ªº¯f¨Ò¡A¦Ó¥B¤£²M·¡¬O«ç»òªv¡ªº¡C«ö±zªº»¡ªk¡A³o¨ÇÃĪ«¤£´N³£¨S¦³»ùȤF¡H ¬ü°êªº Gilead ¬O¾a·R´þ¯fÃĪ«°_®aªº¡A¥¦¦b2006¦~®Éªº¥«È´N¤w¸g¦³¨â¤T¦Ê»õ¬ü¤¸¡C¤¤¸Î²{¦b¬O¤Q¤»õ¡C ¤£¦PªºÃĪ«n¸ò¥¦ªº¹ï¤â¤ñÃĮĸò¥«³õ»ùÈ¡C ªø½K¯¾¤£·|¦º¤H¡A°µ¦×¬r±ìµß¬r¯Àªº¤½¥qÁÙÈ1600»õ¬ü¤¸©O¡C |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2016/2/18 ¤U¤È 08:44:01²Ä 2684 ½g¦^À³
|
°]°È¤j¡A§Ú·Q¤£¥Î¦A°µ¤Ó¦h¸ÑÄÀ¡A¤j®a«ù¦³³£¶W¹L¤T¦~¡A¹ï©ó¨ä¥Lè¤J¤â¤Hªº°ÝÃD¡A·|¦^¨ì¤â»Ä¡A ¦Ó¥B³o¬O¦b¯E¹©ª©¡A¤£¬O¸Îª©¡A§Ú¥´¤F³o¨Ç¦r³£Ä±±o¤â»Ä¤F¡I |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/2/18 ¤U¤È 08:40:22²Ä 2683 ½g¦^À³
|
YUN¤j, ±z¹ï¯E¹©ªº¸Ñ»¡Åý§Ú¬Ý¤F¼ö¦åªmÄË, «H¤ß¤j¼W. ¤£¹L±z¹ï¤¤¸Îªº¸Ñ»¡Åý§Ú¬Ý¤F«oµS¦p˪i¤F¤@½L§N¤ô. «Øij±z°Ñ¦Ò°]°È¤jªº·N¨£, ½½¤¤¸Î°Q½×ªO²`¤JÁA¸Ñ Ibalizumab, ¤S©ÎªÌ¬Ý¬Ý¦~³ø©Î¤WÂd¤½¶}»¡©ú®Ñ. ¬Û«H±z¤@©w·|¹ï¤¤¸Î¦³¤@µf¤£¦Pªº¨£¸Ñ. |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2016/2/18 ¤U¤È 06:08:52²Ä 2682 ½g¦^À³
|
¥Ø«e¬°¤î¡AÁÙ¨S¦³µo²{¨ä¥L·sªº¸ô³~ HIV «I¤J²ÓMªº¼Ò¦¡¡A´N¥Ø«eªºÂå¾ÇÃѪ¾¨Ó±ÀÂ_À³¸Ó¤£·|¦³§ÜÃÄ©Ê¡Aªp¥B¥H Ibalizumab ªº¾÷¨î¡A¦ó¤j¤@¤]ı±o¤£©ö·|¦³§ÜÃĩʪºª¬ªp¡C(Y¤£¬Û«H¦ó¤j¤@¡A§Ú¤]¨S¿ìªk¡C) ¦A±j½Õ¤@¦¸¡A·R´þ¯f¬O½Æ¤èªvÀø¡A¦Ü¤Ön¤G¦Ü¤TºØ¦P®É¨Ï¥Î¡A¯S§O¬O¦h«§ÜÃįf¤H§ó¤£¯à³æ¿W¤@¨ý¡C Ibalizumab ¤@¥N¬OÀR¯ßª`®g(IV) ¡AÂê©wªº¥«³õ´N¬O¿ï¾Ü¤£¦hªº¦h«§ÜÃįf¤H»P¨ü¤£¤F°Æ§@¥Îªº¤H¡A·í±Á{©R¥Í¤Wªº«Â¯Ù®É¡Aª`®g¤£«KÀ³¸Ó¤£·|¬O¦Ò¶q¡CIM ÀH«á´N·|±µµÛ¤W¡A«K§Q©Ê·|¤j¤j§ïµ½¡C Ibalizumab ¤G¥N¬Oªø®Ä«¬(¤@©u©Î¥b¦~)ªº¥Ö¤Uª`®g(SC)¥i¦b®a¬I¥´¡AY¦P®É°t¦X¨ä¥LÃļtªºªø®Ä¥Ö¤Uª`®g¾¯«¬¡A«K§Q©Ê·|¤j¼W¡A³o¬O·R´þ¥ÎÃĪº¨å½dÂಾ¡C¦b¤@¥Nªº°ò¦¤U¡A¤G¥N¦¨¥\ªº¥i¯à©Ê·¥°ª¡A¥«³õ³W¼Ò¤]¬O¥þ½u¾A¥Î¡A¦P®É IV/IM ¾¯«¬¤]·|°h¥X¡C ·R´þ¯fÃĪº¥«³õ¤£¦b¥xÆW¡A¤£n¥xÆWªº¨¤«×¥h¬Ý³oºØÃÄ¡C·Q¶i¤@¨Bªº²`¤JÁA¸Ñ Ibalizumab ¥i¥H¥h½½¤¤¸Î°Q½×ªO¡A²`¤JÁA¸Ñ«á¦A¨Óµû½×¡A¬Û«H·|§ó¥[ÃôÃò¦³¤O¡C |
|
|
·|û¡Gming10140949 µoªí®É¶¡:2016/2/18 ¤U¤È 06:03:14²Ä 2681 ½g¦^À³
|
to YunYunHome ¤j: 1.²{¦b°ê»ÚÃļt¦b¶}µoÃĪ«,¤w¸g¤£¬O¥H¤fªA¬°¥D,¬O¥Hªø®Ä°w¾¯¬°·Ç 2.§ÜÃÄ©Ê°ÝÃD,¤¤¸Î¤w¸g§ï¨}·sªºÃĪ«,©Ò¥H¤£¥Î²q,¤]¤£¥ÎÅG 3.iv½T¹ê¨Ï¥Î¤£«K,¥i²{¦b¤½¥q¤w¥Îlabel extentionªº¤è¦¡,¦bÂX¤j¥«³õ 4.Àù¯g¥«³õ¤j,¦ýÄvª§¤]¦h! 5.¹ê¦b¤£¥Î®³ôô¤ñ§Ì§Ì,©Î§Ì§Ì¤ñôô,¥«³õ¤£¦P |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 05:24:47²Ä 2680 ½g¦^À³
|
Ibalizumab ªº¾÷¨î¨Ó¬Ý¡A¤£·|¦³§ÜÃĩʪº°ÝÃD??? ¨S¿ù¡AIbalizumab¬O¦]¬°¥iÀ³¥Î©ó¦h«§ÜÃĩʯf¤HÀò±o¬ð¯}©ÊªvÀø¡A¦ý¤£·|¦³§ÜÃĩʳo¨Æ±¡¼K§O¤ÓªZÂ_ §O§Ñ¤F¡A¯f¬r¬O·|Åܲ§ªº §ó¦óªp¡A´Nºâ¬O¦³¦h«§ÜÃĩʪº¯f¤H¡A¥¼¥²¥u¦³Ibalizumab¯à¦³®Ä ¦AªÌ¡A°Ñ»P¹êÅç¦ý¥u¦¬¨ì¤@ÓӮתº¤¤°êÂåÃĤj¾ÇªþÂå·P¬V¬ì¥D¥ôÂå®v¤ý¥ô½å«o¤£³o»ò¼ÖÆ[¡A¥L«ü¥X¡A·R´þ¯f±w¤E¦¨¤³£¦bªù¶E¥H¤fªAÃĪ«ªvÀø¡A¥u¦³¤¢H¦í°|¡A³oÓ·sÃĶ·°t¦X¨Ï¥Î쥻ªºªvÀøÃĪ«¡A¨Ã©w´Á¦^Âå°|ÀR¯ßª`®g¡A¥ú¬O¦¬®×´N«Ü§xÃø¡A¥¼¨Ó¯f±w°t¦X«×¬O¤@¤j°ÝÃD¡C ·R´þ¬O±o²×¨ªAÃÄ¡A¦³´XÓ¯f±w¦³¼Ý¤O¡A¤T¤£¤®É©¹Âå°|¶]¡A¥hª`®g¤@°w¡AµM«áÂ÷¶}? ¤¤µØ¥Á°ê¨¾¬Ì¾Ç·|²z¨Æªø¤ý¥ô½å«hªí¥Ü¡A·R´þ¯f¬O¤@ºØºC©Ê¯f¡A¯f¤H¶·ªø´ÁªAÃı±¨î¡A²{¦bÃĪ«ºØÃþ¦h¡A³£¬O¥H¤fªA¾¯«¬¤è«K¯f±wªø´Á¨Ï¥Î¡A³oÓ·sÃĶ·³z¹LÀR¯ßª`®g¡AÄÝ©ó¡u±Ï´©«¬¡v¥ÎÃÄ¡A¥´°w¥i§Ö³t°§C¯f¬r¶q¡A¦ý¯f¤H¨S¿ìªkªø´Á¥´¡A¦h«§ÜÃĩʯf±w¤H¼Æ¤S¤Ó¤Ö¡A¶È¥e¤¦Ü¤Q¢H¡Aµ¥©ó¥u¯à¾ß¤H®a³Ñ¤Uªº°©ÀY¡A«ç»ò·|¦³¥«³õ©M§Q¼í¡H |
|
|
·|û¡GANDY LIN10141792 µoªí®É¶¡:2016/2/18 ¤U¤È 03:54:26²Ä 2679 ½g¦^À³
|
ÁÂÁ §Ö¼ÖªO¼Ò¤u ¤j¤jªº´£¿ô»P¹ªÀy¡C §Ú·|ÄYÂԬݫݦۤvªº°]°Èª¬ªp¡C ·PÁ |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2016/2/18 ¤U¤È 03:52:52²Ä 2678 ½g¦^À³
|
1.ªk»¡¨º¤Ñ¤¤¸Î°õ¦æªø©Ò¹ï¤ñY¤j©Òz,·Pı¬O¤£¦PªºÃÄ 2.®³¯E¹©©M¤¤¸Îpk? ©Ç©Çªº |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2016/2/18 ¤U¤È 03:44:25²Ä 2677 ½g¦^À³
|
Ibalizumab ªº¾÷¨î¨Ó¬Ý¡A¤£·|¦³§ÜÃĩʪº°ÝÃD¡C ²Ä¤@¥N¦]¬°¤À¤lµ²ºc¤Wªº°ÝÃD¡A·|¦³ 10% ªº§ÜÃÄ©Ê¡A¦Ó¤G¥N§ï¨}¤Fµ²ºc¡A¦b¥Ø«eµo²{ªº HIV ºØÃþùØ¡A§¹¥þ¨S¦³§ÜÃĩʪº°ÝÃD¡A¥i¥Hªø¤[¦s¦b¥«³õ¡A³o¤]¬O¬°¤°»ò¡A·R´þ¯fÃĤj¼t·|Ãöª` Ibalizumab ªº¥Dnì¦]¤§¤@¡C |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 03:31:52²Ä 2676 ½g¦^À³
|
>>§ÜÃĩʪº°ÝÃD¡A¦ÑÃÄ·|³vº¥°h¥X¥«³õ¡A³o¤]¬O¤j¼t¤@ª½»Ýn·s«¬ªº·R´þÃÄ ³o¤]¬O¤¤¸Î·sÃĦP¼Ë¥²¶·n±¹ïªº°ÝÃD ·R´þ¯f¬rªº¹x±jÃøªv¡A«Ü®e©ö²£¥Í§ÜÃÄ©Ê¡A«Ü®e©öÅý¬ãµo·R´þÃļ´¤£¨ì¤°»ò¤j¿ú ¤]´N¬O»¡¡A¤¤¸Îªº·sÃĽæÓ´X¦~«á¡A«Ü¦h¯f±w³£¥X²{§ÜÃÄ©Ê«á¡A¦n¤£®e©ö®³¨ìªºÃÄÃÒ´N¬O¼o¯È¤@±i¤F ³o¨Ï±o¤¤¸ÎÁÙ±o¦A§ë¤J¸êª÷¡AÁÙ±o¹B®ð¶W¦n¡A¦A¬ãµo¥t¤@´Ú·sÃĨÓÀ±¸É¯Ê¤f °ê»Ú¤jÃļt¦A¨ú±o¤¤¸Îªº±ÂÅv®É¡AªÖ©w·|§â³o¤@ÂI¦Ò¼{¶i¥h¡A¦Ó¤£Ä@·N¥X¤Ó°ªªºÅv§Qª÷¡A§ó¤£·|¥X²{·mµÛª§¨ú±ÂÅvªº±¡ªp ³o¤@ÂIµ´¹ï¬O¨º¨Ç¯{¤J¼Æ»õ¸êª÷ªº¥D¤O¡Bª÷¥D©Òª¾±xªº¨Æ±¡¡A¥þ³¡³£¥u¬O©ê«ùµÛ¼´²¼´N¨«¤Hªº¤ßºA¦Aª±¤¤¸Î ´²¤á´x´¤¸ê°TºC(¨Ò¦p¤¤¸Î»sµ{¥X°ÝÃD¡A³ø¼o²vöt°ª)¡Aµ¥¨ì§Aª¾¹D«ç»ò¦^¨Æ¤§«e¡AªÑ»ù¦´N¶^¤F¤@¤j¬q¡K. §Ú´N¤£©ú¥Õ¡A¤¤¸Î·ÀI¤ñ¸û§Cªº¹D²z¡A¨ì©³¦bþ¸Ì? |
|
|
·|û¡G§Ö¼ÖªO¼Ò¤u10141754 µoªí®É¶¡:2016/2/18 ¤U¤È 03:24:32²Ä 2675 ½g¦^À³
|
ANDY LIN¤j 20¦~«e è¥XªÀ·|´÷±æ¾Ö¦³¿ú ´N¥|¦ìªB¤Í¤@°_·íªO¼Ò¤u ¨C¤Ñ¨¤W¥u±a¤@¦Ê¶ô ¤u§@°µ¿ùªº½Ð³Ü²D¤ô ªü¹F ¦³®ÉÔ³s100¶ô¤]¨Sªá¨ì ¤@¤Ñ¤u¸ê2500 ¨CÓ¤ë¤u§@¦Ü¤Ö¤G¤Q¤¤Ñ ³o¼Ë¹L¤F¨â¦~ ¦s¨ì¤F¤@¦Ê¸U ³Ì«áÁÙ³Q¦ÑÁóˤF20´X¸U §Ú¸ò¦ÑÁ󻡧A¦³¿ú ¦AÁÙ§Ú´N¦n¤F ¦]¬°¥L¤ñ§Ú§ó¥i¼¦ ³s©Ð¤l¤]½æ±¼¤F 20¦~«eªº§Ú ¦pªGª¾¹D20¦~«áªº§Ú ¤@¤Ñ¤W¤U´N¦Ê¸U ¤£ª¾¹D·|¤£·|½|ż¸Ü ·PÁÂ¦Ñ¤Ñ·Ý µ¹§Ú³o»ò¤jªºÅܤƪº¤H¥Í>>> ¦pªG¥i¥Hªº¸Ü «H¶Un·Q¿ìªk¥ýÁÙ±¼ ¨ºÓ§Q²v¯uªº¤Ó°ª¤F ©Ð¶U¦AºCºCÁÙ ¨ì¤@Ó¶¥¬q ¶}©l§V¤O¶R¶i¹sªÑ ¹LÓ´X¦~ ¯E¹©ªº°t®§ ´N¯àÀ°§Aªº©Ð¶Uú±¼ ¤â¤WªºªÑ²¼°í«ù¦í §Ú¬Û«H§A¤]¥i¥H°]´I¦Û¥Ñ ¥[ªo |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 03:18:45²Ä 2674 ½g¦^À³
|
"§ë¸ê¤¤¸Î¹³¬O½ä21ÂI¼³§J¡A½ß²v§C¨Ç¦ý¬OĹ²v¤j¡F§ë¸ê¯E¹©¹³¬O½ä½ü½L¡AĹ²v§C¨Ç¦ý¬O½ß²v¤j??? §Ú¬°¤°»òı±o¤¤¸Î¬O½ß²v§C¨Ç¡AĹ²v¤]§C? ²³æªº°Ý¤@¥y¡G°Ñ»PÁ{§É¹êÅ窺¯f±w¤¤¡AþÓ°Ñ»P¤¤¸Îªº¯f±w³QÂå¥Í§P©w²¬Â¡¥i¥H¥X°|? ¯E¹©´N¦³ ²{¦b¡A¥u¤£¹L¬O¤¤¸Îªº¶i«×§Ö¤@¨Ç¡A¦Ó¥B§Ö¤@¨ÇÁô§tªº·N¸q¦b©ó¡G´Nºâ¦Y¤F¤¤¸ÎªºÃÄ¡A¤]¨SÅãµÛ§ïµ½¡A©Ò¥H¤~·|¤ñ¸û§Ö¹F¨ìÁ{§É¹êÅ窺¥Ø¼Ð ¬Û¹ï¦a¡A¯E¹©¶i«×«Ü½wºC¡A¥Dn¬O¦bÂùª¼¹êÅ礤¡A¦Y¤F¯E¹©ªºÃÄ¡A¤j³¡¤À³£¨S´_µo©Î¦º¤`¡A´_µo©Î¦º¤`ªº¯f±w³£¬O¤£©¯¨S®³¨ì¯E¹©ªºÃÄ «ö·Ó¬J¦³ªº¶i«×¨Ó¬Ý¡A¯E¹©Á{§É¹êÅçn¹F¨ì·íªì³]©wªº´_µo©Î¦º¤`¤H¼Æ¡A®£©ÈÁÙn3¦~ ¤]´N¬O¡A¯E¹©ªºÀø®Ä¬O»·»·¶W¹L¯E¹©·íªìªº¹w´Á!!! ½Ö»¡¶i«×§Ö´N¬O¦n¨Æ??? ¦b·sÃĬãµo¤¤¡A¶i«×ºC¤~¬O¦n¨Æ!!! ¥xÆW¤H«Ü¦h¤HÁÙ¬O¤£À´·sÃĪѪº§ë¸ê¡A»~¥H¬°¶i«×§Ö¤@ÂI¤~¬O¦n¨Æ¡K.ü¡K. Y¦³³oºØ»~¸Ñªº¤H¡A¯uªºn¦n¦n»{¯uªº²`¤J¤F¸ÑÂùª¼¹êÅç¬O«ç»ò¶i¦æªº |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2016/2/18 ¤U¤È 03:15:41²Ä 2673 ½g¦^À³
|
´¡ªá¤@¤U¡A¦³¨Ç¸ê°T¡A¦b¦¹¸É¥R¤@¤U¡C §Ì§Ìªº Ibalizumab ¤£¬O¾a¨x¥NÁ¡A©Ò¥H¨S¦³¬r©Êªº°ÝÃD¡A°Æ§@¥Î¥i¥H»¡¨S¦³¡A°õ¦æªø»¡¥´ Ibalizumab ¸ò¥´¤ô¨S¤G¼Ë¡C ¶Ç¬V¯f³q±`³£·|¦³¤@©w°ê®aªº¤O¶q¨Ó¨ó§U¨¾ªv¡A©Ò¥H·|¦³¬F©²ÂåÀø«OÀIµ¥¸É§U¡A¤£µM·sÃijo»ò¶Q¡An¦Y¤@½ú¤l¯uªº¬O¦Y¤£°_¡C ¦]¬°§ÜÃĩʪº°ÝÃD¡A¦ÑÃÄ·|³vº¥°h¥X¥«³õ¡A³o¤]¬O¤j¼t¤@ª½»Ýn·s«¬ªº·R´þÃÄ¡AIbalizumab ¨S¦³¶Ç²Î¤p¤À¤lÃħÜÃĩʪº°ÝÃD(¥Ø«e¦³10% µ²ºc¤W³y¦¨ªº§ÜÃÄ©Ê¡A¤G¥N«h¨S¦³³o°ÝÃD)¡A²z½×¤W¥i¥H¤@ª½¦s¦b¥«³õ¡C Ibalizumab ¤G¥NÄÝ·s¾¯«¬(§óªø®Ä)¡A²z½×¤W¥un¹LÁ{§É¤@´Á¡A¤W¥«¥u¬O®É¶¡°ÝÃD¡A³o´ÚÃįà§ð·R´þÃÄ¥þ½u¡A¦Ó·R´þªvÀøÄݽƤè¡A¦UÃļtÄv¦X¨S³o»ò±j¯P¡C Ibalizumab ¤T§å¦¸ 20000L ¶q²£¤w§¹¦¨¡A¥Ø«e·Ç³Æ¥Ó½Ð FDA ¨Ó¬d¼t¡C ¤¤¸ÎÄw½X¡A¬O¦´Á¦b¿³Âd®É¡A¬ü°Ó¤jªÑªF¤G¸U±i¦b¥«³õ¤W¥á¡A³y´N¤µ¤éªº§½±¡C ¦æ¾P¤@ª½¬O¥xÆWÃļtªºP©R¶Ë¡A²¦³º³oªá¶Ë«Ü°ª¡A¤¤¸Î¤£·|¦Û¤v½æ¡Aµ²·ù¬O¶Õ¥²n¨«ªº¸ô¡C ¥¤ß¦Ó½×¡A·Q¹³ªÅ¶¡¡A¯E¹©½T¹ê¤ñ¸û¤j¡A¦Ó¤¤¸Î¬Û¹ï¦Ó¨¥¤£½T©w¤p¡A¤£¹L¥«³õ·Q¹³ªÅ¶¡½T¹ê¤£¦pôô¡A¦ý§Úı±oªº°÷¤j¤F¡C |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 03:08:50²Ä 2672 ½g¦^À³
|
>¼Ú¬ü°µ·R´þ¯fÃĪºÃļt«Ü¦h¡A¦ý¬O³£¬O¤p¤À¤lÃĪ«¡A°µ¥Íª«ÃĪº¤£¦h¡C¥Íª«Ãĸò¤p¤À¤lÃĪº¾÷¨î¤£¦P¡A©Ò¥H¥i¥H¸É¤p¤À¤lÃĪº¤£¨¬¡C·R´þ¯f§ó¬O±`¥ÎÂû§À°sÀøªk¡A©Ò¥H²{¦³·R´þ¯fÃĤj¼t¨Ã¤£»Ýn©ñ¤U¦Û¤vªºÃĨӱÀ¼s¤¤¸ÎªºÃÄ¡A¥i¯à¬O¨Ö¥Î¡C Á¿±o³o»ò½ÆÂø¡A»¡¬ï¤F´N¤@¥y¸Ü¡G¤¤¸Îªº·sÃÄ¡AÁÙ±o·Q¿ìªk±o¨ì°ê»Ú¤jÃļtªºÃö·Rªº²´¯« ´Nºâ³Q¯Ç¤JÂû§À°sÀøªk¡A¤]¥u¬O¨ä¤¤¤@ºØ¡A±o©M¨ä¥LÃÄ«~´£¨ÑªÌ¤À¨É§Q¯q ¦Ó¥B¡A¤¤¸Îªº·sÃĨ쩳¦³¤°»ò±j¤jªº»¤¦]¡AÅý°ê»Ú¤jÃļt§â¬J¦³Âû§À°sÀøªk¤¤ªºÃĪ«ç°£¡A¯Ç¤J¤¤¸ÎªºÃÄ©O? ¥u¬O°Æ§@¥Î¤p¤@ÂI??? ¦AªÌ¡A¥Íª«ÃĪºÀuÂI´N¬O¨ä¯ÊÂI ¥Íª«ÃĬG¦W«ä¸q¡A¨Ã«D¨Ó¦Û¤Æ¾Ç¦X¦¨¡A¦Ó¬O¥Íª«¤ÏÀ³¡AÁöµM¥L¤HÃø¥H¥é®Ä¡A¦Ó»s¦¨¾Ç¦WÃÄ¡A¦ý¥Íª«¤ÏÀ³¥Í°£¥Nªíªº·N¸q´N¬O¥Í²£¦¨¥»¤ñ¸û°ª ¦P®É¥Íª«ÃÄ»sµ{¤¤¡A¥un¨ä¤¤¤@ÓÀô¸`¾D¦¾¬V¡A¥i¯à´N¡u¾ã²ÕÃa¥ú¥ú¡v ³o¤]¬O¬°¤°»òªñ¦~¤]¦³¤£¤Ö¥Íª«ÃÄÁöÃÄ«~Àòã¤W¥«¡A¦ý«oµLªk§JªA¶q²£¶¥¬qªº²~ÀV¡A¦P¼Ë¤]¤£¯à¶¶§Q¦b¥«³õ¾Q³f °£«D¤¤¸Î¦³¤°»òµ}©_ªº»sµ{¯à¤O¡A§_«h´Nºâ¶¶§Q®³¨ìÃÄÃÒ¡A°ê»Ú¤jÃļt¦³·NÄ@±Ä¥Î¡A¯à¤£¯à¶q²£¡Aéw¨Ñ³f¤]¬O¥¼ª¾¼Æ ³o´N¬O¬°¤°»ò«Ü¤Ö°ê»Ú¤jÃļt§ë¤J¬ãµo¥Íª«ÃÄ¡A¤j³¡¤À³£¬O¤p¤À¤lÃĪ« ·RªÛ¯f·sÃĬãµo¥»¨´N§xÃø««¤F¡AÁÙ¦b¶q²£¹Lµ{¡A¦Û§ä³Â·Ð??? ´N¥u¬O¬°¤F°Æ§@¥Î¤ñ¸û§C? ¤¤¸Î³Ì«á¦³¥i¯à±Ñ¦b¶q²£§xÃø¡A·ÀI°ª ®³¨ìÃÄÃÒ¡A¤S¤£¬OÀò§Qªº«OÃÒ¡A¬°¤°»ò·|¥H®³¨ìÃÄÃÒ¶i«×§@¬°·ÀIµû¦ô??? |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/2/18 ¤U¤È 03:06:44²Ä 2671 ½g¦^À³
|
YUN¤j: ÁÂÁ±zªº¦^ÂÐ !! §Ú¤]»{¦P§ë¸ê¯E¹©¸û¤¤¸Î¦³¤jÁȪº¾÷·| ¹x¥Û¤j: ±z»¡ªº§Ú§¹¥þ©ú¥Õ !! ¤@ª½°O±o±z¤§«eÁ|ªº"§ë¸ê¤¤¸Î¹³¬O½ä21ÂI¼³§J¡A½ß²v§C¨Ç¦ý¬OĹ²v¤j¡F§ë¸ê¯E¹©¹³¬O½ä½ü½L¡AĹ²v§C¨Ç¦ý¬O½ß²v¤j¡C"³oÓ¤ñ³ë ! ²³æ©úÁA ¤ÓÁÂÁ±z¤F |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 02:52:26²Ä 2670 ½g¦^À³
|
¯E¹©ªºÃĪ«¡A¬O¤j«¬ªºÁÞ¤À¤l»P³J¥Õ½èªºconjugate¡AÀ³¸Ó¤£¥i¯à¥Î¤fªA¡A¦]¬°µLªk¬ï¶V®ø¤Æ¨t²Î³Q¤HÅé§l¦¬??? ¦pªG¥u¬O³æ¯Â§âOBI-822®³¨Ó¤fªA¡A¨º¦ó¥²n®³¿úµ¹¯E¹©Ä~Äò§@¬ãµo? ¬ãµo¬O¤°»ò·N«ä? ·íµM¬OÅý¨S¿ìªkª½±µ¤fªAªº¡AÅܦ¨¥i¥H¤fªA ´N¹³¯q¥Íµß¥»¨Ó¬OµLªk¤fªA¡A¦]¬°G»Ä·|§â¯q¥Íµß±þÓºë¥ú¡A¦ý¥Î¯S®í«OÅ@½¤¡A´N¯à¨Ï¬¡µß¬ï¹LG»Ä¡A¦Ó¹F¨ì¤fªA¯q¥Íµß |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 02:41:22²Ä 2669 ½g¦^À³
|
³o¤§«e¡A822ªº·ÀI¬O°ªªº¡A©Î¬O»¡822ªºÀø®Ä¬O¤£©ú½Tªº??? §A¥i¥HµoÓ°T®§µ¹°Ñ¥[OBI-822Á{§É¸ÕÅ窺¬ü°ê²¬Â¡¯f±w- Serenity https://www.facebook.com/SerenitysJourney# 2H14¶Ç¥X¼ÆÓ°Ñ»POBI-822Á{§Éªº ¨ÅÀù¯f±w²¬Â¡ªº°T®§¡A®¶¾Ä¥Í§Þ·~¬É¡A«Y¦]OBI-822ªº¦¬®×¯f¤H³æ¾a¹ï·Ó²Õªº¤ÆÀøÃÄÂ_µLªkªv¡¡A¦Ó²¬Â¡±wªÌ¸ÕÅç´Á¶¡¥X²{ªº¬õ¸~¡B§½³¡§K¬Ì¤ÏÀ³»P OBI-822ªº°Æ§@¥Î¬Û¥é¡AÁô§tOBI-822ªºÀø®Ä¥i¯à¶W¥X·íªìªº°²³]¡C |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 02:34:39²Ä 2668 ½g¦^À³
|
§Ú¬Û«H§Ì§ÌªºÃÄÀø®Ä¬OÅãµÛªº,¤£µM¤]¤£·|®³¨ìBTD??? ÅãµÛÔ£? ¨S¦³ªv¡ªº¥i¯à¡A¥u¬O°Æ§@¥Î¤p¤@ÂI¡AÁÙ¤£¬O¤@¼Ën²×¨ªA¥Î¡A¦³´XÓ¤H¦³°]¤O¦³¿ìªk¹³§l¬r¤@¼Ë²×¨ªA¥Î?¦AªÌ¡A¥un¬OÃĪ«´N¬O¦³¬r©Ê¡A³Ì²×¤]³\¤£¬O¦º©ó·RªÛ¯f¡At³d±Æ¬rªº¨xµÇ¥ýÃa±¼ ·R´þ¯f±M®a¦ó¤j¤@¡R¤U¥N¬ì¾Ç®a¤´Ãø®Úªv·R´þ http://indepth.mingpao.com/php/passage.php?seriesno=9&titleno=15 ¦Ü©ó¨ä¥L¤¤¸Î«e´º¸û®tªº²z¥Ñ¡A´N¤£¦A²Öz¡A«H¤£«H¬Ý§A¦Û¤v¤F ¨S»¡¥L¤£¦n¡AÁȤ£¨ì¿ú¡A¥u¬O¤¤¸ÎnÁȨì¼É§Q¬O¤£¥i¯àªº¡A¦Ó¥B¤¤¸Îªº·sÃĶi«×¨ä¹ê¤ñ¸û§Ö¡A¦ý¬ÝªÑ»ù´Nª¾¹D®t¦h¤Ö¤F(¤£¬O«K©y´N¬O¦n³f) https://connectomeblog.wordpress.com/2014/06/30/epsc/ ¦Ü©óBTD¡A«hn¥h°l¨sBTDªº°_·½¡A¤~¤ñ¸û¯à¬ÝÀ´BTDªº¯u¥¿ªº§t·N ¦b¬ü°ê²{¦æªº«P¶iÄY«¯e¯fÃĪ«¼f¬dpµeªº¤èªk¦³¥|ºØ¡A¤À§O¬OFast Track¡B¬ð¯}©ÊªvÀø¡]Breakthrough Therapy¡^¡B¥[³t®Öã¡]Accelerated Approval¡^¤ÎÀu¥ý¼f¬d¥|ºØ ´«¨¥¤§¡A¤¤¸Î·sÃÄ®³±o¨ìBTD¨Ã¤£¬O¥LªºÀø®Ä¬OÅãµÛªº¡A¦Ó¥Dn¤¤¸Î¬ãµoªº·sÃĺâ¬OÄY«¯e¯fÃĪ«¡A¦P®É¨ã³Æ¬ð¯}©ÊªvÀø¡]Breakthrough Therapy¡^¡AÅU¦W«ä¸q¡A¤¤¸Îªº·R´þÃĩұĪºªvÀø¤â¬q¤£¬O¶Ç²Î¤èªk¡A¤£¬O§Ûŧ©Î¼Ò¥éªº ©x¤è§Æ±æ¯à½T©wBTDªºÃĪ«¥i¯à¬O¦w¥þªº¡A´NºÉ§ÖÅý¥L¤W¥«¥h±Ï¤H©R ¦ý¡A¤£¬O§Ûŧ©Î¼Ò¥éªº¬ð¯}©ÊªvÀø¡]Breakthrough Therapy¡^¡AÀø®Ä«OÃÒ´N¤ñ¸û¦n? ½Ö»¡ªº? ¥u¯à»¡¤ñ¸û¦n¦Ó¤w(¨Ò¦pÅý·RªÛ¯f±w¥i¥H¤Ö¦Y¤@ÂI¡A°Æ§@¥Î¤p¤@ÂI) ¨Ò¦p¹³«Â¦Ó¿û³oºØÀø®Ä¬OÅãµÛªº¡A¦ý¥L¤£¬O¥Î¨ÓªvÀøÄY«¯e¯f¡A´N¤£¥i¯à®³±o¨ìBTD¡A¦ý«Â¦Õè¥i¥HÅýÃļtÁȫܦh«Ü¦h¿ú |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/2/18 ¤U¤È 02:34:10²Ä 2667 ½g¦^À³
|
ÁÂÁÂFaith¤jªºÃö¤ß¡A¤p§Ì«Ü¦n§r¡A¹L¦~¥h¤F½ë¤é¥»¦Û¥Ñ¦æ¡A§Ö²ÖÃa¤F ¤£¬Oª±±o¦hºÆ¡A¬O¦~ªñ50¨Å餣¤j¦æ¡A¯á´Õ¦³ÂI»´·L°h¤Æ¡A¸}©³ªO¤]®e©öµmµh ¤é¥»ªF¨Ê¡A¤j¨ÁÀH«K¤@Ó¦aÅK¯¸´N¥i¥HÅý¤H¨«¨ì»Lµm¡AÃø©Ç¤é¥»´X¥G¨S¬Ý¨ìD¤l D¤l¤j·§¨Sªk¨«»·¸ô¡AÀ½¦aÅK§a.... (©Î³\D¤l³£¬O¶}¨®±Ú??) ÁÙ¦³¤@Ó¯S§O²{¶H¡A¤k¥Í¤]³£¬ïµu¸È¡A¤£©È§N¡A¦Ó¥B±q¤p¾Ç¥Í¨ì¦¨¦~¤H³£¤@¼Ë ¦Å¥»¡¤é¥»¤p¾Ç´N¦³@´H°V½m¡A¤p¾Ç¥Í´Nn¦b¥V¤Ñ¬ïµu¿Çµu¸È¤W½Ò¡A¤~¯à@´H¼W¥[©è§Ü¤O ¬Ý¦b¥xÆW¤H²´¸Ì¦´N§â±Ð¨|³¡©xû¹G¨ì¤U¥x§a¡A«¢«¢ ¥t¥~YunYunHome¤]´£¨Ñ³\¦hÄ_¶Qªºª¾ÃÑ¡A¨ü¥Î¤£¤Ö¡A¤£ºÞ¬O¦ÑªB¤Í·s¦P¾Ç¡A"¤@ªÑ¦b¤â¦^¨ýµL½a" ¸£¤¤¤@ª½°jÅT±i¸³»¡ªº"¦nÀ¸¦b«áÀY"....¤U©P«á´Nª¾¹D¤F§a ¥i±¤¥u¬O¼Ò½kÂaÄgªºÁÞ¤k¡A¯u¥¿®i²{·«ººï¬ùªº®ÉÔn¨ì6¤ëASCO¤F§a ¤£¹L³o´Á¶¡¤´¦³³\¦h¨Æ±¡¥i°µ¡A¦nÀ¸¤]¤£·|¤Ö±¼¤@Óªº Ä~Äò¶ß¥Ê¤l¡A³Ü¯ù¤ô¡A¬ÝÀ¸Å¥À¸¨É¨üÁÞ¤k~~ |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/18 ¤U¤È 02:29:25²Ä 2666 ½g¦^À³
|
YunYunHome¤j¡A ¤p§Ì«e¤å¦³Ó¿ù»~¡A¤¤¸Î¦b2014¦~¤]¿ì¹L¤@¦¸¨CªÑ63¤¸ªº²{¼W¡A¦¬¨ì14»õ¤¸¡C ¼Ú¬ü°µ·R´þ¯fÃĪºÃļt«Ü¦h¡A¦ý¬O³£¬O¤p¤À¤lÃĪ«¡A°µ¥Íª«ÃĪº¤£¦h¡C¥Íª«Ãĸò¤p¤À¤lÃĪº¾÷¨î¤£¦P¡A©Ò¥H¥i¥H¸É¤p¤À¤lÃĪº¤£¨¬¡C·R´þ¯f§ó¬O±`¥ÎÂû§À°sÀøªk¡A©Ò¥H²{¦³·R´þ¯fÃĤj¼t¨Ã¤£»Ýn©ñ¤U¦Û¤vªºÃĨӱÀ¼s¤¤¸ÎªºÃÄ¡A¥i¯à¬O¨Ö¥Î¡C ³o¨ÇÃļt¦³µÛ²{¦¨ªº·R´þ¯f¾P°â³q¸ô¡A¦ý¬O¯Ê¥F«á½uªº¥Íª«ÃĨӶñ¸É¤p¤À¤lÃĪºªÅ¯Ê¡A©Ò¥HÀ³¸ÓÁÙ¬O·|¦³¤j¼t¦³¿³½ìªº¡C¦Ü©ó±ÂÅvª÷¦h¤Ö¡A¤p§Ì¤£´±¦kij¡C ¯E¹©ªºÃĪ«¡A¬O¤j«¬ªºÁÞ¤À¤l»P³J¥Õ½èªºconjugate¡AÀ³¸Ó¤£¥i¯à¥Î¤fªA¡A¦]¬°µLªk¬ï¶V®ø¤Æ¨t²Î³Q¤HÅé§l¦¬¡C¥Ø«e©Ò¿×ªºÀù¯g¬Ì]¡A¤]ÁÙ¥¼¨ì¹w¨¾Àù¯gªº¹Ò¦a¡A¥u¬OÅX°Ê§K¬ÌÅé¨t±þ¦º¬J¦³ªºÀù²ÓM¡C ¹xµ£¤j¡A ¤¤¸Î¤G´Á¤w¸g§¹¦¨¡A©Ò¥HÃĮĪº¼Æ¦r©ú½T¡A¹ï©ó¯à§_®³ÃÄÃÒªº·ÀI¸û§C¡CÁöµM¥«³õ¤p¨Ç¡A¦ý¬O·ÀI§C¡A¤W¥«®É¶¡§Ö¡C©Ò¥H§é¦©¤Ö¡C ¯E¹©¦Ü¤µ³s¤G´Á³£ÁÙ¨S¦³¸Ñª¼¡A´Nºâ¸Ñª¼¤]ÁÙnµ¥ASCO¤~¬Ý±o¨ìÃöÁ䪺¹êÅç¼Æ¾Ú¡C³o¤§«e¡A822ªº·ÀI¬O°ªªº¡A©Î¬O»¡822ªºÀø®Ä¬O¤£©ú½Tªº¡C¥[¤W¤T´Án°µ¦h¤[®Ú¥»¨SÃСAÃÄÃÒ¦ó®É¨ú±o¤]¤£ª¾¡A©Ò¥H·ÀI»P®É¶¡ªº¶K¤ô¥i¥H«Ü°ª¡C ¯E¹©ªº¥¼¨Ó»ùȰ϶¡¤W¤U«Ü¤j¡A¹ê²{»ùȪº®É¶¡¥i¯àn«Ü¤[¡C©Î³\¦³¤H½ä¹ï¤F¡A¯E¹©¨â¦~«á´N®³¨ìFDAÃÄÃÒ¡A¨º´NÀò§QÂ׫p¡C¦ý¬O¤]¥i¯à·|¤jÁ«°Ú¡I¦³¤H¬Ý¦h¦³¤H¬ÝªÅ¡AÁ`¦³¤H·|ÁÈ¡B¤]¦³¤H·|Á«¡C ¤p§Ì»{¬°¡A¥«³õÁÙ¬O¦³®Ä²vªº¡C¯E¹©ªº¦X²z»ùÈnµ¥¤»¤ë¨£¨ìASCOµ²ªG¤~¯à»¡¡C |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 02:11:43²Ä 2665 ½g¦^À³
|
¦³Ãö©ó¯E¹©ªºÀù¯g¬Ì]¡A§Ú¥»¨Ó¤£¬O«ÜÀ´¥Lªº·N«ä¡AÀù¯g¥i¥Hªv¡´N°½¯º¤F¡A¦p¦óÁÙ¯à¹w¨¾??? «á¨Ó¬Ý¤FªvÀø°Êª«ªº¤ßµ·ÂΪº¨âºØÃĪ«Às°¨340®(IMMITICIDE®)¡B¤ü·sÄ_«á¡A´N©ú¥Õ¤F http://tw.merial.com/Dog/Pages/heartworm.aspx ²³æÁ¿¡A¤ü·sÄ_¥u¹ï©è§Ü¤O¤ñ¸û®zªº¤ßµ·ÂÎ¥®ÂΤ~¦³®Ä¡A¦ÓÀs°¨340«h¹ï¤ßµ·ÂΦ¨ÂΤ]¦³®Ä ¤]´N¬O»¡¡A©Ò¿×¤ü·sÄ_¥i¥H¹w¨¾¤ßµ·ÂΡA¥Dn¬O¨CÓ¤ëÅýÃdª«ªA¥Î«á¡AYÃdª«Å餺¦³¤ßµ·ÂÎ¥®ÂδN±þ¦º¡AÅý¤ßµ·ÂΨS¾÷·|ªø¤j¦¨¬°¦¨ÂΡAY¨S¦³¡A¤ü·sÄ_´N¥u¬O¥Õ¦Y ¬Û¹ï¦a¡A¯E¹©ªºÀù¯g¹w¨¾ÃĪ«¡A¨ä§@¥Îì²zªÖ©w¸òOBI-822¬O¤@¼Ò¤@¼Ë¡A¥u¬O¥Î¨Ó¹w¨¾Àù¯gªº¿@«×¤£¥Î¤Ó°ª¡A¤]¤£»ÝnÀR¯ßª`®g¡A³z¹L®ø¤Æ¨t²Î¶i¤J¤HÅé´N¨¬°÷±þ¦º¡A¼Æ¶q·¥¤ÖªºÀù¯g²ÓM(²z½×¤W·|¬O¤Ö¨ì³Ìºë±Kªº»ö¾¹³£ÀË´ú¤£¥X¨Ó) ÅýÀù¯g²ÓM¨S¾÷·|¤j¶qÁc´Þ¡A¦Ó¥e¦í¤j¶q¥¿±`²ÓM¡AÅý¤HÅé¯S©w¾¹©x¥¢¥h쥻¥¿±`¥\¯à¡A¦ÓÅý¤H¥X²{¯f¯g¡AY¦b¨Å©Ðµo²{³o¨Ç¤j¶qªºÀù²ÓM¡AÂå¥Í´Nµ¹Ó¦Wµü¡X¨ÅÀù (´N¹³µ²¥Û¥X²{¦b»H¯Ö¡A´NºÙ¤§¬°»H¯Öµ²¥Û¡A¥X²{¦bµÇŦ¡A´N¬OµÇµ²¥Û) ¤£¹L¡A¥¿¦pOBI-822´X¥G¨S¦³°Æ§@¥Îªºì²z¤@¼Ë¡AOBI-822¥u·|°»´úÀù²ÓMªí±¤~¦³ªº¦hÁÞÅé¨Ã¶i¦Ó®ø·À¥L¡A¦]¦¹±N§C¾¯¶qªºOBI-822·í§@°·±d¹«~¨Ó¨C¤ÑªA¥Î¡A¨Ã¤£·|¶Ë®`¤HÅé°·±d¡A¥u¬O°¸¦Ó¦Y¤Fµ¥©ó¥Õ¦Y¡A¦]¬°§ä¤£¨ì¦³Àù²ÓM ²³æÁ¿¡A¥un¯à°÷¦AÀò±o§ó¦hÂå¾ÇÃÒ¹ê¡A©x¤è±¾«OÃÒ¡A¤@¤j°ï¦³¿ú¤HªÖ©w¤H¤H¶R¨Ó¨C¤Ñ¦Y ¥Ñ©óÀù¯g¬Ì]ªºì²z»POBI-822¬Û¦P¡A¥u¬O¥i¯à¾¯¶q¸û§C¡A¹ê»Ú¤W¯E¹©ªºÀù¯g¬Ì]¤w¸g¬ãµo§¹¦¨ Y¦³ºÞ¹Dªº¦³¿ú¤H¡AÀ³¸Ó¦´N¶}©l¨C¤Ñ¦Y¯E¹©ªºÀù¯g¬Ì]¡A¦Ü¤Ö¥i¥HÁקK¦h¹F16ºØªºÀù¯g |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/2/18 ¤U¤È 02:00:11²Ä 2664 ½g¦^À³
|
YunYun¤j: ¤p§Ì¥H¬° ôô¸ò§Ì§Ì³Ì¤jªº®t¶Z¦b¤ÑªáªOªº°ª§C..§Ì§Ì²{¦bªº¼ç¦b¥«³õ¬O·R´þ¯f¥|¤½u,¥¼¨Óªº¹Ú¦b©ó¶i¤J«e½u¥ÎÃÄ..ôô¦pªG¸Ñª¼¶¶§Q,¥ú¨ÅÀù«á´Á¯f¤H¥ÎÃĪº¼ç¦b¥«³õ´N°ª©ó§Ì§Ìªº¥|¤½u¥«³õÁ`©M¤F,§ó¦óªp¦pªG¶¶§Q®³¨ì¨ä¥LÀù¯gªºÃÄÃÒ ¦ý§Ú¬Û«H§Ì§ÌªºÃÄÀø®Ä¬OÅãµÛªº,¤£µM¤]¤£·|®³¨ìBTD §Ú»{¬°¥xªÑ¥Í§ÞÃþªÑ¸ê¥»¥«³õ¬O¨S¦³®Ä²vªº,ôô¸ò§Ì§Ì¥H¥«È¨Ó¬Ý¤£¦X²z, ¤£¬O§Ì§Ì°ª¦ô,´N¬Oôô©úÅã§C¦ô ¤p§Ì§Ú¨â®a³£¶R,ôô¤ñ«°ª«Ü¦h,©Ò¥H§Ú§Æ±æ¬O«áªÌ... ¥u¬OÀH·N¶¢²á...Áٽбz«ü±Ð ! |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤U¤È 01:50:14²Ä 2663 ½g¦^À³
|
´«¤@ºØ»¡ªk¡G¤¤¸Î¤ñ°_¯E¹©¡A¤¤¸Î«e´º¤ñ¸û¤£¬Ý¦n¡A¨Ï±o¤¤¸Î»Ýn¥Î¤ñ¸û¤jªº¸ê¥»ÃB¨Óºû«ùÀç¹B(©Ò¥Hn¥Î¸û§C»ù®æ¿ì²z²{ª÷¼W¸ê) ¦ý¡A¥Ñ©ó¤¤¸Îªº·RªÛ·sÃĨä¹ê¤]µLªkªv¡(½Ðgoogle¦ó¤j¤@ªº»¡ªk¡A³o¤@¥N¬ì¾Ç®aµLªkªv¡¡A¤U¤@¥N®£©È¤]¨S¿ìªk¡A¦]¬°¬ÛÃö°ò¦¬ã¨s¤´µM»·»·¤£¨¬)¡A¦p¦ó¯àÅý°ê»Ú¤jÃļt©ñ¤U¦Û¤v¬ãµoªº·RªÛ¯fÃÄ¡AÀ°¦£¤¤¸Î±À¼s??? ¬Û¹ï¦a¡A¯E¹©ªºÀøªk¦³ªv¡Àù¯gªº¥i¯à¡A¥u¬O¥Ø«eÁÙ»Ýn§óªøªº®É¶¡¥hÆ[¹î ¤S©Î¬O»¡¡A¦b³oºØ±¡ªp¤U¡A¬°¤°»ò·|¦³°ê»Ú¤jÃļt¥HÅå¤H¤Ñ»ù·m±o¤¤¸Îªº·sÃĪºÅv§Qª÷? ¦b³oºØ±¡ªp¤U¡A´N¦³¥i¯à·|¦³°ê»Ú¤jÃļt¥HÅå¤H¤Ñ»ù·m±o¯E¹©ªº·sÃĪºÅv§Qª÷! ¦AªÌ¡A¬JµM¤¤¸Îªº·RªÛ¯f·sÃĨèS¦³ÅãµÛÀø®Ä¡A¥Nªí¨ä¤èªk¨Ã¨S¦³¦h¤jªº¬ð¯}©Ê¡A±N¨ÓÄ~Äòªu¥Î¨ÃÂX®i¨ì¨ä¥L·sÃĬãµoªº¥i¯à©Ê¤]¤£°ª ³o¨Ï±o¡A¤¤¸ÎªºÃD§÷«Ü§Ö´N¥ÎºÉ ¦ý¡A¯E¹©ªºªvÀø¤â¬q¨ä¹ê¾A¥Î©ó¦hºØÀù¯g¡A¦Ó¥BÁÙ¦³¥i¯àÅܦ¨°·±d¹«~ªº¡y¬Ì]¡z¡A¨S¯f±j¨¡A¦³¯fªv¯f ÁöµM¥Ø«e¼È®ÉÁÙ¥i¥H¥Î²Vªº¡A¨C¦¸¯E¹©¤jº¦¡A«Ü¦h¤H´N·|²ö¦W²£¥Í¤Ûı¡A¥h´Á«Ý¤¤¸Î ¯E¹©¤Ó¶Q¶R¤£°_¡A§ï¶R¤¤¸Î? ¦ý¡A¬°¤°»ò¤£¬O¥h¶R¯E¹©ªº¹sªÑ´N¦n??? |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/2/18 ¤U¤È 12:27:44²Ä 2662 ½g¦^À³
|
YunYunHome¤j¡A§A¦n¡G ¯E¹©ªº¸³¨Æªø¬O¡u±i©À·O¡v¢w¢w ´x¦³OBI-822¤§Ãþ²£«~ªº¶}µo§Þ³N ¤¤¸ÎªºÁ`¸g²z¬O¡u±i©Àì¡v¢w¢w ´x¦³TMB-355¤§Ãþ²£«~ªº¶}µo§Þ³N ¡u±i©À·O¡v©M¡u±i©Àì¡v¬O¥S§Ì¡A¤@°_¦Y¡u¦~©]¶º¡vªº¡A©Ò¥H§Ú̱`ºÙ¡u¯E¥S¡v¡B¡u¸Î§Ì¡v¡A¬O³oÓ·N«ä¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/18 ¤U¤È 12:12:49²Ä 2661 ½g¦^À³
|
YunYunHome¤j¡A ¯E¹©»P¤¤¸Îªá¿ú¦h¤Ö¡A¬Ý¸ê¥»ÃB¤£·Ç¡An¬Ý¸ê¥»§Î¦¨¡C ¤¤¸Î¦b¤W¥«¤§«e¡A²{ª÷¼W¸ê³£¬O¨CªÑ10¤¸¡A¦]¦¹¾ÉPªÑ¥»¼W¥[§Ö³t¡C¯E¹©´¿¦b2013¦~¿ì²z¨CªÑ158¤¸²{¼W¡Aµo¦æ950¸UªÑ¡A¦¬¨ì15»õ¤¸¡CY¬O¸Ó¦¸²{¼W¤]¬O¥Î10¤¸µo¦æ¡A¨º¯E¹©ªÑ¥»´Nn¨ì30»õ¤¸¤F¡C ¤W¥«»ù®æ¡A¯E¹©¨CªÑ310¤¸¡Aµo2000¸UªÑ¦¬¨ì62»õ¤¸¡C¤¤¸Î¨CªÑ115¤¸¡Aµo¦æ3000¸UªÑ¦¬¨ì34.5»õ¤¸¡C©Ò¥H¤¤¸Î¦¬¨ìªº¼W¸ê´Ú¸û¤Ö¦ý¬OªÑ¥»¿±µÈ§ó§Ö¡C °µ·R´þ¯fªáªº¿úªÖ©w¬O¤ñ°µÀù¯gn¤Öªº¡A¥Dn¦b©óÁ{§É¹êÅ窺ªøµu¡C·R´þ¯fÆ[¹î´Áµu¡AÁ{§É¹êÅçµ²§ô§Ö¡A¦ÓÀù¯g¯f±wÆ[¹î´Áªø¡A¹êÅçµ²§ô¯Ó®É¸ûªø¡CÁ{§É¶O¥Î³\¦h»P¹êÅç®É¶¡ªøµu¬ÛÃö¡C ·íµM¡A¦pªG¯E¹©ªºÃĨS®Ä¡A¯f¤H¦¦PDµ²®×¡A¨ºÁ{§É¶O¥Î¤]·|¸û§C¡CÃĮĶV¦n¡AÆ[¹î´Á´¶¹M°¾°ª¡AÁ{§É¶O¥Î´N¶V°ï¶V°ª¤F¡C |
|
|
·|û¡GANDY LIN10141792 µoªí®É¶¡:2016/2/18 ¤W¤È 11:47:29²Ä 2660 ½g¦^À³
|
ÁÂÁ§A¡C ´Á«Ý¯E¹©³yºÖ¥@¬É¡C |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2016/2/18 ¤W¤È 11:22:28²Ä 2659 ½g¦^À³
|
Ãø¹D¤µ¤Ñnº¦°±...¤£n°Ú... ¦]¬°º¦¤£°± ¤ñ º¦°±¦n°Ú ~~~ |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/2/18 ¤W¤È 11:09:49²Ä 2658 ½g¦^À³
|
ANDY LIN¤j: §Úı±o±z«Ü¦³²´¥ú! Åwªï¥[¤J.§Ṳ́@°_¬°¯E¹©¥[ªo! |
|
|
·|û¡GANDY LIN10141792 µoªí®É¶¡:2016/2/18 ¤W¤È 10:57:31²Ä 2657 ½g¦^À³
|
ÁÂÁ³oÓ°Q½×°Ïªº¦U¦ì±M®a¡C ¤p§ÌÂù¿Ë³£¬OÀù¯g¹L¥@¡A©Ò¥H«ÜÃö¤ßÀù¯gÂåÀøµo®i--- ¯E¹©·íµM¤]«Ü¦ª`·N¨ì--- ¦ý¬O¹L¥ht¾á¤Ó¦hÂåÀø¶O(ªÍÀù¥¼´Á¡A¦Û¶OªvÀø5¦~¦h)¡A¥[¤W©Ð¶U¡AÅý§Ú¨S¦³¸êª÷ÁʤJ¡C ¥h¦~9¤ëªì¡A¯E¹©¶^¨ì300¤¸¥H¤U®É¡A¦]½t»Ú·|±ÀÂ˵¹¿Ë¤Í--- «á¨Ó¥ß§Yº¦¤F¤@ªi¡A¿Ë¤Í·íµM¶}¤ß--- §Ú«Ü¤£¥Ì¤ß¡A§Ú¨S¶¢¿úÁʤJ¡A´N¦b12¤ë¥hÉ«H¶U¡Aµw¬O¶R¤F¤@±i¡C ·íµM§Ú¬O¥h°l°ª¡A¶R¨ì740¤¸¤F¡C ¦ý¬O§Ú¯uªº¤£¾á¤ßµu½uªÑ»ù¦p¦ó¡A§Ú¥u¾á¤ß§Ú¨S¦³¥ô¦ó«ùªÑ¡C «Ü°ª¿³¦A´X¤Ñ´Nnª¾¹Dµª®×¤F¡C ÁöµM¥u¦³¤@±i¡AÁÙ¬O¶}¤ß¡C ¸òª©¤W³\¦h¤H¯à¤@°_´Á«Ý¡A¬O¥ó¿³¾Äªº¨Æ¡C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/2/18 ¤W¤È 10:20:37²Ä 2656 ½g¦^À³
|
YunYunHome¤j§A¦n, ÁÂÁ§A |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/2/18 ¤W¤È 10:15:48²Ä 2655 ½g¦^À³
|
·PÁÂYunYunHome¤jµL¨pªº¤À¨É Åý§Ú©ê¦n¯E¹©ªº«H©À§ó°í©w¤F |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤W¤È 10:09:42²Ä 2654 ½g¦^À³
|
§Ì§Ì? ¬O«ü¤¤¸Î·sÃĶÜ? ¤¤¸ÎÀ³¸Óºâôô§a? ¤¤¸Îªº¸ê¥»ÃB¤ñ¯E¹©¦h¤F7»õ¡A´X¥G¬O¯E¹©¤@¥bªº¸ê¥»ÃB ¦ý¡A¦³¤H·Q¹L¡A¬°¤°»ò¤¤¸Î»Ýn¤ñ¸û¤jªº¸ê¥»ÃB?ì©lªÑªF¨S¨Æ§ë³o»ò¦h¿ú¶i¥h·F¹À??? ·íµM¬O¦]¬°¤¤¸Îªº·RªÛ¯f·sÃĬãµo¦¨¥»¤ñ¸û°ª¡AÃø«×§ó°ª ¦Ó¥B¡A³ÌÁV¿|ªº¬O¡A¥Ø«e¨S¦³¤@¶µ·RªÛ¯fÃĦ³©_®Äªº¡A³£¥u¬O¦hª§¨ú®É¶¡¡A¤£¦YÀH®É¥i¯à·|¯fµo¨¤` ¨S¿ù¡A·RªÛ¯f¨S¿ìªkªv¡¡A¹ïÃļt¬O¥ó¦n¨Æ¡A¥i¥HÁÈÓ¤£°± ¦ý¡A¤£Ãø·Q¨£ªº¬O¡A·RªÛ¯fÃĪ«¬O¦U¤jÃļt¥²ª§ªºÃĪ«¡AÄvª§ªÌ²³¦h ¤p«¬·sÃļt°£«D¦³©_®Ä¡A§_«h¦U¤jÃļt¬°¤°»òn¥Î¦Û¤vªºÃĪ«³q¸ô¥hÀ°¦£½æ©O? ¤£n§Ñ¤F¡A·sÃÄÁÙ¬On¾a°ê»Ú¤jÃļt¤~¦³¿ìªk¯u¥¿½æµ¹»Ýnªº¯f±w ¯f±w¤£¥i¯à¦Û¤v·|¦³ª¾ÃÑ»P¸ê°T¡Aª¾¹Dn¦Y¤°»òÃÄ¡A³q±`³£¬O¥DªvÂå®v¶}ªºÃÄ¡A¯f±w´N·Ó¦Y ¦]¦¹¡A¤@Áû·sÃÄ¡A®³¨ìÃÄÃÒ¡A¤S«ç¼Ë? ¨C¦~¦³¤@°ï³Q®Ö㪺·sÃĤW¥«¡A³o¨ÇÂå¥Íþ¦³¶¢¤u¤Ò¥hÅ¥¤@Ó·sÃĤ½¥qªº·~°È¸Ñ»¡? ·íµM¬OÂå¥Í¥»¨Ó´N«Ü¼ô±xªº°ê»Ú¤jÃļtªº·~°È¡A¤~¦³¾÷·|±µÄ²¨ì¡A¤~¦³¾÷·|¤¶²Ð·sÃÄ À´¤F¶Ü? Ãļtªº·~°È¬°¤°»ò±`±`¬Æ¦ÜÅܦ¨Âå¥Íªº§K¶O¨p¤H¹²¤H¡A´N¬O¬°¤F«Ø¥ß°_«H¿àÃö«Y¡A«Ø¥ß³q¸ô ¤]´N¬O»¡¡A³oºØ³q¸ô¬O«D±`«D±`Ãø«Ø¥ß°_¨Óªº¡Aµ´¹ï¤£¬O¯E¹©³oºØ¤p¤½¥q¦³¿ìªk¤Á¤Jªº ¬Û¹ï¦a¡A¨ÅÀù¡A¤×¨ä¬O¨ÅÀù¥½´Á¡A¥Ø«e®Ú¥»¨S¦³ÃĪ«¯à°÷¦³®Ä±±¨î¦í ¦]¦¹¡A¦b¨ÅÀù¥½´ÁªºÃĪ«¤¤¡A´X¥G¨S¦³Ävª§ªÌ¥i¨¥ ¯E¹©ªº·sÃijQÃҹ꦳©_®Ä«á¡AªÖ©w¯à§l¤Þ°ê»Ú¤jÃļtªºª`·N¡A¦]¬°À°§O¤H½æÃÄ¡A¤]¯à¼´¤@µ§¿ú ¤Ï¥¿³q¸ô¤w¸g«Ø¥ß¦n¡A¦h½æ¤@´ÚÃÄ¡A´N¯à¼´¿ú |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/2/18 ¤W¤È 09:51:58²Ä 2653 ½g¦^À³
|
YunYunHome §AÁ¿ªº«D±`¦³¹D²z¡I À³¸Ó¬OÂåÃĬÛÃö¦æ·~ªº¤j¤º°ª¤â§a¡I ÁÂÁ§A¤À¨É¨º»ò¦h¸ê®Æ¡I |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤W¤È 09:50:15²Ä 2652 ½g¦^À³
|
¶°«O¤áªÑÅv¤À´²ªí¬d¸ß https://www.tdcc.com.tw/smWeb/QryStock.jsp ¦pªG¦U¦ì¤ñ¸û³ßÅw°µªi¬q¡A¤£³ßÅw¾ú¸g¤j¶^ªºÀ£¤O¡A«Øij¥i¥H¸òµÛ¥D¤O¡Bª÷¥D¤@°_¾Þ§@ ´Nºâ¥bºC©ç¡A¤]¬O¯à½æ¦b¬Û¹ï°ªÂI ±q¶°«O¸ê°T¨Ó¬Ý¡A¯E¹©¦¦b11¤ë©³´N¥X²{¥D¤O¡Bª÷¥D´î½Xªº±¡ªp «ùªÑ¤d±iªÌ¡A¦b11¤ë20¤é¨º¤@©P¡A«ùªÑ¹F¨ì°ª®p¨Ã¶}©l´î¤Ö¡A¨Ã¦b12¤ë4¤é¨º¤@©P¡A©úÅã´î¤Ö¡A¤j·§Á`¦@«ùªÑ´î¤Ö¤F3000¦h±i ÀH«á¡A´î¤Ö«ùªÑªº±¡ªp«ùÄò¡A¦ý¤£¦A©úÅã(¼o¸Ü¡A¥D¤Oª÷¥Dn½æªÑ²¼¡A«ç»ò·|½æ¦b¬Û¹ï§CÂI?) ¦b1¤ë30¤é¨º¤@©P¡A«ùªÑ¤d±iªÌ¡A¨äÁ`«ùªÑÅܦ¨¼W¥[ ¦P®É¬Û¹ï©ó11¤ë20¤é¨º¤@©P«ùªÑ¤d±iªÌ¤H¼Æ¦³22¤H¡A¦b1¤ë30¤é¨º¤@©PÅܦ¨23¤H (¤]´N¬O¡A¼W¥[¶q¥i¯à¥Dn¨Ó¦Û³o¦h¥Xªº¤@Ó) ¦U¦ì¦Û¤v¦A¥h¹ï·Ó¯E¹©ªºªÑ»ù¨«¶Õ¡A¦³¨S¦³µo²{¨ä¹ê¬O¦³³s°Ê©Êªº? «ùªÑ¤d±i¥H¤WªÌªºÁ`«ùªÑÅܤơAÁ`¬O·m¦bªÑ»ù¥X²{©úÅãÅܤƤ§«e? ¼o¸Ü¡A´±®³¥X5~6»õ¤¸¸êª÷(1¤d±i¯E¹©)¨Ó³æ¤@§ë¸êӪѡA¨S¦³¤Q¦¨¤Q§â´¤¡A«ç´±¤W±ç¤s¡H Á`¤§¡A¸òÀH³o¨Ç¤j©@¶i¥X¡A¤£¦Ü©ó¤j½ß¡A¤]¤£¦Ü©ó®M¦b°ªÂI §Ú¬O¦³«Ü°ªªº«ùªÑ«H¤ß¡A©Ò¥Hµu´Á¤ºªÑ»ù¾_Àú¡A®Ú¥»¤£¦b·N ¦b·Nªº¬O¡A¸U¤@¥X²{³sÄò«æº¦®É¡A¤â¤¤«ùªÑ¡yè¦n¡z¥ý¥X¤@½ë ¦]¬°¤@¯ë¤H³»¦h¥u¯à¬Ý¨ì¤W¤@©P«ùªÑªºÅܤơA¯Ê¥F²Ä¤@¤â¸ê°Tªº¤H¡AÁÙ¬O¥HÀR¨î°Ê¬°©y |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/2/18 ¤W¤È 09:43:11²Ä 2651 ½g¦^À³
|
YunYunHome¤j§A¦n, ¤]½Ð±Ð¤U §A¹ï§Ì§Ì¬Ýªk ·PÁ¤F |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/18 ¤W¤È 09:29:07²Ä 2650 ½g¦^À³
|
§Ú¤À¨É¤@¤U§ÚÆ[¹î°ê¥~·sÃĪѨ«¶Õªº¤ß±o¡G º¥ý¡A·sÃĤ½¥q¦p¦óÁÈ¿ú?·íµM¬O®³¨ìÃÄÃÒ¡A±ÂÅv¡A½æÃÄÁÈ¿ú ¦ý¡A¦bÁÙ¨S®³¨ìÃÄÃÒ¤§«e¡AÀ禬·íµM¬O±¾¹s(¤½¥q·íµM¥i¥H½æ¤@¨Ç¾Ç¦WÃÄ¡AÁÈÂI¤p¿ú¡A¦ý¦ó¥²®ö¶O¸ê·½¥hÁȤp¿ú?) ¤£¹L¡A¤@¦ý®³¨ìÃÄÃÒ¡A¦¨¥\±ÂÅv¥X¥h¡A¥Ñ©ó¤ò§Q²v¬ù90%¥ª¥k¡AÀ禬´X¥G´N¬OÀò§Q¡A©Ò¥HÀò§Q¬O«Ü®e©ö¶W¹L¤@Ӫѥ»(EPS 10) ´«¨¥¤§¡AY¥H¤@¯ë¥»¯q¤ñªºÆ[©À¨Ó±Àºâ·sÃĪѪº¦X²zªÑ»ù(Y¥H30¿¨Óºâ)¡A¥»¨Ó10¤¸¡A¦¨¥\±ÂÅv¥X¥h¡AªÑ»ù°¨¤W¨Ó¸õ¨ì300? «ç»ò¥i¯à? ¥u¬O¡A¯E¹©¨s³º¯àÁȦh¤Ö¿ú¡A¦X²zªÑ»ù¤S¬O¦h¤Ö¡A¨ä¹ê²{¦b®Ú¥»¨S¤Hª¾¹D¡A¦]¬°¨CÓ¤H¥Î¤£¦P¦ôºâ¤è¦¡¡A³£·|±o¨ì«D±`¤j¸¨®tªºµ²ªG ¦ý¡A¦³¤@ÂI¬O¥i¥H½T©wªº¡GÀHµÛ¯E¹©¥i¯àªºÀò§Q¯à¤O¶V¨Ó¶V²M´·¡AªÑ»ù´N·|ºCºC¦V¥Lªº¦X²zªÑ»ù¾aªñ ¤°»ò¸ê°T¥i¥HÅý¯E¹©¥i¯àªºÀò§Q¯à¤O¶V¨Ó¶V²M´·? ·íµM´N¬O¨Ò¦p¤¤´ÁÁ{§Éµû¦ô³ø§i¡B¸Ñª¼µ²ªG¡B¦b¸~½F¨ó·|¤½¥¬§ó§¹¾ãªº¼Æ¾Ú¡B°ê»Ú¤jÃļt®³¥X¯uª÷¥Õ»È·m¥ý¥d¦ì¡B®³¨ìÃÄÃÒ¡B®³¨ì²Ä¤G±i¡B²Ä¤T±i¡KÃÄÃÒªº¥i¯àµ¥µ¥ ¨S¿ù¡A¦b¯E¹©Àò§Q¯à¤OÁÙ¤£²M·¡ªº®ÉÔ¡A½T¹ê¦³ÂI¹³½M¤lºN¶H¡AºN¨ì¤°»ò´N»¡¥L¹³¤°»ò ¦ý¡AªÑ²¼§ë¸ê´N¬O¦p¦¹¡A«Ü¦h³¡¥÷³£¬O¾a·Q¹³¡A¹Ú·Q¶V¤j¡AªÑ»ù¤Wº¦ªÅ¶¡´N¶V¤j ¦ý¡A¤@¦ý½ü¹ø¶V¨Ó¶V²M´·®É¡A¨S¦³§ó¦h·Q¹³ªÅ¶¡¡A·íµM´N³¾Ã~´² ´N¦p¦P¤j¥ß¥ú¨º¼Ë¡A¥h¦~«×À禬»PÀò§Q³£¬OÅå¤Hªº°ª¡A¦ý¤j¥ß¥ú«o±q°ª®p¶^±¼1000¤¸ ¹D²z¦b©ó¡A¤j¥ß¥ú¤w¸g¨S¦³§ó¦hÅý¤H¥i¥H§@¹ÚªºÃD§÷¤F Á`¤§¡A¯E¹©³Ì¤jªº§Q¦h¨ä¹ê¤£¬O®³¨ì²Ä¤@±iÃÄÃÒ¡A¦¨¥\±ÂÅv¥X¥h¡A¦Ó¬O¥L¨ì©³¥i¥H®³¨ì´X±iÃÄÃÒ °£«D¥i¥H®³¨ì´X±iÃÄÃÒ³oÓ½ü¹ø¶V¨Ó¶V²M´·¡A¯E¹©ªÑ»ù¯u¥¿ªº¤j°ª®p¤~·|¯B²{¥X¨Ó¡AµM«á¤~·|¥X²{¯u¥¿ªº¤j¶^¨«¶Õ ¦b³o¤§«e¥X²{ªº¤U¶^¡A³£¥u¬OÀò§Q¤F¸Ñªº½æÀ£¡A¨Ã¤£¬Oª¾±¡ªÌ˳f¨«¤Hªº½æÀ£ |
|
|
·|û¡Gwison3710140346 µoªí®É¶¡:2016/2/17 ¤U¤È 12:20:36²Ä 2649 ½g¦^À³
|
®¥³ß«ù¦³¯E¹©ªº¤H.¤µ¦~¬OµU¦~.´Á«Ý¬Ý¨ì¯E¹©ªº·sÃĦ¨¥\.ÃĮġ§µU¶ë¹p¡¨ |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/2/17 ¤U¤È 12:07:25²Ä 2648 ½g¦^À³
|
Yun YunHome¤j¡A¥u¯à»¡±z«Ü´Î¡A·PÁµL¨pªº¤À¨É¡A¯E¤ÍªG¯uª×ªêÂÃÀs¡I |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/17 ¤W¤È 11:40:00²Ä 2647 ½g¦^À³
|
§Ú¬O¦b¯E¹©¤WÂd«á¤@¸ô¨«¶^¦Ü300¦h¡A¬Æ¦Ü³Ì«áÁÙ¥X²{³sÄò«æ¶^¨ì250¡A¶}©l¤@¸ô©¹¤W¶R(·í®Én°f¶Õ¶R¡A¯uªºn«Ü¦³«i®ð¡A¦]¬°±q½u«¬¹Ï¨Ó¬Ý¡A¯E¹©¬O©úÅ㨫ªÅÀYªºªÑ²¼¡K) ·í§Ú¤pÁȤ@µ§¡AªÑ»ù¤j·§400~500¤¸¡A¨ì³B¸ò¿ËªB¦n¤Í¤À¨É(¤§«eÁÙ¤£½T©w¯à«ùÄò¤Wº¦¡A¤£´±Á¿¡A400¤¸¥H«áªÑ»ù¨«¶ÕÅܦ¨¦hÀY±Æ¦C) ¨S¤H¦³¿³½ì¡A¬Æ¦ÜÁÙ¦³¤Hı±o¬O®ö¶O¥L®É¶¡ ÁÙ¦³¤H¤Ï¹L¨Ó¼J¿Ø§Ú¡G¼K¡A®¥³ß§A¡A§A¥i¥H¾a¯E¹©´£«e°h¥ð¤F¡I ¼K¡A§Ú¤£¤z¥Ü®zªº¤Ï¶æ¡G§Ú´N¬O¥´ºâ¾a¯E¹©¹ê²{´£«e°h¥ð¤F¡I¡I¡I§A«ç»òª¾¹D¡H ¦b¹L¥h¡A¥xÆW¤£´¿¦³·sÃĬãµo¯u¥¿Àò±o¦¨¥\ªº¡A¦]¬°¸êª÷ªùÂe¤Ó°ª¡A¦nªºÃD§÷¡A¦b¤@¶}©l´N«Ü¦³¼ç¤Oªº¡A®Ú¥»½ü¤£¨ì¥xÆW°]¹Î§ë¸ê ©Ò¥H¡A¨S¤H·|¬Û«H¯E¹©¯à¹³¤j¥ß¥ú¡A¬Æ¦Ü¤ñ¤j¥ß¥ú§ó¼F®`ªºÃzµo¤O¡A¨ä¹ê¤£·N¥~ ¥xÆW¤H³£¤Ó²ßºD§ë¸ê¹q¤lÃþªÑªº¡A¦Ó§â³oºØ¸gÅçªk«hµw®M¦b¯E¹©¤W¡A¦h¼Æ¤HÁÙ¤£¬Ý¦n¯E¹©¨Ã¤£·N¥~ «ö·Ó°ê¥~·sÃĪѪºªÑ»ù¨«¶Õ¨Ó¬Ý¡A¯E¹©¥Ø«eªºµo®i¶¥¬q¡AªÑ»ù¦¸Ó¯}1000¤¸ ¦ý¡A¯E¹©«oÁÙ¥d¦b600¦h¤¸¡A¨ä¹ê´N¬O¥xÆWªº§ë¸êÀô¹Ò¤¤¡A¸ò¥»¤£¨ã³Æ·sÃħë¸êªºDNA µM¦Ó¡A¥xÆW§ë¸ê¥«³õ¦V¨Ó³£¬O¤ñºÆªº¡A¯S§O¬O·sÂAªºÃD§÷¡A¨Ò¦p¦h¦~«eªº·s»È¦æªÑ¡B¤Ó¶§¯àªÑ ·í·s»È¦æªÑ¡B¤Ó¶§¯àªÑ¥u¬O¤pÁȤ@µ§®É¡A§ë¸ê¤H¹³§ì¨g¤@¼Ë¡AºÆ¨g°l±· §ó¤£¥Î»¡¡A¯E¹©¦³¥i¯à¦b¤µ¦~©Î©ú¦~¡A¥ýÀò±o¤@µ§¹w¥I´Ú¡A¦Ó¥B¯E¹©¥u·|¯uªº¶V¨Ó¶VÁÈ¿ú¡A¤£¹³·s»È¦æªÑ¡B¤Ó¶§¯àªÑ¥u¬O¾èªá¤@²{ ¨ì®É¡A¥xªÑ§ë¸ê¤H·|¦³¤°»ò¼Ëªº¤Ï¬M??? ¦^ÀY¤@¬Ý¡A¾a¡G600¦h¦n«K©y¡A¥u¥i±¤¡A¦ª¾¹DÁn¥|°_¡K. |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/17 ¤W¤È 11:24:28²Ä 2646 ½g¦^À³
|
¨ä¹ê¡A¼í®õ¤¨l¼Ù¥»¨Ó¬O¤£»{ÃѯE¹©±i©À·Oªº¡A¦Ó¥u¬O¤@Ó¥©¦X¡A¤¨l¼Ù»{ÃѤF¯Î±Ò´f¡A¶i¦Ó¤Þ¤¶¤F±i©À·O ¤j·§¤Q¦~«e¡A¤¤¬ã°|Äw¨ì¤@µ§¿ún»\°ò¦]Å餤¤ß¡A¦ÓÀç«Ø°Ó´N¬O¼í®õ ¤¨l¼Ù»{¬°³o¬O°ê®a«nªº¤uµ{¡A¦]¦¹ÁÙ±`±`¿Ë¦Û¶]¤u¦aºÊ¤u ·í®É¡A¤¤¬ã°|°|ªø¯Î±Ò´f¨Ã¤£»{ÃѤ¨l¼Ù¡A²Ä¤@¦¸¦b¤u¦a¹J¨ì¤¨l¼Ù¡AÁÙ¥H¬°¤¨¥u¬OÓ¤uÀY¡K ³o¤~Åý¤¨ª`·N¨ì¯Î±Ò´f²¦¥Íªº¬ã¨s¦¨ªG¡A¥H¤Î¯E¹©ªº¼ç¤O §ó¦¥H«e±i©À·O¦b¬ü°ê³Ð¿ìªº Optimer¡A¤]¬O¸êª÷¿N¥ú¤F¡A¥u¦n¤Þ¤J¤@Ó§ë¸êªÌªº¸êª÷¡A¦ý²z©À¤£¦X¡A±i©À·O¥u¦nÂ÷¶}¦Û¤v³Ð¿ìªºOptimer ©Ò¥HnÅý¦³³o¼Ë¸gÅ窺±i©À·O¦A¬Û«H§ë¸êªÌ¨ä¹ê¤£®e©ö¡AY¤£¬O¤¨l¼Ùµ¹¯Î±Ò´f¯d¤U«Ü²`¨èªº¦L¶H(¤j¦ÑÁó©~µM¿Ë¦ÛºÊ·þ¤@Ó¤p¤uµ{???)¡A¤]³\´N¤£·|¦³«á±³o¤@³s¦êªº¬G¨Æ ¯uªº¬O¤Ñ·N¡A¤@³s¦êªº¥©¦X |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/2/17 ¤W¤È 11:13:21²Ä 2645 ½g¦^À³
|
YunYunHome¤j §â¨ÓÀs¥h¯ß¦A²M·¡ªº¸Ñ»¡¡AÆg¡IÁÂÁ±z¡I ¤p§Ì¦³®É·Q¡A³o¤§¤¤ÁٿĦX¤F¤Ñ·N§a¡I §_«h¡A«ç»ò·|Åý¯Î°|ªøªº¾Ç¥Í¦b¥©¦X¤U¡A¥©§®ªº¸Ñ¥X¨Ó¡I ÁÂÁ±z¤F¡I Åó±ø±ø¤j ¦n¹³¤@°}¤l³£¨S¤Wª©¤F¡A³ÌªñÁÙ¦n¶Ü¡H |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/2/17 ¤W¤È 11:08:47²Ä 2644 ½g¦^À³
|
YunYun¤j: ±z¯uªº»¡¨ì¤ß§¢¸Ì¤F ¦n·P°Ê ÁÂÁ±z §Ṳ́@°_·í¯E¹©ªºªÑªF ¦n¶Ü? :) |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/17 ¤W¤È 11:06:58²Ä 2643 ½g¦^À³
|
Yun ¤j «D±`»{¦P±zªº¬Ýªk Æg |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/17 ¤W¤È 10:57:40²Ä 2642 ½g¦^À³
|
Pharmacyclics³Â³¶ÅÜ»ñ°Äªº¬G¨Æ http://m.biodiscover.com/news/company/149786.html ¦p¦P¯E¹©¤@¼Ë¡APharmacyclics¦P¼Ë¤]¬O¤@®a´¿¸gn˳¬ªº¤½¥q(¤£µM¼í®õ«ç»ò·|¦³¾÷·|¥H¨CªÑ1¬ü¤¸¦¬ÁʳпìªÑªF¤â¤¤ªº«ùªÑ?) ¦p¦P¯E¹©¤@¼Ë¡APharmacyclics´¿¸g¥H«Ü¤pªº¥N»ùÁʱo«á¨Ó¤j¼´¤@µ§ªºImbruvica·sÃĬãµoÅv§Q (¦pªG¦h¦~¥H«e¡AMemorial Sloan-Kettering Cancer Center(MSKCC)ªº¬ãµo¦¨ªG¯à³Q¬Ý±o¤W¡A«ç»ò½ü±o¨ì¸êª÷¹ê¤O¤£¨¬ªº¯E¹©¨ú±o±ÂÅv?) ¦h¦~¥H«e¡A¨S¤H¬Ý±o¤WMSKCCªº¬ãµo¦¨ªG¡A¥Dn¬O·í®É¦hÁÞÅ骺¦X¦¨¦¨¥»¬O¤Ñ»ù(¦X¦¨¹Lµ{»Ýn1~2¦~)¡A§¹¥þ¤£¨ã³Æ°Ó·~¤Æªº»ùÈ¡A¥u¦³¾Ç³N¬ã¨s»ùÈ ¦ý¡A¯Î±Ò´f¦¦b30¦~«e¡A´N§ë¤J«D±`§Nªùªº¦hÁÞÅ骺¬ã¨s¡A¨Ã³Ì²×¨ú±o¬ð¯}©Êªº¬ã¨s¦¨ªG¡A¤j´T«×ÁYµu¦hÁÞÅ骺¦X¦¨¤èªk¡A³o¤~ÅýMSKCCªº¬ãµo¦¨ªG¦³¤F°Ó·~¤Æªº¥i¯à ¼í®õ¶°¹Î¦b¥Í§Þ¤è±§ë¸ê¦³©Ò¦¨ªG¡A¦Ó¯à¥Î«Ü§Cªº»ù®æ±q¯E¹©ì©lªÑªF¦¬ÁÊ¡A®£©È´N¬O¦]¬°»{ÃѯαҴf¡A¦Ó¬Ý¥X¯E¹©ªº¼ç¤O¡A¤jµ§¸êª÷»P¸ê·½ª`¤J¡A³o¤~¶}ªáµ²ªG ¯E¹©¯à¨«¨ì²{¦b¡A¬O¦³¦hºØ¦]¯Àªº²Õ¦X¡A¨Ã¤£¬O¨º»ò®e©öªº ¤]´N¬O¡A¦pªG·sÃĬãµoªºªì´Á´N«Ü¶¶§Q¡A®Ú¥»¤£¥i¯à¦³¾÷·|§C»ù¨ú±o±ÂÅv¡A¥xÆW°]¹Î¸ò¥»¤£¥i¯à¦³¹ê¤O¥h§ë¸ê¡A¯à®³¨ìªº¤j¦h¼Æ³£¬O²@µL°Ó·~»ùÈ ©Ò¥H«Ü¦hªÑ²¼¦Ñ®vÁÙ¹ª§j§ä¥X¤°»ò¯E¹©²Ä¤G¡A¸ò¥»¬O®`¤H ²³æÁ¿¡A¥xÆW§ä¤£¨ì©Ò¿×ªº¯E¹©²Ä¤G¤F¡A´N¹³¥x¿n¹q¬O°ß¤@ªº ±N¨Ó¯E¹©´N¹³¥x¿n¹q±a°Ê¤FÃe¤jªº¥b¾ÉÅé²£·~¤@¼Ë ¦ý¡A¨s³º¯E¹©¯à¤£¯à¦¨¬°¥x¿n¹q²Ä¤G¡A´N¬Ý¼í®õ¶°¹Î¯à¤£¯à¸g±o¦í°ê»Ú¤jÃļt¥X·¥°ª»ù®æ¦¬Áʪº»¤´b¡A¤S©Î¬O¦¬Áʱø¥ó¬OnÅý¯E¹©®Ú¯d¥xÆW §è»·¤F¡A¤Ï¥¿¤£½×¦p¦ó¡A·í¯E¹©ªºªÑªF¤£·|¦YÁ«ªº ¯E¹©©Ò±a¨Óªº¼vÅT¤£¥u¬OªÑ»ù¤jº¦¡A¦Ó¬O¼vÅT¥xÆW¥¼¨Ó30¦~ªº²£·~µo®i¡A¬Æ¦Ü¬O¤HÃþ§ÜÀùªº¾ú¥v ¥u¤£¹L¡A¼vÅT¥xÆW¥¼¨Ó30¦~ªº²£·~µo®i¡A¬Æ¦Ü¬O¤HÃþ§ÜÀùªº¾ú¥v¡AÁÙ¯à¤À¨É¨ìÅå¤Hªº¸gÀÙ¦^³ø¡A¤£¬O§ó¬ü§®? |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/17 ¤W¤È 10:19:08²Ä 2641 ½g¦^À³
|
«ö·ÓÁú¬üÃÄ«~(Hanmi Pharm)ªºªÑ»ù¨«¶Õ(¦p©³¤U)¡A¥ý¦b¾Ç³N·|ij³õ¦Xµoªí¦¨ªG«á¡AªÑ»ù¥u·|¥ýº¦¤@¤p¬q¡AÀH«áÀò§Q¤F¸Ñ½æÀ£¥XÅ¢¡AªÑ»ù¤p´T·Æ¸¨ (¤]´N¬O¤µ¦~6~7¤ë·|¦A¦³¤@ªi¤ñ¸û©úÅ㪺¤U±þ) http://www.bloomberg.com/quote/128940:KS ¦ý¦b¥b¦~«á¡A¦¨¥\±ÂÅv¡A®³¨ì²Ä¤@±íª÷¡AªÑ»ù´N·|½¿¤Wº¦ ¦ý¡A¯E¹©ªºªø´Á¨«¶Õ±N·|§ó¹³¬OPharmacyclics, Incªº¨«¶Õ¡A³Ì«á³Q°ê»Ú¤jÃļtAbbVie¥H210»õ¬ü¤¸²{ª÷¥[ªÑ²¼¡]¨CªÑ261.25¬ü¤¸¡^¦¬ÁÊ https://www.google.com/finance?cid=658410 ¦]¬°¦p¦PPharmacyclics¾aµÛ³æ¤@Áûn®³¨ì3±iÃÄÃÒ ¯E¹©ªº¦hÁÞÅé°»´ú¨Ã®ø·ÀÀù²ÓMªº§K¬ÌÀøªk¡A¨ä¹ê¤£¶È©óªvÀø¨ÅÀù¥½´Á(·|¥ý¿ï¨ÅÀù¡A¬O¦]¬°¤ñ¸û®e©öÀò¨úÅå¤HÀø®Ä¡A¨Ã§Ö³t®³¨ìÃÄÃÒ)¡A¦Ó¥i¯à¥i¥HªvÀø¦h¹F16ºØÀù¯g ¤]´N¬O¡A®³¨ì²Ä¤@±iÃÄÃÒ«á¡A¨Ã¦¨¥\±ÂÅv¥X¥h¡A¨Ã¤£·|§Q¦h¥XºÉ¡A¦Ó¬O¤@³s¦ê§Q¦hªº¶}©l¦Ó¤w! ¦]¬°¥un®³¨ì²Ä¤@±iÃÄÃÒ«á¡A¹ê»Ú³c°â¡A¨Ã¦¨¥\ªv¡¥H«eÃøªvªº¨ÅÀù¥½´Á¡A¥²©w¤ÞµoÂåÃĬɪº¾_¾Ù µM«á¡A¯E¹©´N«Ü®e©ö¨ú±o¨ä¥LÀù¯gªvÀøªº¤HÅé¹êÅç¸ê®æ¡A¦P®É¥u»Ýn§@¤ñ¸û¤p³W¼Ò¡A¦Ó¥i¥H§Ö³t®³¨ì§ó¦h±iÃÄÃÒ ³Ì²×¡A¦]¬°¯E¹©ªº«e´º¤ÓÅå¤H¡A¼ç¤O¤Ó¤j¡A°ê»Ú¤jÃļt¥Í©È¥¼¨Óªº¥«³õ³£³Q¨ä¥LÄvª§ªÌ·m¨«¡Aª§¥ý®£«áªº¥XÅå¤H°ª»ùn¶R¤U¯E¹©»P¨ä¥¼¨Ó§ó¦hºØÀù¯gÃĪ«ªºÅv§Q! ¥ú¥u¬O¾a·Q¹³¡AªÑ»ù´N¤£ª¾¹D·|¼Q¨ìþ¸Ì¥h µM¦Ó¡A«o¦³¤H¼g¤å³¹ÄU¤j®a¤£n°l°ª¡A¦P®ÉÁÙ«o¤j®a¥ý½æ¤@¥b??? ªÑ¥«¦Ñ®vÁÙ«Ü¡y¦n¤ß¡z´£¿ô¯E¹©ªº¡y·ÀI¡z¡A¦P®É¤S«´£°ò¨È¨Æ¥ó??? §Ú¬Û«H¡A¼í®õ·|Ä~Äò¤ä«ù¯E¹©ª½¨ì³Q°ê»Ú¤jÃļt¦¬Áʪº¡A¨ì¨º®É«á¤~¬O©Ò¿×ªº¦¬³Î´Á |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/17 ¤W¤È 09:58:35²Ä 2640 ½g¦^À³
|
¦b2015¦~5¤ë29¤éASCO¦~·|µ²§ô«á´XӤ몺11¤ë23¤é¡A Áú¬üÃÄ«~(Hanmi Pharm Co Ltd)»P¤¤°ê¥Íª«ÂåÃĦA¹©¥ø·~¤½¥q(ZAI Lab)ñq§ÜªÍÀù·sÃħ޳N¡]HM61713¡^ÂàÅý¦X¬ù¡A¦X¬ùª÷ÃB³W¼Ò¹F9200¸U¬ü¤¸¡A³Ð¤UÁú°êÃÄ¥ø³æµ§¥X¤f¦X¬ùª÷ÃBªº³Ì°ª¬ö¿ý¡C http://ww2.money-link.com.tw/RealtimeNews/NewsContent.aspx?sn=833675002&pu=News_0001_1 |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/2/16 ¤U¤È 07:17:57²Ä 2639 ½g¦^À³
|
À°YUN¤jªº¤å¦r¤p¤p×¥¿¡G Áú¬ü»sÃĸ󨬸~½F»P¿}§¿¯f»â°ì »PÁÉ¿Õµáñ¬ù¬O°ò©ó2015¦~6/5~6/9ªº¿}§¿¯f·|ij¤Wªº³ø§i,¦Ó«DASCO³ø§i ÁÉ¿Õµá»P¿Õ©M¿Õ¼w¤@¦V¦b¦¹»â°ì¿E¯PÄvª§ÀsÀYÄ_®y American Diabetes Association (ADA) 75th Scientific Sessions 4 studies will be presented orally and other 7 studies will be presented on poster and paper |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/16 ¤U¤È 06:42:38²Ä 2638 ½g¦^À³
|
Yun¤j À³¸Ó»¡¬O¯E¹©¥[ªo¯¸³á Æg |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/16 ¤U¤È 05:34:02²Ä 2637 ½g¦^À³
|
¦b2015¦~5¤ë29¤éªºASCO(¬ü°êÁ{§É¸~½F¨ó·|)¦~会¤W¡A韩¬ü»sÃĤ½¥¬¤FHM61713ªºI/II´Á临§É试验¤¤´Á数Õu¡A结ªGªí©ú该药ª«¦b¦³®Ä©Ê©M¦w¥þ©Ê¤è±§¡ªí现¥X¦â¡C http://www.bioon.com/3g/id/6675384/ ¦b2015¦~5¤ë29¤éASCO¦~·|µ²§ô«á´XӤ몺11¤ë¡A韩¬ü¨î药获±oªk°êÁÉ¿ÕµáÃļt¡]Sanofi¡^4亿¬ü¤¸预¥I´Ú©M°ª达35亿¬ü¤¸ªº开发¡B监ºÞ©M销°â¨½µ{¸O´Ú项¡A¦}获±o°ª达净销°â额2¦ì数ªº´£¦¨¡C http://news.bioon.com/article/6674354.html ¤]´N¬O»¡¡A¯E¹©Y¯à»°¦b¤µ¦~5¤ëASCO¦~·|¤WµoªíÅå¤Hªº¦¨ªG¡A«Ü®e©ö¦b¤µ¦~¤º´N§l¤Þ¨ì°ê»Ú¤jÃļt¡A´£¨Ñ¤jÃBªº¹w¥I´Ú¡A¦bÁÙ¨S®³¨ìÃÄÃÒ¡AÁÙ¨S¶}©l½æÃÄ¡A´N¥ýÁȤ@¤jµ§¿ú ±i©À·O¦³¹L·sÃĬãµoªº¦¨¥\¸gÅç¡A«Ü¼ô±x¬ü°ê·sÃĹCÀ¸³W«h¡A¥L¤@©w«Ü²M·¡ª¾¹D¦p¦ó´À¯E¹©ª§¨ú¨ì³Ì¤jªº¸ê·½»P§Q¯q |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/16 ¤U¤È 05:01:58²Ä 2636 ½g¦^À³
|
¦³¤HÁÙ¯S§O¼g¤å³¹ÄU´²¤á¤£n¥h°l°ª¯E¹©¡A¬Æ¦ÜÁÙÄU¥ý¥X¤@¥b¡A³o¤£Â\©ú¦¹¦aµL»È¤T¦Ê¨â¡H ¥ý»¡¤£n°l°ª¡A´N¥NªíÄU¤j®a§O¶R¡A¬JµM®Ú¥»¨S¶R¡A¦ó¨Ó¡y¥X¡z¤@¥bªº»¡ªk¡H ¨ä¹D²z¦b©ó¡A«ù¦³¯E¹©ªºªÑªF¤H¼Æ¶V¦h¡A¥D¤O´N¶V¤£®e©ö¶°¤¤¤O¶q©Ô©ïªÑ»ù¡A©Ò¥H»Ýn³z¹L´CÅéÁקK´²¤á¤H¤â¤@±i¡A¦P®É³z¹L¦b¥«³õ¤¤¬G·NÄé±þ¡A¼W¥[¡y·ÀI¡z¡A»¡ªA´²¤á§O¶Rªº»¡ªA¤O |
|
|
·|û¡GYunYunHome10141776 µoªí®É¶¡:2016/2/16 ¤U¤È 04:56:13²Ä 2635 ½g¦^À³
|
¯E¹©¨ä¹ê¤w¸g¦¨¥\¡A¥u¬OÁÙ»Ýn§ó¦h¾÷ºc¡B±M®a¨Ó±¾«OÃÒ¡A¤~·|Åý§ó¦h¤H¬Û«H¯E¹©ªº¦¨¥\ ¦Ü©ó¬°¤°»ò§Ú´±Á¿¯E¹©¤w¸g¦¨¥\¡A¯A¤Î¨ìÃÒ¥æªk¡A¤£¯àÁ¿¤Ó¦h Á`¤§¡A¼í®õ¶°¹ÎÁ`µô¤¨l¼Ù´¿Á¿¹Lªº¡u¥Í§Þ²£·~«e´º«Ü¦n¡A¦ýÁÙ¤£¨ì¦¬³Îªº®ÉÔ¡A¡]¦n®É¥ú¡^¤~èè¶}©l¡v ¯uªºn¬Û«H¡A¥L·íµM¬Oª¾±¡¤H¤h¡A¦ý¤£¯àÁ¿¤Ó¦h ¥u¬O§â¥Í§Þ§ï¦¨¯E¹©´N¬Ý±o§óÀ´¤F? «Ü¦h¤H³£¥H¬°¯E¹©ªÑ»ùªºº¦¶Õ¬O¼í®õ¶°¹Îª£¥X¨Óªº¡A¦ý¼í®õÁÙ¦b¡y§C»ù¡z(¦pªGªÑ»ùÁÙ¥i¥H¦Aº¦¼Æ¿¡A²{¦b³£ÁÙ¬O§C»ù)®ÉÀqÀq¦Y³f¡A¤]ºâ¬Oª£ªÑ²¼¶Ü¡H |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/2/15 ¤U¤È 09:34:41²Ä 2634 ½g¦^À³
|
ÁÂÁ¤p©_¤j,·P®¦ |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/2/15 ¤U¤È 08:32:36²Ä 2633 ½g¦^À³
|
¤p©_¤j·PÁ±z~ |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/2/15 ¤U¤È 08:26:26²Ä 2632 ½g¦^À³
|
¤p©_¤j~~~ ¦³±z³o¥y¸Ü¯E¤ÍÌ«H¤ß¤Q¨¬ |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/2/15 ¤U¤È 06:44:44²Ä 2631 ½g¦^À³
|
¤p©_¤j ¦³¦p¦Y©w¤ß¤Y ·PÁ¡I |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/2/15 ¤U¤È 06:35:33²Ä 2630 ½g¦^À³
|
¤p©_¤j ¹L¦~´Á¶¡ÁÙ³Ò¤ß³Ò²Ö ´À¯E¤Í̱Àºâ¼ÆÈ «D±`·PÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/15 ¤U¤È 06:22:17²Ä 2629 ½g¦^À³
|
ÁÂÁ¤p©_¤j¡I·P®¦¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/2/15 ¤U¤È 06:04:04²Ä 2628 ½g¦^À³
|
ÁÂÁ¤p©_¤j¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/2/15 ¤U¤È 05:58:10²Ä 2627 ½g¦^À³
|
¦U¦ì¤j¡A ·Ç³Æ¶}¶}¤ß¤ß¨Óªï±µ¸Ñª¼ªº«Å§i§a ³ÌºC´N2/26 ¹L¦~ªø°²´Á¶¡ ¤p§Ì¤w¸g¥Î¸Ñª¼®É©Ò¥Îªº²Îp¤èªk§âPȪº¥i¯à©Êºâ¹L¤F ¤£·|¦³¥O¤H¥¢±æªº·N¥~¥X²{ªº ¦ýpºâªº¤èªk¦³ÂI½ÆÂø ¦pªG¤½¥q¸Ñª¼«Å§i®Éªº¼Æ¾Ú©Î¤å¦r¦]¬°°Ñ¥[ASCOªº¦]¯À¤£¯àÁ¿±o¤Ó²M·¡ »Ýnªº¸Ü ¤p§Ì¦A·Q¿ìªk§â¼Æ¾Çªºpºâ¦¡§e²{¤W¨Ó¨Ñ¤j®a°Ñ¦Ò |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/7 ¤U¤È 12:31:57²Ä 2626 ½g¦^À³
|
¤p©_¤j¡A ¦hÁ¤F¡I |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2016/2/6 ¤W¤È 09:49:42²Ä 2625 ½g¦^À³
|
ÀH¤f»¡»¡,¤FµL·s·N,¾Ô°«¤O0. Á¿ªº³£¬O§O¤Hªº¹L¥h¸ò²{ªp,»P"Å¥»¡",¦Ó«D¯E¹©§Þ³N¦b¥¼¨Ó¹ï¾ãÓ²£·~ªº¥i¯à¼vÅT,©Ò¥H´N¤£¶K³sµ²¤F... ÁÙ¦³¿³½ì,´N¸ò§Ú¤@¼Ë¦Û¦ægoogleÅo. "ptt ¯E¹© 2016¦~1¤ë¦X¨ÖÀ禬¸U¤¸" |
|
|
·|û¡G¸¯T10140363 µoªí®É¶¡:2016/2/6 ¤W¤È 12:49:44²Ä 2624 ½g¦^À³
|
Mr¤j¡A¥LÌ»¡ªºÀYÀY¬O¹D¡H¤£§«§â»¡ªk¶K¥X¨Óµ¹¤j®a¬Ý¬Ý°Q½×¡A´N¥i¥Hª¾¹D¬O§_¯uªºÀYÀY¬O¹D¤F~ |
|
|
·|û¡G¤s¤¤10141474 µoªí®É¶¡:2016/2/5 ¤U¤È 09:23:25²Ä 2623 ½g¦^À³
|
Mr¤j±z¦n ¤p§Ì¤]¤~¥[¤J¥»ª©¤£¨ì´XӤ몺®É¶¡¡A¦ýÂsÄýª©¤W¤å³¹¤w¦h¦¸¡A¦³¤FÆZ¤jªº«H¤ß¡A±z·|³o¼Ë°Ý¬Û«H±z¤â¤WÀ³¸Ó¤]¦³«ùªÑ¡A«Øij±z©¹¤U¦A¦h¾\Ūª©¤W½Ñ¦h¤j¤jªºµo¤å¡A¤p§Ì¥u¯à¥H¯«¤H¯Åªº±M·~¨Ó§Î®e¡A¬Û«H¯à¹ï±z¦b¸Ñª¼«e¨M©wn¤£n«ù¦³¯E¹©¦³«Ü¤jªºÀ°§U. ¯¬ºÖ±z¡A·s¬K´r§Ö¡AµU¦~¤j¦N |
|
|
·|û¡GMr.10022347 µoªí®É¶¡:2016/2/5 ¤U¤È 09:05:02²Ä 2622 ½g¦^À³
|
¤£¦n·N«ä·Q½Ð±Ðª©¤W¤j¤jÌ §Ú¬Ýptt¤WÀY¦³Ãö[·s»D] ¯E¹© 2016¦~1¤ë¦X¨ÖÀ禬¸U¤¸ ¦~¼W999999ªº°Q½×¥H¤Î¦^À³ µo²{¤j¦h¼Æ¤H¤£¬Ý¦n¯E¹©ªº¸Ñª¼ ¦Ó¥B¥L̤]»¡±oÀYÀY¬O¹D «Ü¾á¤ß³o¦¸ªº¸Ñª¼·|¤£·|¤S¹³¤W¦¸ªº°ò½E¯ë ±N¥Í§Þ·sÃÄÃþªÑ¥´¤J¸U¤V²`²W ¤£ª¾¹D³o¸Ìªº¤j¤j̦p¦ó¬Ý«Ý§Y±N¨ì¨Ó¤§¯E¹©¸Ñª¼¡H¡H¡H ²{¦b°w¹ï¥Í§Þ·sÃĦü¥G¶i°hºû¨¦ ÁÂÁ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/5 ¤U¤È 05:44:26²Ä 2621 ½g¦^À³
|
ÃÙ¦¨¤½¥D¤jªº¨£¸Ñ ¤p§Ì°ápsy ¤£À´ÂåÃÄ ¦ý¬O¤ÀªR±i±Ð¥Dªº¨¥½× »P¦^°ê°^Äm¤ßºA ½T¹ê¬O¬°¤F±N¯E¹©±À¦V°ê»Ú ¦b¥ú©ú¹©¤W ¾_¾Ù¤E¤jªù¬£ |
|
|
·|û¡G¤½¥D©@°Ø10141343 µoªí®É¶¡:2016/2/5 ¤U¤È 03:01:19²Ä 2620 ½g¦^À³
|
¯E¹©¨ÅÀù·sÃįà§_§l¤Þ¿WÅQ¥«³õù¤ó²´¥ú¦¨ÃöÁä ¬ü°êÁ{§É¸~½F¨ó·|¦~«×·|ij¦³¦h«n¡HÁú¬ü»sÃĪº¿}§¿¯fÃĦ]¬°°Ñ¥[¤F·|ij¡A¤Þ¨ÓÁÉ¿Õµá¤T¤»õ¬ü¤¸ªº±ÂÅvª÷¡F¯E¹©´£«e¸Ñª¼ªº¯u¥¿¥Î·N¬°ªº´N¬O³oÓ¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/2/5 ¤U¤È 02:59:25²Ä 2619 ½g¦^À³
|
¥xÁÞ¤j¡G ´L·q¶Õ¥²±q©R... ®a¤÷¤@¥ÍÄY¼F¥ç°V»|¡A¦uÅ@¯E¹©¤@¤ÁÅ¥±z±Ð¾É¤£±o³y¦¸¡C µL½×ºÖº×¦Û¦³¨ä©R¦Û¦³¨ä³d¡A¬O©Ó¨ü¬O¨É¨ü³£¤£±o³y¦¸¹ï±z¥¢·q³y¦¸¡C ÁÂÁ±zªº«ü¥Ü¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/5 ¤U¤È 02:09:15²Ä 2618 ½g¦^À³
|
999¤j §Ú¥u¬O¤@¦W¤p¤p§ë¸ê¤H,¥O´L ¤¤¹D¤j«e½ú§ë¸ê¸gÅçÂ×´I,¹ï§ë¼Ðªºªº¿ï¾Ü¦Û¦³¨ä¿W¨ìªºÆ[ÂI ,¥O´L¹ï§Aªº´Á¬ß¤]¬O¦U¦ì¤j¤j¦@¦Pªº´Á¬ß»P§ë¸êµ¦²¤,¤¤¹D¤j«e½úªº¸gÅç¬OµL»ù¤§Ä_,¤]¬O§Ún¾Ç²ßªº¦a¤è ,§Ú°O±o¥h¦~6¤ë¥ª¥k ¥O´L ¤¤¹D¤j«e½ú¦³¶K¤å¤À¨É, ¥i¯à¬O¨º®ÉԦ污§C°g ,§Ú¨S¦³¦]¦æ±¡§C°g§ïÅܧڹï¯E¹©ªº«H¤ß ¯à±o¨ì¥O´Lªº»{¦PÓ¤H²`·P°ª¿³! ¯à¤£¯àºÙ©I§Ú¥xÁÞ¤j¤ñ¸û¦ÛµM §Ú¤~©Ó¨ü±o°_! ¦b³o·³¥½®É¨è¦P¼Ë ¯¬ºÖ 999¤j·s¬K§Ö¼Ö,ºÖ³øº¡º¡ Âó®a¥¦w¦p·N¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/2/5 ¤U¤È 01:29:45²Ä 2617 ½g¦^À³
|
¥xÁÞ¤j®v´L¦Ñ®v {¦ò¤ß¦p¨Ó}¯uªº¦b¥@... {¦ò¤ß¦p¨Ó}¯uªº¦b¥@... {¦ò¤ß¦p¨Ó}¯uªº¦b¥@... ³o¤@½ú¤l¯uªº«ô¨£¨ì¤F¡A¯uÀ³ÃÒ¤F¦òÁô©ó¥@ ¬¡¦b¥@¶¡©~µM¦³¦¹ºÖ®ð ......¦A¦hªºÄß³£¤Æ¬°ºÖ... ...... ¬O®a¤÷©óÂå°|®É¤´¨C¤é«ôŪ±zªº±Ï¥@¤å®É¡A¸g±`ªº¦Û»y... ¤]¤@¦AªºÄY°V§Ú¡An¦æ¤d¨½¸ô¦uÅ@¯E¹©¥²µMn¦b¥¼¨Ó¤é¤é¤ß¦s·q·Nªº«ôŪ¥²´Iºô¨ú¸g²ß¤§¡C ´¿¹w´ú¥²´Iºô¥²µM·|¦³¶V¨Ó¶V¦hªº¯«¤H²§¤h¡A¦b{¦ò¤ß¦p¨Ó}·P¥l¤§¤U¸s»E¦Ó¨Ó... §Ú¥u¯à«ôŪ²ß¤§¤£±o³y¦¸µo¨¥¡A¥H°@¸Û¤§¤ß§V¤O²ß¤§...¶Õ¥²¾ÖºÖ...µ¥µ¥ ¡K¡K¡K³o¬q¤é¤l¿í¦u®a¤÷¿ò°V¡A¶V¨Ó¶V©ú¥Õ®a¤÷©Ò¨¥¬O¦ó´º... ¶V¨Ó¶V©ú¥Õ®a¤÷Á{²×¬O¯uªº·NÃѤ´²M¿ô... ·PÁ®v´Lªº¦uÅ@...·P©À®a¤÷ªº±Ð¾É... ·PÁºô¤W½Ñ¦hµÐÂÄ¡A¯«¤H¤é¤é¦h¤¸ªº±Ð¨|»P¦uÅ@¡C ²`¨è²`«×ªº¤TÁù°`¡AÁÂÁ¡A¦A¥nºªºÁÂÁ±z̤@¦~¨ÓªºÅ@«ù¡C ¬èÄ@¥Í¥Í¥@¥@ºÖ³ø»P±zÌÀH¦æ¡C ¥xÁÞ¤j«e½ú ®¥·qªº¯¬ºÖ±z·s¬K§Ö¼Ö¡A¦~¦~¨Åé±d®õ¡A¼u«üÀÙ¤H¬yºZ¦Û¦b¡A´I¡AºÖ³øº¡º¡¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/2/4 ¤U¤È 04:20:15²Ä 2616 ½g¦^À³
|
¹x¥Û¤j¡A ¯u©êºp¡Acopyºô§}®É«á±¦³¨âӼƦrº|±¼¤F ¥H¤U¬O¥¿½Tªº¡G http://www.ncbi.nlm.nih.gov/pmc/articles/PMC403858/ ½Ð°Ñ¦Ò¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/4 ¤U¤È 02:41:01²Ä 2615 ½g¦^À³
|
²q·Q¤j¡B¤p©_¤j¡A ·Q¬Ý¬ÝPȪºpºâ¨Ò¡C¥i¬O¿é¤J¤U±ºô§}ªº¦^À³¬O Page Not Found, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038 ³Â·Ð±z¦³¨ä¥L¸ê°T¨Ó·½¥i¥H¤¶²Ð¶Ü¡H |
|
|
·|û¡GªÑ¥«¦W®·10141738 µoªí®É¶¡:2016/2/3 ¤W¤È 08:19:09²Ä 2614 ½g¦^À³
|
°ò¥»¤W¦]¬°¥xÆW·sÃĸ}¦âÁÙ¨S¦³¯à¯¸¨ì°ê»Úªº¤j¸}¦â ©Ò¥H¥L®Ú¥»¤£¬Ýtfda ¥u¬Ýfdaµ²ªG°ò¥»¤W¥~¸êÁÙ¬Oµû¦ô¬ü°ê¶i«×¬°¥D ¥BÀ³¸Ó¬Ý¤£°_¥xÆW³o¤p¨¤¦â ©Ò¥Hµû»ù¯uªº»Ýµ¥¨ì°ê»ÚASCOµoªí«á¤~¦³¾÷·|±o¨ìÃöª` ¯E¤Í¥ý´Á«Ý¸Ñª¼¹LÃö ¥B»¡¯uªº°Õ¤£¤Ó¥i¯à¬ü°êª½±µ®³ÃÄÃÒ§O§â822·í¯«ÃÄ Y¯uªº¼Æ¾Ú°÷¦n·í¦¨¾ß¨ì |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/2 ¤U¤È 09:37:29²Ä 2613 ½g¦^À³
|
¤p©_¤jªºµ²½×¬Ý¦ü¥²HµL©_¡A«o¤@»y¹DºÉ¡C ÁöµM¯E¹©±q¥¼¤½¥¬¥»¦¸Á{§É¤¤©Ò¦³¨ü´úªÌ¹ïGlobo H ªº¤ÏÀ³¤ñ¨Ò¡A¦ý¬O±qLR¨Ã¥¼©ó2015¦~3¤ë¯}ªíªºµ²ªG¨Ó¬Ý¡A¨ü¸ÕªÌ¹ï©óGlobo H ªº¤ÏÀ³²vÀ³¸Ó°ª©ó80%¡C³o¤]¹ï¥¼¨Ó822ªº¥«³õG¯Ç¶q´£¨Ñ¤F¤@Ó¦ôpªº°Ñ¦ÒÈ¡C ¦hÁ¡I ¦hÁ¡I ¦A¦hÁ¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/2 ¤U¤È 08:43:48²Ä 2612 ½g¦^À³
|
¦U¦ì¤j¤j ©ú¤Ñ´Nn«ÊÃö¤F,·PÁ¦U¦ì¤j¤j±q¤£¦P±¦V´£¨Ñ¯E¹©²£«~¬ÛÃö¸ê°T,Ó¤H¨ü¯q¨}¦h,·PÁ¤j®a ¯¬ºÖ¦U¦ì¤j¤j¤þ¥Ó¦~¦æ¤j¹B ¤p©_¤j:ÁÂÁ¸Ѵb Faith ¤j: ©Ô©Ô¶¤ªø«D§A²öÄÝ ¤º¥\²`¤£¥i´ú ¥H¤U¬O¾ã¦XÓ¤H¤µ¤Ñ¶K¤å¥[¥H×¥¿«á ¦X¬°¤@ ¯E§J¤j pie ¤j 1§AÌ»¡ªº¨S¿ù ¨ÅÀùOBI822 ¬O»P¹ï·Ó²Õ¬I¥´ªº cyclophosphamide ¨Ó¶i¦æ¤ñ¸û 2¦]¬°ÁÞ¤À¤l·sÃĦpªG³Q®Ö㪺¸Ü,¦o¬O¥þ²y²Ä¤@Áû¥Î¦b¨ÅÀùªºÃĪ«,¥H«e¨S¦³¬Û¦P¾÷¨îªºÃĪ«¤W¥«,¦b¨S¦³¥ô¦óBenchmark±¡ªp¤U¯E¹©¥ÎSurrogate ´À¥N²£«~Herceptin ªºÀø®Äªí²{¨Ó°µ Benchmark (°ò·Ç) 3Ó¤H»{¬°¬ü°êFDA ¹ï¤W±1 2 ¨âÂI»P¨ä¥L¯à¦Ò¼{¨ìªº¦]¯À³£·|¶i¦æ¥þ±ªºµû¦ô 4¥x¤jÁ{§É¤¤¤ß³¯¥D¥ôªº³X°Ý´£¨ìªº°ò¥»Æ[©À Åý§Ú·Q¨ìYK3 (p value ®t¤@ÂI >0.05)¡A822¦]¬°¬O·sÃÄ¡A°Æ§@¥Î§C¡A°²¦p¦³¤@©wªºÀø®Ä¬ü°êFDA¤]·|¦³±ø¥óµ¹¤©®ÖãÃÄÃÒ¡A³o¬O822³Ì®tªº±¡ªp¡C(YK3 ¨ä¹ê¬O«O¥¦wªºÅ@¨²Å) 5³¯¥D¥ô³X½Í´£¨ìªº: P¡Õ0.05¬O«ü¦s¬¡´Á©µªø¤F50¢H¡APȬO«n¼Æ¾Ú¡A«o¤£¬O°ß¤@¼Ð·Ç¡A¬ü°êFDA«Ü¤Ö³æ¿W¥Î¤@Ӽƾڨӻ{¥i¡C(¦s¬¡´ÁÀ³¸Ó¬O«üPFS) ( ½Ð·j´M:Á{§É¼Æ¾Ú¤½¥¬ ¤£¬O¤@½¨âÀü²´) Ó¤H¸ÑŪ¦p¤U: A¹êÅç²ÕªºPFS¹ï¤ñ¹ï·Ó²ÕªºPFS ©µªø¤F50¢H °²³]¹ï·Ó²ÕªºµL¯e¯f´c¤Æ¦s¬¡´ÁPFS¬O6Ó¤ë ¹êÅç²Õ¬O9Ó¤ë ´N²Å¦X¹w´Á P¡Õ0.05 (YK2) °²³]¹ï·Ó²ÕªºµL¯e¯f´c¤Æ¦s¬¡´ÁPFS¬O5.8Ó¤ë ¹êÅç²Õ¬O8.7Ó¤ë ´N²Å¦X¹w´Á P¡Õ0.05 (YK2) B¹êÅç²ÕªºPFS ¹ï¤ñ¹ï·Ó²ÕªºPFS ©µªø¤F100¢H °²³]¹ï·Ó²ÕªºµL¯e¯f´c¤Æ¦s¬¡´ÁPFS¬O6Ó¤ë ¹êÅç²Õ¬O12Ó¤ë ¶W¹L¹w´Á P¡Õ0.001 ©Î P¡Õ0.0001 (YK1) °²³]¹ï·Ó²ÕªºµL¯e¯f´c¤Æ¦s¬¡´ÁPFS¬O5.8Ó¤ë ¹êÅç²Õ¬O11.6Ó¤ë ¶W¹L¹w´Á P¡Õ0.001 ©Î P¡Õ0.0001 (YK1) 6¤£½×¨ÅÀùOBI822¸Ñª¼µ²ªG¬O YK1 ©Î YK2 ³£¨¬¥H¾_¾Ù¥þ²y ( §Ú¥HYK2¬°¥Ø¼Ð) ¦U¦ì¤j¤j¤w¦³¥´¬Ì]¨Ã¤w²£¥Í§K¬Ì¤O¤F,¹ï©ó¸sÅ]¶Ã»Rªº¸ê°T ¤ß¤¤¦¦³©w¨£ ťť¯º¯º´N¦n ¥H¤WÓ¤H¬Ýªk ¶È¨Ñ°Ñ¦Ò °ö¾i¿W¥ß«ä¦Ò¯à¤O §ë¸êª`·N·ÀIºÞ±± |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/2/2 ¤U¤È 07:53:20²Ä 2611 ½g¦^À³
|
¤p©_¤j ÁÂÁ±z¡I ¤]¹ï¡AYµL®Äªº¤ñ¨Ò¦û40-50%¡A À³¸Ó¦´N¥i¥H¸Ñª¼¤F¡A¤]¤£»Ý§ï¦¨LR¤F¡I ªGµM¤p©_¤j¼F®`¡AÁÂÁ±z¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/2/2 ¤U¤È 06:56:42²Ä 2610 ½g¦^À³
|
Faith¤j¡A¹x¥Û¤j¡A²³¤j¤j ¡y¦pªG233¦ì¹êÅç²Õªº¯f¤H·í¤¤¦³20/30/40%¯f¤H¤£±a¦³Global H ®É¡A¹ïPFS©Î¬OPȪº¼vÅT¦³¦h¤Ö¡z ¹ïPFSªº¼vÅT¥i¥H°Ñ¦Ò ·|û¡G¤p©_10138298 µoªí®É¶¡:2015/6/15 ¤U¤È 02:05:37(¦b5112ª©) ³o¤@½g»P²q·Q¦Ñ¤j¤@°_°Q½×¥X¨Óªº¶K¤å¡C ²¦Ó¨¥¤§¡A822µL®Ä¤ñ¨ÒÀ³¸Ó¦b20%¤W¤U¡A30%¥i¯à¬O¤W¡AY¬O¨ì40%©ÎªÌ¸Ø±iªº50%¡A¨º»ò¦¹233¤H¹êÅç²ÕªºM PFS´X¥G¬O¥ÑµL®Äªº¨º40%©Î50%±wªÌ©Ò¨M©w¡A¥X¨ÓªºM PFS¼Æ¦rÀ³¸Ó¬O¤£¦n¬Ý¡A¦ý40%©Î50%µL®Äªº°²³]¡A·|¹H¤Ï187©M229³o¨âÓ¤wª¾ªº¼Æ¦r¡A©Ò¥H¤£·|µo¥Í¡C ¹ï©óPȪº¼vÅT¡A¤p§Ì¥uª¾¹DµL®Äªº¤ñ¨Ò¶V°ª¡Apºâ¥X¨Óªº¥d¤èÈ´N¶V§C¡A¤]´N¬OPȶV°ª¡A¦Ü©ó¼vÅT¨ì¤°»òµ{«×¡A¨S¦³¹ê»Úªº¼Æ¦r¡A¤p§Ì¤]¤O¦³¥¼¶e¡C PȪºpºâ¤½¦¡©M¨Ò¤l¦b ²q·Q¦Ñ¤j´£¨Ñªºhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038 ¥H¤W¨Ñ¤j®a°Ñ¦Ò¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/2 ¤U¤È 03:34:27²Ä 2609 ½g¦^À³
|
¯E§J¤j pie ¤j 1§AÌ»¡ªº¨S¿ù ¨ÅÀùOBI822 ¬O»P¹ï·Ó²Õ¬I¥´ªº cyclophosphamide ¨Ó¶i¦æ¤ñ¸û 2 ¦]¬°ÁÞ¤À¤l·sÃĬO²Ä¤@Áû¥Î¦b¨ÅÀùªºÃĪ«,¥H«e¨S¦³¬Û¦P¾÷¨îªºÃĪ«¤W¥«,¦b¨S¦³¥ô¦óBenchmark±¡ªp¤U ¯E¹©¥ÎSurrogate ´À¥N²£«~--Herceptin ªºÀø®Äªí²{¨Ó°µBenchmark (°ò·Ç) 3 Ó¤H»{¬°¬ü°êFDA ¹ï¤W±1 2 ¨âÂI³£·|¶i¦æ¥þ¤è¦ìªºµû¦ô |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/2/2 ¤U¤È 03:17:12²Ä 2608 ½g¦^À³
|
À³¸Ó¤£¹ï Âæ·|¥´¶Ã822ªº¥«³õ¥¬§½ «áÄò·|«Ü³Â·Ð ¤£ª¾¹D¤p§ÌJ¶Ã·Qªº |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/2/2 ¤U¤È 03:10:36²Ä 2607 ½g¦^À³
|
·Q·Q¤j ì¨Ó¬OÂæ°Ú ¤p§Ì¸£µ¬¤Ó¥Õ±q¥h¦~·Q¨ì²{¦b ¤@ª½·Q»¡¦ó¤£¯E¹©¦Û¤v¿ì³õ°ê»Ú°OªÌ·|¤½¥¬§¹¾ã¼Æ¾Ú~«¢«¢ ²×©ó¦³¸Ñ¤F ¦pªG¯à§ð¯}¶PÀù©Wªº25%¯f±w¦³®Ä³Ì¦n Y³Ì®t³Ì®tªº±¡ªp¥¤â ¦ý¯E¹©À³¸Ó¤]¥i®³¨ì75%ÂåÀø¥¼³Qº¡¨¬ªº¥«³õ ¤£ª¾Â檺Á¿ªk¹ï¶Ü? |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/2 ¤U¤È 02:57:26²Ä 2606 ½g¦^À³
|
Âd¶R¤¤¤ßªí¥Ü¡A¤WÂd¥Í§ÞÂåÀø²£·~®a¼Æªñ¦~¨Ó«ùÄò¦¨ªø¡A±¾µP®a¼Æ¥Ñ101¦~ªº43®a«ùÄò¦¨ªø¨ì¤µ¡]105¡^¦~1¤ë©³ªº67®a¡A¤j´T¦¨ªøªñ¤»¦¨¡C ¬°´£¤É¥Í§ÞÂåÀø«ü¼Æªº¯à¨£«×¡A¦Û¬Q¡]1¡^¤é°_¦bÂd¶R¤¤¤ß©xºô´£¨ÑÂd¶R¥Í§ÞÂåÀø«ü¼Æªº§Y®É¨«¶Õ¹Ï¤Î¾ú¥v¨«¶Õ¹Ï¡C Âd¶R¤¤¤ß«ü¥X¡A¥Í§ÞÂåÀø²£·~¤À¬°»sÃÄ¡]§t·sÃĬãµo¡^¡BÂåÀø¾¹§÷¡B¹«~¥Í§Þ¤Î¦A¥ÍÂåÀø¥|¤jÃþ¡AÂd¶R¤¤¤ßªº¥Í§ÞÂåÀø¤½¥q¦b«ez¥|¤jÃþ§¡¦³±Mºë¡A¨Ã¥B¾î¸ó¦U¤ÀÃþªº¤W¡B¤¤¡B¤U´å¡A¬O°ê¤º¥Í§ÞÂåÀø²£·~ªºÁY¤pª©¡A¨ä¤¤¦³14®a¤WÂd¤½¥q¤w³q¹L¸gÀÙ³¡®Ö©w¬°¥Í§Þ·sÃIJ£·~µo®i±ø¨Ò»{¥i¤§¡u¥Í§Þ·sÃĤ½¥q¡v¡AÂd¶R¥Í§ÞÂåÀø«ü¼ÆÀ³¨¬¥H§@¬°°ê¤º¥Í§ÞÂåÀø²£·~µo®iªºÆ[¹î«ü¼Ð¡C ¸Ó14®a¥Í§Þ·sÃĤ½¥q¡A¥]§t°ò¨È¡B¤¤¤Ñ¡B¤¤¸Î¡B¥x·LÅé¡BF*¤Ó´º¡B´¼Àº¡BÁÞÁp¡B¯E¹©¡B¦w¦¨ÃÄ¡B§ö°ê¡B¥Ã©ý¡BÂù¬ü¡B¦X¤@¡B¼w^µ¥¡C ¥HÂd¶R¥Í§ÞÂåÀø²£·~Á`¥«ÈÆ[¹î¡A104¦~©³Á`¥«È¹F5,881.82»õ¤¸¡A¸û«e¤@¦~«×ªº¦¨ªø´T«×°ª¹F42¢H¡A¥e¥þÅ饫Ȥñ«¤]©Ô°ª¨ì22¢H¡A¥Dnì¦]°£³°Äò¦³±Mªù¬ãµo·sÃĪº¦w¦¨ÃÄ¡]4180¡^¡B¯E¹©¡]4174¡^¤Î¤¤¸Î¡]4147¡^¥[¤J¥~¡A§óÅã¥ÜÂd¶R¥Í§ÞÂåÀø¥«³õ¤wÀò±o¦U¬Éªº«C·ý¡A¦]¦¹§l¤Þ³\¦h¨ã¦³¥Nªí©Êªº¥Í§Þ¤½¥q¨ìÂd¶R¥«³õ±¾µP¡C Âd¶R¤¤¤ßªí¥Ü¡A¬°´£¤É¥Í§ÞÂåÀø«ü¼Æªº¯à¨£«×¡A¦Û2¤ë1¤é°_¦bÂd¶R¤¤¤ß©xºô¡A´£¨ÑÂd¶R¥Í§ÞÂåÀø«ü¼Æªº§Y®É¨«¶Õ¹Ï¤Î¾ú¥v¨«¶Õ¹Ï¡A§ë¸ê¤H¥i¦bº¶ªº¡uÃÒ¨éÂdÂi¶R½æ¥«³õ¸ê°T¬ÝªO¡vªº¡u½L¤¤¨«¶Õ¡v¬d¸ß·í¤é½L¤¤¨«¶Õ¡A¥ç¥i¦b¡u¾ú¥v¨«¶Õ¡v¬d¸ß¤À§O¥H³Ìªñ¤@©P¡B¤ë¡B©u¡B¦~¬°°Ï¶¡ªº¾ú¥v¨«¶Õ¡A¥H´x´¤Âd¶R¥Í§ÞÂåÀø«ü¼Æªº³Ì·s°Ê¦V¡C £¸£¸£¸£¸£¸£¸£¸ ¤p§Ì¤S©ñ·¤F ¯E¤Í»ÝnÁA¸Ñ¹ï·Ó²Õ¥ÎÃĤ£¬O¶PÀù¥®@ |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/2/2 ¤U¤È 02:50:45²Ä 2605 ½g¦^À³
|
kokfish¤j, "§Ú̦A²Ó²Ó«ä¦Ò©Ò¿×¡y§CªÅ¸¹L¡zªºÆ[ÂI¡K ¹êÅçµ²ªG¡A¹L¬O¤ñ¶PÀù¥Àø®ÄÀu50%ªº·sÃÄ" ¯E¹©Á{§É¹êÅ窺¹ï·Ó²Õ¬O¬I¥´cyclophosphamide, ¤£¬O¶PÀù¥. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/2 ¤U¤È 02:34:10²Ä 2604 ½g¦^À³
|
3¯à°Ñ»P American Society of Clinical Oncology ¨Ã¨üÁܵoªí½×¤åªí¥Ü¦³¿W¯S«GÂI,¯à´£°ªÃn¥ú«×¤]¦³§Q©ó ¦X§@±ÂÅv©Îµ¦²¤Áp·ù 4 ¦³¦nªºÃĮĻP³Ð·s©Êªº¯SÂI¤~¬OÀò±o¼Ú¬üÃÄÃÒªººVªù¿j, ¦p¤S¯à°Ñ»P¥@¬É¤T¤jÀù¯g°ê»Ú·|ij, ·|¦¬ÀA¤W²Kªá¤§®Ä |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/2/2 ¤U¤È 02:22:45²Ä 2603 ½g¦^À³
|
ASCOªº°ò¥»Æ[©À 1¤½¥q§Æ±æ¥i¥H¨Ó±o¤Î°Ñ¥[©ú¦~¤T¤jOncology Meetings¡A¤À§G¦b6¤ë¡B9¤ë¡B12¤ë¡A ³Ì§Æ±æ¦b6¤ëªºASCO¡C»Ýn®É¶¡°µ·Ç³Æ»P¥þ²y¦³45ÓÁ{§ÉÂå¾Ç¤¤¤ßn±K¤Á°t¦X¤~±o¥H§¹¦¨¡C 2¬ü°êFDA ¨Ã¨S¦³§â°Ñ»PASCO·í¬°®³ÃÄÃÒªº¥²n±ø¥ó 6¤ë¨Ó¤£¤ÎÁÙ¦³9¤ë 3°Ñ»PASCO ¯à´£°ªÃn¥ú«×¦³§Q©ó¦X§@±ÂÅv©Îµ¦²¤ |
|
|
·|û¡G´µ¤p¤å10139040 µoªí®É¶¡:2016/2/2 ¤U¤È 02:20:01²Ä 2602 ½g¦^À³
|
ÁÂÁ¦U¦ì¤j¤jªº»¡©ú ¤½¥q»Ýn¦b¦¬¥ó¤é«e¸Ñª¼¨Ã§¹¦¨°e¥ó |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2016/2/2 ¤U¤È 02:17:12²Ä 2601 ½g¦^À³
|
¥t¥~, ¦b¤½¥q³Ìªñªº·s»D¸Ì(¥Í§Þ·~16±j¾÷·|¥u¤@¦¸) ¤j®a¤]³£·Pıªº¥X¨Ó, ®É¶¡ºò¢; ¸Ì±¤]´£¨ì¨ä¥L¨È¬w°ê®a³£¦³¤@¨Çµo®i¬ð¯}, °ß¿W¥xÆWÁÙ¨S¦³¯¸¤W»R¥x. ¤½¥q¤ñ½Ö³£ÁÙn«æ, ¦ý¬O«æ¤]¨S¦³¥Î,§ón±o¨ì¥@¬É¤W±M®a̪º»{¥i ³o¥i¬O¥þ¥@¬É²Ä¤@Ó..¦ý¬O¾Ì¬Æ»ò¬O§A¥xÆW§@¥X¨Ó? ¥L̤£«H°Ú.. ¦ý¬O..Y³oÁûÃĨS¦³³oÓ¤Þ¤H´Á«Ý, ·íªì·Q§â³oÁûÃįd¦b¥xÆWªº®ÉÔ, ¬°¤°»ò¤Ï¦Ó³Q¨º¨Ç¥~³¡½Ð¨Óªº¾¥«È±M·~¸g²z¤H¥Î¤@¨Ç¤â¬q,¦b¿³Âd«eµo¥Í¨º¨ÇOOXX¨Æ±¡? ¥L...¬O¦n³f...¯Eª©ªº±·¤Í̳£À´...²{¦b»Ýn¤@Ó¥¿¦¡ªººÞ¹D¦V¥@¬ÉµoÁn.. n¥ýÀ½¶i16±j...¤~¯à¶ix¥@¬É¤jÁÉ°Ú!! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/2/2 ¤U¤È 02:08:31²Ä 2600 ½g¦^À³
|
ASCO¦b6¤ëªì¥l¶}¡An±Æ¤J·|ijªº½×¤å¸ê®Æ¡A³£n´£«e¶}©l·Ç³Æ¡A¨Ò¦p¤U±®É¶¡ÂI Abstract Submission Key Dates NOVEMBER 13 Abstract Submitter Launches Abstract Submission Deadline MARCH 15 Late-Breaking Data Submission Deadline MARCH 16-17 Scientific Program Committee Meets to Select Abstracts LATE MARCH First Authors Notified of Abstract Selection Decision APRIL 5 Abstract Withdrawal Deadline APRIL 25 Release of Abstract Titles (Accessible via ASCO¡¦s iPlanner tool) MAY 18 AT 5:00 PM (EDT) Abstracts Released on ASCO¡¦s Meeting Library http://am.asco.org/abstracts |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2016/2/2 ¤U¤È 02:04:03²Ä 2599 ½g¦^À³
|
ASCO¦³³W©wYn°Ñ¥[±N¦³³\¦hÃö©ó¸Ñª¼³ø§iÄY®æ³W©w, ¸Ô¨£: am.asco.org/policies-and-exceptions (¤Þz¥v¤jªº¸ê®Æ,·P®¦) - ¦³¦¬¥ó¤é(3¤ëªì): ©Ò¥H¦¬¥ó¤é«e¤½¥qn§â²³¦h¼Æ¾Ú¾ã²z§¹, ¨Ã´£¥Xµ¹¤j·|¼f®Ö. - ¸Ñª¼"¼Æ¾Ú"¬ÛÃö¤º®e¤£¥i¦b¤j·|«e¤½¥¬, Ynµo¥¬·s»D½Z, ¥i¨Ï¥Î¨ä¥L©w¶q»¡©ú ½d¨Ò: ÃÄ®Ä50%¦n©ó¥H©¹ =< ÄÝ©ó¸ÑÄÀ¼Æ¾Ú, ¤£¦æ ¹ï©óÃĮĬݨì¥O¤H®¶¾Äªºµ²ªG<= ¨S¦³´£¥XÃö©ó¼Æ¾Úªº¸ÑÄÀ, ¥i¥H - ³Ì¦n¦b·s»D½Z¸Ì±ª½±µ´£¨ì: ¬ÛÃö¼Æ¾Ú±N¦bASCO¤j·|´£¥X»¡©ú - ©È¤j®a¥Ç³W, ©Ò¥HASCO¤]¥t¥~¤]¦³´£¨Ñ¨î¦¡½d¥»»¡©ú,Åý¤j®afollow . ¬°¦ón³o¼Ë? ASCO¤j·|¥i¥H§l¤Þ¤j®a¥Ø¥ú, ¤ÞÀV´Á«Ý ; ¤½¥q¤]±o¨ì¤@Ó¤WASCO»R¥xªº¾÷·|, ¦b¨ºùØ, °ª¤â¦p¶³, ·|±o¨ì«D±`«D±`¤jªºÁâ¥ú¿O §A»¡...§Ú¤£²n..§Ú°¾n¦Û¤v¶}Ó°OªÌ·|»¡©ú¤@¤UÃÄ®Ä,ºÞ§A¬Æ»òASCO... ¨º§A´NGG¤F....ª`·N...³o¬O¥Õ¦â¥¨¶ð(?!)¤£¬O¹q¤l·~...§Aªº²£«~¦n¦Û¤v·dµoªí·|¬O¦æ¤£³qªºù ¦æ¦³¦æ³W°Ú...¤½¥q¬O¤º¦æ¤H, ³£¦³¼Æ¤Q¦~ªº¸gÅç..¥L̪¾¹D«ç»ò§@¹ï¦Û¤v"¼Æ¤Q¦~"ªº¤ß¦åµ²´¹³Ì¦n ¥L̤ñ§ÚÌÁÙn¨D¦n¤ß¤Á°Ú~ |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/2/2 ¤U¤È 01:46:20²Ä 2598 ½g¦^À³
|
¤p¤å¤j¡G ¤p§Ìªº²z¸Ñ¬O,¦]¬°·Qn»°°Ñ¥[¤»¤ëªºASCO,»Ýn´XӤ몺®É¶¡°µ¸ê®Æ¤ÀªRµ¥µ¥,¦pªG¤»¤ë¸Ñª¼·|¨Ó¤£¤Î http://obipharma.blogspot.tw/search?updated-min=2016-01-01T00:00:00-08:00&updated-max=2017-01-01T00:00:00-08:00&max-results=3 ¬P±á¤j©Ò¼g¥h¦~11¤ëªk»¡·|Q&A²Ä¤CÃD¥i¯à¦³¬ÛÃö..°Ñ¦Ò°Ñ¦Ò ¦A½Ð¦U¦ì¤j¤j«ü±Ð !! |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/2/2 ¤U¤È 01:45:51²Ä 2597 ½g¦^À³
|
¤p¤å¤j ¤p§Ì»{¬°À³¸Ó³Ì¤jªºì¦]´N¬On¦¬¶°¼Æ¾Ú°Ñ¥[ASCO¦~·|,¤@Á|¦¨¦W¤Ñ¤Uª¾§a! |
|
|
·|û¡G´µ¤p¤å10139040 µoªí®É¶¡:2016/2/2 ¤U¤È 01:24:45²Ä 2596 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¤½¥q¿ï¾Ü¦~«á¸Ñª¼ ¦ý6¤ë¤~·|ª¾¹D¸Ô²Ó¼Æ¾Ú ¸ò¤½¥q¿ï¾Ü6¤ë¦A¸Ñª¼¨Ã¤½¥¬¸Ô²Ó¼Æ¾Ú ³o¼Ëªº¦w±Æ ¹ï¤½¥q¨Ó»¡ ¦³¤°»òÀuÂI¶Ü? |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/2/2 ¤U¤È 12:27:45²Ä 2595 ½g¦^À³
|
¹x¥Û¤j:·PÁ±z´£¨Ñ¼öÄËÄ˸ê°T»P°ª¨£~ kokfish¤j:·PÁ±zªº¸àÄÀ,¤@°w¨£¦å. 6¤ë ASCO¨£¯u³¹. |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/2/2 ¤W¤È 11:25:32²Ä 2594 ½g¦^À³
|
»{¦Pkokfish¤jÆ[ÂI¡A¨M³ÓÂI¦b6¤ëASCO¡A¦~«áªº¸Ñª¼¶È¬O¤½§GÁ{§Éµ²ªG²Å¤£²Å¦X¹w´Á¡ALR¼Æ¾Ú¤£·|¤½§G¡Aµ¥¨ì6¤ëASCO©¡®ÉCR¼Æ¾Ú¤]¥X¨Ó¤F¡A¬Æ¦Ü¥i¯àµoªí¦bASCO¡A»EµJ¥þ¥@¬É¥Ø¥ú¡A¯u¥¿ªº¥¨Æs¥~¸ê¦¹®É¤~¥i¯à¤j°Ê§@¡A¨º»ò§AÁÙ¤¶·NLR©MCRªº®t¶Z¼vÅTPFS¶Ü¡H |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/2/2 ¤W¤È 11:21:36²Ä 2593 ½g¦^À³
|
kokfish¤j¡B¹x¥Û¤j Æg+1 ¤¤ªÖ+1 ·PÁÂǦì |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/2/2 ¤W¤È 11:08:16²Ä 2592 ½g¦^À³
|
§¹¥þ»{¦Pkokfish¤j¤jªºÁ¿ªk! ÁÂÁ¤À¨É ! §Ú·Q¥þ¥@¬Éªºbuyside¦h¤Ö³£¦³¤@ÂI¦w¶h, ¯uªº·|ª`·N¨ì»Ýnsell side¤j¤O±ÀÂ˩άOroadshow«á¤ñ¸û¦³¥i¯à.. ÁÂÁ¹x¥Û¤jªº¤j¼¯³ø§i¤º®e¤À¨É ¡I¡I ¦¤W¤@¥h¤½¥q´N¥Îbloomberg¸ò¸ô³z§ä§ä¬Ý,§ä¤£¨ì.¥i¯à¬OÅv¤£°÷¡]¤½¥qúªº¿ú¤Ó¤Ö¡^©Î¬O¥Ø«e¥uµ¹¨ä«È¤á. ÁÂÁ¹x¥Û¤j¤jªº¤À¨É !!·P¿E¤£ºÉ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/2 ¤W¤È 11:04:33²Ä 2591 ½g¦^À³
|
Kokfish¤j «D±`»{¦P±zªº¤ÀªR ¦p¦Pcliff¤j ¥xÁÞ¤j©Ò¨¥ ¥~¸ê§ë¸ê¹p¹FÁÙ¨S±½¨ìglobo h·sÃÄ ASCO¤~¬O¤j»ï¤j©ñ ¤G¤ë¸Ñª¼¥u¬O«eµæ |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/2 ¤W¤È 10:47:12²Ä 2590 ½g¦^À³
|
»{¦P kokfish ¤jªº»¡ªk¡C ¨ä¹ênÅý¥~¸ê¥[½X¯E¹©¡A¥i¯àÁÙn¬Ý¨ì¯Ã¬ù©ÎÆW°Ïªº¥Í§Þ¤ÀªR®v©Ò¼gªº³ø§i¤~ºÞ¥Î¡A¥L̪º«È¤á¡BŪªÌ¤~¬O¹ï·sÃĶ}µo¦³¸gÅ窺§ë¸ê¤H¡C¦ÓnÅý³o¨Ç¬ü°ê¥»¤gªº¤ÀªR®vÄ@·N©ï²´¥h¬Ý¤@®a¥xÆW¤½¥q¡A¨º´Nn¦bASCO¤W¦³¨¬°÷ªº¾_¾Ù¤Oªí²{¡C ¸Ñª¼¼Æ¾Ú¥X¨Ó¡A¤j·§¥u¯àÅý½ä¸Ñª¼¸ò¤£½ä¸Ñª¼ªº¤j¤á©M´²¤á§¹¦¨´«¤â¡C¥~¸ê buy-side ¥i¯àÁÙnµ¥¤@µ¥¡C |
|
|
·|û¡Gkokfish10140320 µoªí®É¶¡:2016/2/2 ¤W¤È 10:19:08²Ä 2589 ½g¦^À³
|
¤j®a³£«Ü¦b·N¥~¸êªº¬Ýªk¡A©Î¥~¸êªº¶i¥X¡A§Úªº¬Ýªk¬O¡K ²{¦b¡u¨S¦³¥~¸ê¡v·|ª`·N¨ì¯E¹©¡A¦]¬°¡K ¸ò¬ü°ê¥Í§Þ·~¤ñ°_¨Ó¡A§â¸êª÷©ñ¦b¤@®a¦b¥xÆWªº¦W¤£¸g¶Ç ¥«È30eÁ⪺¤p¤½¥q¡A¬O¤£¦X±¡²zªº¡K ¬ü°ê¨º»ò¦h¾÷·|¡A§ä³£§ä¤£§¹¤F¡A¨Ó¥xÆW? why? °£«D¡K §A«Ü«G¡A«G¨ì»·¦b¬ü°êµØº¸µóªº¨º¨Ç¥Õ¤Ñ¦£Â½¡A©]±ß²n½ªº°òª÷¸g²z¤H¬Ý±o¨ì¡A¦Ó³on¾aasco¤~¦³¿ìªk! ³o¬O¤½¥q¥Hlr¨Ó¸Ñª¼¨Ó«e¶iascoªº³Ì¤j²z¥Ñ!(²{¦bªº¥~¸ê¶R½æ´N¬O¤º¸êªº¥~¸ê±b¤á¡A©ÎªÌ¬O³Q°Ê°òª÷¦]À³¯E¹©¥«È¤W¤É©MmsciªºÅv«½Õ¾ã¡A¦Ó¥~¸ê±i¼Æ³Ì¤j¤@³¡¥÷§Ú·Q¬O¤jªÑªF¦b¥~¸ê¨é°Óªº«ùªÑ) ¥~¸ê¹ï©ó¹Ò¥~ªº§ë¸ê¡A·|¶R¦b½T»{ÂI¡A¦Ó«D¥i¯àÂI¡C¤G´Á¼Æ¾Ú¥X¨Ó¡A¶R800©M¶R500¡A¹ï¥LÌ·N¸q¤£¤j¡Kº¦¨ì5000¡A´N¬O¤jÁÈ©M¶WÁȪº®t§O¡C¦ýn¬O¹êÅ祢±Ñ¡A¨º´N¬O¼É½ß50%°_¸õªº¼Æ¦r¡A¦Ó³o«ÜÃø¹ï§ë¸ê¤H¥æ«Ý¡K ¦pªG§Ú¬O¥~¸ê¡An«÷¸Ñª¼¤]·|¿ï°ê¤º¤½¥q¦Ó«D¨ì°ê¥~¡A¦Ó¥BÁÙ¥h¥xÆW³oºØ¥Í§ÞÁÙ¤£µo¹Fªº«D^¤å°ê®a«õ? ©Ò¥H·|¦b¥xÆW°Ñ»P¸Ñª¼ªº¡A´N¬O¦b¬Ýª©ªº±z¡A¦]¬°¥¿±`¤H¤£·|³oºØ°µ¡K §Ú̦A²Ó²Ó«ä¦Ò©Ò¿×¡y§CªÅ¸¹L¡zªºÆ[ÂI¡K ¹êÅçµ²ªG¡A¹L¬O¤ñ¶PÀù¥Àø®ÄÀu50%ªº·sÃÄ¡A ¥~¸ê¤£·|¹³¦b¥xÆWªº¤ÀªR®vºëºâpfs¦b16¥H¤W¡K ©Ò¥H»{©wpfs9Ӥ뤣¦p¹w´Á¡A¥LÌ¥u·|¬Ý¨ì¹êÅç¡y¹L¡z¤F¡K ¦Ó¥B¬O¥Îlr·í¼Æ¾Ú¹L¡A¤»¤ëÀ³¸Ó´N¦³crªº¼Æ¦r¡A15Ó¤ë¥H¤W¡A´N¨¬°÷¾_Åå¥@¬É¤F~ ¹LÃö¤G´Á©M´XªñµL°Æ§@¥Îªº·s¾÷¨î¥¥x·sÃÄ¡A³o¤w¥i¥HÅý¥«³õºÆ¨g¤F¡K ¦A¹ï·Ó²{¦bªº¥þ¥@¬Éªº¸êª÷¬y¶q¡B¬ü¤¸ªº±j¨«¶Õ¡A¯E¹©®³¨ìªº±ÂÅvª÷¡AÀ³¸Ó¬O¶W¹L·Q¹³¡K ¤jÃļt¯Êªº¤£¬O¿ú¡A¦Ó¬O¦nªº·sÃľ÷¨î~ §Ú«Ü¬Ý¦n¯E¹©¡A¦ýÃö©ó¥~¸ê¡A¤@¤Áªº¶}©l³£¦b¸Ñª¼¹L¤F¤§«á~ ps¡B³o¥u¬O§Úªº±À½×¡K |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/2/2 ¤W¤È 09:30:42²Ä 2588 ½g¦^À³
|
ÁÂÁ¹x¥Û¤jªº¤À¨É !! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/2/2 ¤W¤È 08:39:47²Ä 2587 ½g¦^À³
|
¹x¥Û¤j »{¦P±zªº¤ÀªR ·Q¥²buy side ¥~¸ê ·Qµ¥¸Ñª¼¤~¦æ°Ê§a |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2016/2/2 ¤W¤È 12:41:18²Ä 2586 ½g¦^À³
|
·PÁ¹x¥Û¤j¤À¨É¦¹«nªº¸ê°T! |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/2/2 ¤W¤È 12:06:29²Ä 2585 ½g¦^À³
|
²Ä¤@½g¥~¸ê¬ã¨s³ø§i by Morgan Stanley, SG, Tam and Wu ³ø§i·í¤¤¹ï©ó¸Ñª¼ªºµ²ªG¬Û·í«O¦u¡Aªí¥Ü·íªì¬ü°êªºÁ{§É¹êÅç¥u¬O¥Ó½Ð¤G´Á¡AY¬Oµ²ªG¨}¦nÁÙ¥²¶·°µ¤T´ÁÁ{§É¡A¤£¦ý¤£¥i¯à¥H¦¹µ²ªGª½§ðNDA (À³¸Ó¬OBLA°Õ)¡A¬Æ¦Ü¨S¦³³W¹º¥Ó½Ð¬ð¯}©ÊÀøªk (BTD)¡C³ø§i¦P®É«ü¥X¡A§Y¨Ï¬ü°êªº¤G´ÁÁ{§É¾ãÅé¼Æ¦r¨Ã¤£¤Q¤À²z·Q¡A³o¤]¤£¥Nªí822´N¨SÀ¸°Û¤F¡C¦]¬°¦¹¦¸Á{§É¹êÅç·íªì¦¬¯f±w®É¤@µø¦P¤¯¡A¨Ã¥¼°w¹ïGlobo H°µ¿z¿ï¡C©Ò¥H¯E¹©ÁÙ¬O¥i¥H±N¨ü´ú¯f¤H¤À¦¨sub-group¡A¤ÀªR¦UÃþ§O¸s²ÕªºÀø®Ä¡A§ä¥X¦³®Ä¸s²Õ§@¬°¤T´ÁÁ{§É¹êÅç³]pªº¨Ì¾Ú¡C ¸Ó³ø§i1/19µoªí¡A¦¹«á´X¤éªº¥~¸ê¶R½æ¶W¬ö¿ý¡A½æ¦h¶R¤Ö¡A¦ý¼Æ¶q¤£¤j¡C ³ø§i¤¤³Ì¦³·N«äªº¬Oªñ´X¦~®Ö㪺¨ÅÀù¼Ð¹vÃĪ«©ó2015¦~·í¤¤ªº¾P°âÃB¡C Herceptin (1998®Öã) ³Ì°ª¡A21»õ¬ü¤¸¡CAfinitor (2012)¡A7.7»õ¬ü¤¸¡CPerjeta (2012)¡A7»õ¬ü¤¸¡CIbrance (2015/Feb)¡A5.2»õ¬ü¤¸¡CFaslodex (2002)¡A3»õ¬ü¤¸¡CKadcyla (2013)¡A2.6»õ¬ü¤¸¡C ®Ú¾Ú¯E¹©¤½¥qªºµû¤ñ¡AAfinitorÄݩ󤤫×Àø®Ä/§C¦w¥þ©Ê¡A»PPerjeta (°ªÀø®Ä/¤¤«×¦w¥þ©Ê) ´X¥G¦P®É¤W¥«¡A¦Ó¾P°â¶W¶VPerjeta¡C¥i¯àì¦]¬OGenentech¤â¤¤¤TÓ¨ÅÀù¼Ð¹vÃĪ«Herceptin, Perjeta, Kadcyla³£¬O§ðHER2-positive¥«³õ¡A¦ÓNovartis¥u¦³¤@ÓAfinitor§ðHER2-negative¥«³õ¡C ¯E¹©¨S¦³¦C¤Jµû¤ñªºIbrance¡A©ó2015¦~2¤ë³q¹L¡A·í¦~§Y³Ð¤U5»õ¬ü¤¸¥H¤Wªº¾P°âÃB¡AÀ³¸Ó»P¥¦±M§ðHER2-negative¥«³õ¦³Ãö¡A¥un¥´Ä¹Afinitor´N¦n¤F¡C ¤p§Ì¬Ýªk¡G µL½×¸Ó¤ÀªR®vªº½×ÂI¬O§_»P¯E¤Í̪º»{ª¾¬Û²Å¡A¦Ü¤Ö²Ä¤@½g¯u¥¿ªº¥~¸ê¤ÀªR³ø§i¥X¥x¤F¡C ¤£¦P¼Ð¹vªº¥«³õ¬O©úÅ㪺°Ï¹j¥«³õ¡A¤£¬ÛÄvª§¡C¬Û¦P¼Ð¹v«h¤À¹¥«³õ¡CÀø®Ä»P¦w¥þ©Ê¤ÀªR¥u¦b¦P¤@°Ï¹j¥«³õ¤¤¤~¦³·N¸q¡C¯E¹©ªº822¸ó¶VHER2-positive / negative¡A¸ò©Ò¦³²{¦³ÃĪ«¬Ò¥iÄvª§¡AˬO¦³¤@³õ¦nÀ¸¥i¬Ý¡C ªñ´Á©Ò¿×¸Ñª¼µ²ªG¥i¯à¤£·|¤Ó¦n¡AÀ³¸Ó¬O¦]¬°¦¬¯f±w®É¥¼°µGlobo H¿zÀË¡A¼vÅT¾ãÅé¨ü´ú²ÕÀø®Äªº®t²§©Ê¦Ó¨¥¡C¨ü¨ìASCO³W©w¨î¡A¤G¤ë¸Ñª¼¥u·|¤½¥¬¾ãÅ骺¼Æ¾Ú¡A¯u¥¿µ²ªGn¬ÝASCO¤j·|¤W®Ú¾Ú¤£¦Psub-groupªºÀø®Ä¤ÀªR¡A¤~¯à¨M©w822ªº»ùÈ¡C ³o¥÷¬Û·í«O¦uªº³ø§i¥X¥x¥H¨Ó¡A¥~¸ê¶i¥XÁö¬O½æ¦h¶R¤Ö¡A¦ý¬O½æ¶W¶q»P¥~¸êªº«ùªÑ¦s¶q¨â¸U¦h±i§¹¥þ¤£¦¨¤ñ¨Ò¡C³o¬O§_¶¡±µÃÒ©ú¯E¹©¥Ø«eªº¥~¸êªÑªF¨ä¹êÁÙ¬O¥H°²¥~¸ê¬°¥D¡H |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2016/1/31 ¤U¤È 04:55:59²Ä 2584 ½g¦^À³
|
http://money.udn.com/money/story/5612/1478009-¥Í§Þ·|ijÀÀ«±Ò-±NÁܤj©@¨Ó¥x ¥Í§Þ·|ijÀÀ«±Ò ±NÁܤj©@¨Ó¥x 2016-01-31 02:14:16 Áp¦X³ø °OªÌ§õ¶¶¼w¡þ¥x¥_³ø¾É ¦æ¬F°|¦³·N«±Ò°±¿ì¥|¦~¦hªº¡u¬ì§ÞÅU°Ý·|ij¡v¡AÂê©w¥H¥Íª«¬ì§Þ¬°¥Dªº¡u¥Íª«¬ì§ÞÅU°Ý·|ij¡v¡A¹w©w¦~©³«e¡B©ú¦~ªì«ì´_Á|¦æ¡C³o¶µ·|ij±NÁܽЦ³¿Õ¨©º¸¼úÀY»Îªº°ê»Úª¾¦W¾ÇªÌ¤Î±M®a¡A¨Ó¥x¶}·|¿Ô¸ß¡A§Æ±æÂǦ¹¸£¤O¿EÀú¡Aq¥X¥xÆW¥¼¨Ó«e¤©Ê¥Íª«¬ì§Þµo®i¤è®×¡C ·ÇÁ`²Î½²^¤å¦bÄv¿ï¬F¨£¤¤ªí¥Ü¡A¥Á¶iÄÒ°õ¬F«á¡A±N¥Î¤»¶µ¦æ°Ê±À°Ê¥Í§Þ²£·~¦¨ªø¡AÅý¥Í§Þ·~¦¨¬°¥xÆW¤UÓ¶¥¬q¸gÀÙ¦¨ªøªº°Ê¤O¡C¦]¦¹¦æ¬F°|¬ì§Þ·|³ø¨â¤jn¨¤¡A§Y¥x¿n¹q¸³¨Æªø±i©¾¿Ñ»P¤¤¬ã°|°|ªø¯Î±Ò´f¡A©ó³Ìªñ¤@¦¸·|ij¤@PÒ¨¥«ì´_¥Íª«¬ì§ÞÅU°Ý·|ij¡A·Ç»Õ´}±iµ½¬F¤]»{¬°«ì´_Á|¦æ¦³¨ä¥²n¡A§Æ±æ¯à»P¥Á¶iÄÒ¥¼¨Ó¬ì§Þµo®i¤è¦V¡u±µy¡v¡C ±iµ½¬F¬QÁܯαҴf¡B·Ç°Æ»Õ´}§ùµµx¡B½ÃºÖ³¡ªø½±¤þ·×¡B¬ì§Þ³¡ªø®}Àï¥Áµ¥¡A´N¡u¥Íª«¬ì§ÞÅU°Ý·|ij¡v¬O§_«ì´_¡B¦ó®ÉÁ|¦æ¡BÁܽÐþ¨Ç°ê»Ú¥Í§Þ¡u¤j©@¡v¨Ó¥x¡A¥H¤Î¥¼¨Óµo®i·s¤è¦Vµ¥¼sªx¥æ´«·N¨£¡C ±iµ½¬Fªí¥Ü¡A¤@¤E¤C¤E¦~¥xÆW¬°¤Fµo®i¬ì§Þ¡A¦¨¥ß¬ì§ÞÅU°Ý·|ij¡A¿ï©w¥xÆWµo®i¥DÃD¡A¥b¦~¶}¤@¦¸·|ij¡AÁܽаê»Úª¾¦W¾ÇªÌ±M®a¡A¥]¬A·í®Éªº¢×¢Ð¢ÛÁ`µô¡B·í®É¦b¬ü°ê¼w¦{»ö¾¹ªA°Èªº±i©¾¿Ñµ¥¤H¨Ó¥x¡A´N¬ì§Þµo®i±¦Vµ¥¡A¦h¤¸¥DÃD¿Ô¸ß·N¨£¡A·|ij«á´£¥X¬ì§ÞÅU°Ý·|ij¬ÛÃö¤è®×»P¤åÄm¡C ¥L»¡¡A¹L¥h¤@ª½¬O¦æ¬F°|¬ì§ÞÅU°Ý²Õ¦bÄw¿ì¬ì§ÞÅU°Ý·|ij¡A¦ý¦æ¬F°|²Õ´§ï³y®É¡Aì¬ì§ÞÅU°Ý²Õ¥ô°È½s²Õµ²§ô¡A§ï¬°¦æ¬F°|¬ì§Þ·|³ø¡A¬ì§ÞÅU°Ý·|ij¤]¦]¦¹¤¤Â_¥ð¤î¡C ¯Î±Ò´f¦b·|ij¤W¤ä«ù¥Íª«¬ì§ÞÅU°Ý·|ijÀ³«ì´_Á|¦æ¡A¨Ã«Øij¥H¥Íª«¬ì§Þ¬°¥D¡A¿Ô¸ß°ê»Ú¦³Án±æªº¤j®v¡A¦pºaÀò¿Õ¨©º¸¼úªº¤j®v¡A¾®»E·N¨£¡Aµo®i¸û«e¤©Êªº¥Íª«¬ì§Þ¡C ¾Ú¤F¸Ñ¡A¬ì§Þ·|³øªº°õ¦æ¯µ®Ñ¡A¥x¤j¹q¾÷¨t±Ð±ÂÄÁ¹Å¼w¬°±µ¥ô¬ì§Þ¬F©e¡A¤w¦V¥x¤j¥Ó½Ðɽը줤ë¤Q¤E¤é¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/29 ¤W¤È 10:00:31²Ä 2583 ½g¦^À³
|
§ó¥¿»P¸É¥R»¡©ú: 4§Ú»{¬°³o·|¥[§Ö®É®Ä,¤]¨É¦³Priority ReviewÃÄÃÒ6Ӥ뤺»Ý¼f®Ö§¹²¦ªºÀu¶Õ, >>§Ú»{¬°³o·|¥[§Ö®É®Ä ,¦pªG¬ÛÃö¼Ð·Ç¤]²Å¦Xªº¸Ü¤]·|²Å¦X Priority Review(¨É¦³ÃÄÃÒ6Ӥ뤺»Ý¼f®Ö§¹²¦ªºÀu¶Õ) 5 2015µo²{Àò±oFast Track »P Priority Review ¦@84% >>2015¦~ªº²Îpµo²{Àò±oÃÄÃÒ¤¤±o¨ì Fast Track »P Priority Review ®Ö㪺¦@84% Fast Track 31% 2 Breakthrough 22% 3 Priority Review 53% 1 Accelerated Approval 13% 4 ¤W±31%+22%+53%+13%=119% >100% (ªí¥Ü¦³¨ÇÃÄì±oFast Track ,BTD ®Öã«á¤]¦P®É²Å¦XPriority Review ©Î Accelerated Approval) 2015¦~¦³14ÁûÃÄÀò±oFast Track®Öã«á ±o¨ìÃÄÃÒ >>¦³14ÁûÃÄÀò±oFast Track®Öã«á©ó2015¦~Àò±o¨ìÃÄÃÒ 2015¦~¦³10ÁûÃÄÀò±oBTD ªº®íºa >>¦³10ÁûÃÄÀò±oBTD®Öã«á©ó2015¦~Àò±oÃÄÃÒ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/28 ¤U¤È 11:45:42²Ä 2582 ½g¦^À³
|
Cliff ¥S «Ü°ª¿³¯à»P§A¤À¨É¥æ¬y ¬Û¤¬¤Á½R §Aªº¸ê°TÀ³¸ÓµL»~ ¥H¤U¬O§Úªº¸ê°T¤À¨É ¥ý¦V§A»¡ÁnÁÂÁ»P·P®¦! 1³q±`Àò±oFast Track»{ÃÒªº·sÃĦpªG¬ÛÃö¼Ð·Ç²Å¦X¤]·|²Å¦X ¥[³t®ÖãAccelerated Approval »PÀu¥ý¼f¬dPriority Review Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met http://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm 2§Ú¦b«ä¦Ò¬°¦ó¥u¦³Priority Review¦³qÃÄÃÒ6Ӥ뤺»Ý¼f®Ö§¹²¦ ¨ä¥L¨º¤TÓ¾÷¨î¨Sq(Fast Track, Accelerated Approval, Breakthrough Therapy) 3³oÓºô¯¸´£¨ì: Àò±o¥Ó½ÐFast Track»{ÃÒªº·sÃıN¦Û°Ê¥HPriority Review»PAccelerated Approval ªº¼Ð·Ç¨Ó¼f®Ö¬O§_¤]¦P®É²Å¦X https://en.wikipedia.org/wiki/FDA_Fast_Track_Development_Program A fast track application is automatically considered for both of these designations. 4 ¦]¬°¬OYK±¡ªp1¬O¨«Fast Track,¦pCliff ¥S©Ò¨¥ ¤@¥¹¶i¤J¸ÕÅç²×ÂIn¥Ó½ÐÃÄÃҮɡA¥i¨É¦³ºu°Ê¦¡¼f¬d¡]Rolling review¡^ªºÀu´f¡A¥i§â¤w§¹¦¨ªº³¡¤À¼Æ¾Ú¸ê®Æ³v¦¸°e©¹FDA¥ý¼f¡A¦Ó¤£¥²¹³¶Ç²Î¼f¬d·sÃĤ@¼Ë¡A¶·§â©Ò¦³¥Ó½Ð·sÃļf¬dªº¸ê®Æ²Î²Î³Æ»ô«á¤~¯à°e¥hFDA §Ú»{¬°³o·|¥[§Ö®É®Ä,¤]¨É¦³Priority ReviewÃÄÃÒ6Ӥ뤺»Ý¼f®Ö§¹²¦ªºÀu¶Õ, (³Ìªñ§K¬ÌÀøªkªºÃĪ«¤]¦³3 , 4 Ó¤ë´N¼f¥X¨Óªº) »P2Ó¤ë¨ä¹ê¬Û®t¤]¤£»· §Ú¤Þ¥Îªº±´°Q¬ü°êÄY«¯e¯f¥ÎÃÄ«P¶ipµe¤U ´£¨ì 1.§Ö³t³q¹D¾÷¨îFast Track Fast TrackÃĪ«µo®i¾÷¨î¬O¬ü°êFDAªº¥[³t¸ÕÅ礤·sÃĨú±o¤W¥«®Ö㪺¤è¦¡¡C³oºØ¤è¦¡¬O§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð À³¬O¤¤¤å½Ķª© ¦³¥i¯à¬O½Ķ¿ù»~ ¥t¥~¦]¬°¬OYK±¡ªp1 ¨«§Ö³t³q¹D¾÷¨îFast Track ¸û©öÀòãÀ³¸Ó¤]¬O¦Ò¼{¤§¤@ 2015¦~¦³14ÁûÃÄÀò±oFast Track®Öã«á ±o¨ìÃÄÃÒ Avycaz, Corlanor, Cotellic, Daklinza, Darzalex, Entresto, Genvoya, Kanuma, Lonsurf, Orkambi, Portrazza, Strensiq, Tagrisso, Viberzi 5 2015 µo²{Àò±oFast Track »P Priority Review ¦@84% Fast Track 31% 2 Breakthrough 22% 3 Priority Review 53% 1 Accelerated Approval 13% 4 6 YK±¡ªp2¬O³W¹º¨« BTD , ¬ü°êFDA³Ì«á·|µ¹¤©¦óºØ¯S®í§¹J »Ý¬Ý¸Ñª¼¼Æ¾Ú¦Ó©w¤F (OBI822¯àÀò±oBTD³o¶µ®íºa PFS 15¬O§ÚÓ¤Hªº¥Ø¼Ð )( YK±¡ªp1 ´N¬Ý¦U¦ì¤j¤jªººÖ³ø¤F ) 2015¦~¦³10ÁûÃÄÀò±oBTD ªº®íºa (2015 ¦@®Öã45ÁûÃÄ ) Alecensa, Darzalex, Empliciti, Ibrance, Kanuma, Orkambi, Praxbind, Strensiq, Tagrisso, Xuriden http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm 7 ¤£½×YK±¡ªp1©Î±¡ªp2 ³£ºâ¬O¥xÆW¤§¥ú ¾_¾Ù¥þ²y!!! ¥H¤W´£¨Ñ¤À¨É°Ñ¦Ò ¦³»~½ÐCliff ¥S »P¦U¦ì¤j¤j §ó¥¿ |
|
|
·|û¡GªÑ¥«¦W®·10141659 µoªí®É¶¡:2016/1/28 ¤U¤È 10:20:48²Ä 2581 ½g¦^À³
|
¨Ó·½ https://connectomeblog.wordpress.com/2014/08/25/epsc-2/ 1.§Ö³t³q¹D¾÷¨îFast Track Fast TrackÃĪ«µo®i¾÷¨î¬O¬ü°êFDAªº¥[³t¸ÕÅ礤·sÃĨú±o¤W¥«®Ö㪺¤è¦¡¡C³oºØ¤è¦¡¬O§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð¡C³q±`¬Oµ¹¨º¨Ç¦³§Æ±æªvÀøÄY«¡B«Â¯Ù¥Í©Rªº¯e¯f¡A¦Ó¥B³o¨Ç¯e¯f¥Ø«e¨Ã¨S¦³¨ä¥LªºÃĪ«¥iªvªº¡C Fast Track¬O¥Î¨Ó«P¶i·sÃĶ}µo¤Î¥[³t¥Î¨ÓªvÀøÄY«¯e¯f©Îº¡¨¬¥¼³Qº¡¨¬ªºÂåÃĻݨDªºÃĪ«ªº¼f¬dªºµ{§Ç¡C¨ä¥Ø¼Ð¬On¨Ï¨º¨Ç«nªº·sÃįà°÷¾¨¦Åý±wªÌ¥i¥H¨Ï¥Î¨ì¡CFast Track¥i¥H¥Î©ó¼sªxªº¦UºØÄY«¯e¯f¡]serious disease¡^¤W¡C ¬ü°êFDA¹ïFast Track¥Ó½Ðªºn¨D¬O¥²¶·±oº¡¨¬¤@Ó¥¼³Qº¡¨¬ªºÂåÃĻݨD¡A¥ô¦ó³Qµo®i°µ¬°ªvÀø©Î¹w¨¾¥Ø«e¨S¦³ªvÀø¤èªkªº¯e¯fªºÃĪ«³£¥i¥H³Qµø¬°º¡¨¬¤@Ó¥¼³Qº¡¨¬ªºÂåÃĻݨD¡C¦Ó¦pªG¬O¹ï©ó¥Ø«e¤w¸g¦³ªvÀø¤è¦¡ªº¯e¯f¡An·Q¦¨¬°Fast TrackªºÃĪ«¥²¶·®i¥Ü¨ä»P²{¦æªvÀø¡]available therapy¡^¬Û¤ñ®i²{¥XªºÀu¶Õ¡A¨Ò¦p¡G®i²{Àu©ó²{¦æªvÀøªºÀø®Ä¡B¯à°÷ÁקKµo¥Í²{¦æªvÀø¤è¦¡·|²£¥ÍªºÄY«°Æ§@¥Î¡B§ïµ½¤@¨Ç¦´Á¶EÂ_¯à°÷¦³¸û¨Î¹w«áªºÄY«¯e¯fªº¶EÂ_¯à¤O¡B»P¤w³Q±µ¨üªºªvÀø¬Û¤ñ¯à°÷¦bÅãµÛ´î¤ÖÁ{§É¤Wªº¬r©Ê¡C YÃĪ«Y¨ú±oFast Trackªº¸ê®æ´N¥i¥H±o¨ì¥H¤U³¡¤À©Î¥þ³¡ªº¼úÀy¡G ¯à°÷§óÀWÁc¦a»PFDA¶i¦æ·|ij°Q½×ÃĪ«¶}µopµe»P½T»{¥Î©ó¨ú±oÃĪ«³\¥iªº¸ê®Æ¬O§_¾A·í¡C ¯à§óÀWÁc¦a»PFDA®Ñ«H©¹¨Ó¬ãij¨Ò¦pÁ{§É¸ÕÅç³]pªºÄ³ÃD¡C ¦³¸ê®æ¨Ï¥ÎFDA¥[³t®Öã¡]Accelerated approval¡^µ{§Ç¡A¦p¨Ï¥Î´À¥N«ü¼Ð¶i¦æÁ{§É¸ÕÅçµ¥¡C ºu°Ê¦¡¼f¬d¡]Rolling review¡^¡AÃļt¥i¥H¦b·sÃĤW¥«³\¥i¥Ó½Ð¡]NDA, New Drug Application°e¼f¸ê®Æªº¤@³¡¤À§¹¦¨«á´N¥ý°e¥ó¡A¦Ó¤£¥Îµ¥¨ì°e¼f¸ê®Æªº¨C¤@Ó³¡¤À³£§¹¦¨«á¤~¯à°e¥ó¡C¤@¯ëªº·sÃĤW¥«³\¥i¥Ó½Ðªº¼f¬d³£¬On¨ìÃļt§â§¹¾ãªº¸ê®Æ³£°e¥ó«á¤~·|¶}©l¶i¦æ¼f¬d¡C YÃļt¹ïFDAªº¤£±Â»PFast Track¸ê®æªº¨M©w¤£º¡®Éªºª§Ä³¸Ñ¨M¡C °£¦¹¤§¥~¡A¤j³¡¤À¨ú±oFast Track¸ê®æªºÃĪ«³£¥i¥H±o¨ìÀu¥ý¼f¬d¡]Priority Review¡^ªº¯S§O«Ý¹J¡C Fast Track¥²¶·¥ÑÃļt¥D°Ê´£¥X¥Ó½Ð¡C¦bÃĪ«ªº¶}µo¶¥¬qªº¥ô¦ó®ÉÂI³£¥i¥H´£¥X¥Ó½Ð¡CFDA±N¼f®Ö¸Ó¥Ó½Ð¨Ã¦b¦¬¥ó¤é°_60¤é¤º°ò©óÃĪ«¬O§_¹ï¤@ÓÄY«¯e¯fº¡¨¬¤F¥¼³Qº¡¨¬ªºÂåÃĻݨD¶i¦æ½T»{¡C·í¸ÓÃĪ«±o¨ìFast Track¸ê®æ«á¡AÃļt·|³Q¹ªÀy©ó¸ÕÅ窺¦´Á´N¶}©l»PFDAÀWÁcªº·¾³q¡CÀWÁc¦a·¾³q¯à½T«O¦UºØ°ÝÃD©MijÃD³£¯à°÷¾¨§Ö³Q¸Ñ¨M¡A¦]¦¹¯à°÷¨ÏÃÄ«~¯à°÷¾¨¦³Q³\¥i¤W¥«¨Ã¨Ï±wªÌ¯à°÷¨Ï¥Î¨ì³o¨Ç·sÃÄ¡C ®Ú¾ÚFDAºô¯¸©Ò°µªº²Îp¡A±q1998¦~3¤ë¨ì2011¦~9¤ëªº³o¬q®É¶¡¦@¦³248¥óFast Trackªº¥Ó½Ð¡A¨ä¤¤FDA¦b60¤Ñ¤º§¹¦¨¸ê®æ¼f¬dªº¦³236¥ó¡A¨ä¤¤¨ú±o¸ê®æªº¦³152¥ó¡B³Q©Úµ´ªº¦³87¥ó¡B¥Ø«e¤´©µÌX¤¤ªº¦³2¥ó¡C¼f¬d´Á¶W¹L60¤Ñªº®×¤l¦³12¥ó¡A¨ú±o¸ê®æªº¦³4¥ó¡B³Q©Úµ´ªº¦³1¥ó¡B¥Ø«e¤´©µÌX¤¤ªº¦³7¥ó¡C 2.¬ð¯}©ÊªvÀø¡]Breakthrough Therapy¡^ ¬ð¯}©ÊªvÀø¬O¤@ºØ¥[³t¥Î©óªvÀøÄY«¯e¯f¥Bªì¨BªºÁ{§ÉÃÒ¾Ú¤w¸gÃÒ©ú³oÓÃĪ«¤w¦³»·¸û²{¦æªvÀø¬°ÀuªºÃĪ«¶}µo»P¼f®Öªºµ{§Ç¡Cn¨M©w¬O§_¤ñ²{¦æªvÀø¤è¦¡¦³©ÒÅãµÛ§ïµ½¬O°ò©óªvÀø®ÄªGªº±j«×¡A¥]§t®ÄªGªº´Á¶¡¡A¥H¤ÎÆ[¹î¨ìªºÁ{§Éµ²ªGªº«n©Ê¡CÁ`Åé¨Ó»¡¡AÁ{§ÉÃÒ¾ÚÀ³¸Ón¯à®i²{¥X©úÅãÀu©ó²{¦æªvÀøªºÀu¶Õ¡C ¬ð¯}©ÊªvÀøªºÁ{§É¸ÕÅçÀø®Ä«ü¼Ð¡]Endpoint¡^³q±`«üªº¬O¬YÓ´ú¶q¤£¥i°fªºµo¯f©Î¦º¤`¾÷²v¡]irreversible morbidity or mortality, IMM¡^©Î¬O¯e¯fªº¬YÓÄY«ªº¯gª¬¡C¤@ÓÁ{§É¤W©úÅ㪺Àø®Ä«ü¼Ð¤]¥i¥H¬O¦bªº¹ïIMM©ÎÄY«¯gª¬¡]serious symptoms¡^ªºµo²{¡A¥]§t¡G ¦b¤@Ó¤wª¾ªº´À¥NÀø®Ä«ü¼Ð¤W¨ã¦³Àø®Ä¡C ¦b´À¥NÀø®Ä«ü¼Ð©Î¬O¤¤¶¡Àø®Ä«ü¼Ð¡]intermediate clinical endpoint¡^ªºªí²{¤W¥i¥H¦X²z¦a¹w´ú·|²£¥ÍÁ{§É¤Wªº§Q¯q¡C ¦bÃĪ«°Ê¤O¾Çªº¥Íª««ü¼Ð¡]biomarker¡^¤W¨Ã¥¼²Å¦X¤@Ó¥i±µ¨üªº´À¥NÁ{§É¸ÕÅç²×ÂIªº¼Ð·Ç¡A¦ý¤w±j¯P¦a·t¥Ü¥X¥i¯à¹ï¯e¯f²£¥ÍÁ{§É¤W¦³·N¸qªºÀø®Ä¡C »P²{¦æªvÀø¬Û¤ñ¦b¦w¥þ©Ê¸ê®Æ¤W¦³©úÅã¦a§ïµ½¡A¦Ó¥B¨âªÌªºÀø®Ä¬O¬Û¦üªº¡C ÃĪ«¨ú±o¬ð¯}©ÊªvÀø¤§«á¥i¥H±o¨ì¥H¤Uªº¼úÀy¡G ¥þ³¡fast trackªº¼úÀy¡C ±qÁ{§É¸ÕÅç¤@´Á¶}©l´N¥i¥H¦bÃĪ«¶}µopµe¤W±o¨ì¼sªx©Êªº«ü¤Þ¡C ¬ð¯}©ÊªvÀø¬O¥ÑÃļt´£¥X¥Ó½Ð¡CYÃļt¨S¦³¥D°Ê´£¥X¥Ó½Ð¡A¦b¥H¤Uªº±¡ªp®ÉFDA·|¥D°Ê«ØijÃļt¦Ò¼{´£¥X¬ð¯}©ÊªvÀøªº¥Ó½Ð¡Ga.¦b¼f®Ö§¹Ãļt´£¥æªº¸ê®Æ«á¡AFDA»{¬°³oÓÃĪ«ªºµo®ipµe¥i¯à²Å¦X¬ð¯}©ÊªvÀøªº¥Ó½Ð¼Ð·Ç¡Fb.Y±o¨ì¬ð¯}©ÊªvÀø¸ê®æ¯à¹ï«áÄòªºÃĪ«¶}µopµe¦³§Q¡C ²z·Q¤W¨Ó»¡¡A¦b¬ð¯}©ÊªvÀøn¨Dªº¼Ð·Ç¤¤¤w¦³²Å¦Xªº±¡ªp¤U¡A¤@Ó¬ð¯}©ÊªvÀø¥Ó½Ð»Ýn¦b¤G´ÁÁ{§É¸ÕÅç·|ijµ²§ô«e´£¥X¡C¦]¬°±Â»P¬ð¯}©ÊªvÀø¸ê®æªº¥Øªº¬O¦b©óÅý¥i¥Î¨Ó¤ä«ù·sÃĤW¥«ªºÁ{§ÉÃÒ¾Ú¯à°÷¾¨¥i¯à¦³®Ä²v¦a³Q¼f®Ö½T»{¡CFDA¨Ã¤£·|§Æ±æ¬ð¯}©ÊªvÀø¥Ó½Ð¬Oµo¥Í¦bBLA©ÎNDA©Î¬O¸É¥ó¤§«á¡CFDA·|©ó¬ð¯}©ÊªvÀø¥Ó½Ð¦¬¥ó«á60¤Ñ¤º°µ¥X¦^À³¡C |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/1/28 ¤U¤È 04:53:19²Ä 2580 ½g¦^À³
|
Y¶È¤½¥¬¸Ñª¼¬O§_¹LÃö©ÎÀu©ó¹w´Áµ¥©w©Ê¸ê®Æ,¨ä¥L¬ÛÃö¼Æ¾Ú¸ÔASCO¤j·|, ¹ï¯E¹©¬O¦³¨Ç¤º½u¥æ©ö·ÀIªº,¦pªG¦p¦¹§Æ±æ¤½¥q¯à±±ºÞ¼Æ¾Ú«O±K,³Ì¦n¥u¦³±i¸³¤@¤Hª¾¹D¼Æ¾Ú³Ì¦n,¥un¦³¤G¤H¥H¤Wª¾¹D¼Æ¾Ú´N¤£¦n±±ºÞ¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/28 ¤U¤È 04:51:31²Ä 2579 ½g¦^À³
|
Cliff ¥S ³oÓ°ÝÃD±ß¤W¤p§Ì¦A¶K¤å»¡©ú ÁÂÁ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/1/28 ¤U¤È 02:13:04²Ä 2578 ½g¦^À³
|
Cliff ¤j¤j: ÁÂÁ±z²M·¡ªº¸Ñ»¡. Á`ºâ¹ï³o¥|ºØ¾÷¨î¦³¤F¸û²M´·ªº·§©À½ü¹ø¤F. ·PÁ !! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/1/28 ¤U¤È 01:11:15²Ä 2577 ½g¦^À³
|
¥xÁÞ¤j¡G Fast Track¡u60¤Ñ¡v©Ò«ü¦óª«¡H¬d¬ÝFDAµ¹·~¬Éªº¸t¸g: ¡uGuidance for Industry¡GExpedited Programs for Serious Conditions¡VDrugs and Biologics.¡v ¡]http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf ¡^ ¸Ì±ªºFast Track¤ñ¸ûªí®æ¡]©³¶p.8¡^¤Î³¹¸`ùØ¡]©³¶p.29¡^¦U´£¨ì¤F60¤Ñ©Ò«ü¬°¡u§¹¦¨§å㦹»{ÃÒ¡v¡A¨S¦³´£¨ì¡u60¤Ñ¤º§¹¦¨·sÃļf¼f¬d¡v¡A60¤Ñ¤º§¹¦¨·sÃļf¬d¬O«Ü§xÃøªº¡C ©³¶p.8ªí®æ¡G ¡uTimelines for FDA response¡GWithin 60 calendar days of receipt of the request¡v ©³¶p.29¡G ¡u4. FDA Response FDA will respond to fast track designation requests within 60 calendar days of receipt of the request.¡v ±z»PCONNECTOME§@ªÌ³£¥i¥H¦A¥h½T»{¤@¤U¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/28 ¤U¤È 01:03:37²Ä 2576 ½g¦^À³
|
¦U¦ì¤j¤j: ¬P±á¤j¥²¬Ý¬ö¿ý: http://obipharma.blogspot.tw/2016/01/20151112.html 2015/11/12 ¯E¹©ªk»¡·| ¶À¨q¬üÁ`¸g²z http://obipharma.blogspot.tw/2016/01/20150904.html 2015/09/04 ¥þ²y¥Í§Þµo®iÁÍ¶Õ ¯Î±Ò´f°|ªø http://obipharma.blogspot.tw/2015/06/2015627.html 2015/06/27 ´CÅé³ø¾É¯Î±Ò´f¨ÅÀù¬Ì]§Y±N¤W¥« http://obipharma.blogspot.tw/2015/06/201463-104.html 2015/06/03 104¦~«×ªÑªF·| http://obipharma.blogspot.tw/2015/03/2015333q.html 2015/06/03 104¦~«×ªÑªF·| 5619¤j §Aªº°ÝÃD§Ú¤w¶K¤å¦^µª (©¹¤U§ä) ÁöµM822«e´X¦~¥u¯à¨Ï¦b¨ÅÀù±ß´Á¡A´X¦~«á¯uªºÁ{§É¦¨¥\±À¦V¦¤¤´Á¨Ï¥Î ¦ý¬O822¾A¥Î¤H¤f°ª¹F80% ¥[´î¼°£«á¤]®t¤£¦h,¥[¤W¦Ñ´¤j¤w»¡¹L ¦Û¶O¬I¥´¤£¨ü´Á§O¼vÅT,¤½¥q¤]´£¨ì¦´ÁªvÀø®ÄªGÀ³§ó¦n ¦b³oºØ±¡ªp¤U¨S¦³¤H¯à¦ôp¯u¥¿ªº¥«³õ |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/1/28 ¤U¤È 12:43:04²Ä 2575 ½g¦^À³
|
¥xÁÞ¤j¡A¤p§Ì¦b¦¹ª©©Ó»X±z»P¨ä¥L¤j¤jªº«üÂI±Ð¾É¡AÀò±o¯E¹©»P¬ÛÃöÀù¯gÂåÀøª¾ÃѬƦh¡A¸U¤À·P¿E¡Cªñ¤éŪª©¡A¤ß¤¤¦³¤@Ó°ÝÃD¡A§xÂZ¤£¤w¡C½Ð±z«ü±Ð¡C °ÝÃD¬OÃö©ó822¥ÎÃĪº¨î¡C¤@¯ë¹w®Æ¡A822ÃÄ®ÄÅãµÛ¡Aº¡¨¬¤§«eªº¤£¨¬¡A¬O¨ÅÀù±ß´Á¯f¤HªººÖµ¡A¤£¦ý«Ü°ª¾÷²v¯à©µªø¹Ø©R¡A¬Æ¦Ü¥i¯à²¬Â¡¡A©Îªø´Á¥ÎÃĪø´Á¦³®ÄÃþ¦üºC©Ê¯f¡C¨ÅÀù°ªP©R¡A¥ÎÃĬO¬°¤F¨D¥Í±Ï©R¡A¹ï¯f¤H©M®aÄÝ¡A¥Í¦º§ñÃö¡A³o¥i¬O»·¤ñªÑ¥«ÁȽ߫¤j¤d¸U¿ªº¨Æ¡C Ãö©ó822¥ÎÃĪº¨î¡A®e¤p§Ì¶K¤T«h½å¹F¤j¤jªº°Ýµª¡A¦p¤U¡C ¥xÁÞ¤j¦b½Í½×¦~¾P°âÃB®É¡A»¡¡G¤À¦¤¤±ß´Á¤T´Á¡A822«e´X¦~¥u¯à¨Ï¦b¨ÅÀù«á´Á¡A´X¦~«á¯uªºÁ{§É¦¨¥\±À¦V¦¤¤´Á¨Ï¥Î¡C Faith¤j°Ý¡GY¥¼¨Ó822¦b¥x¤W¥««á¡A0-3´Áªº¨ÅÀù¯f±w¥in¨D¡u¦Û¶O¡v¬I¥´¶Ü¡H ¦Ñ´¤jµª¡G822¥Ø«e¬O°w¹ïÀù¥½°µªºtrial¡A©Ò¥H´Nºâ°w¹ïÀù¥½µ¹¥I¤F¡A¤]¥u·|³Q©ñ¦b¤G½u¥ÎÃÄ¡A¦Ó¥BÁÙ·|¦³¼Æ±øcriteria¡A²Å¦X¤~¥i¥H¥Î¡I¤£ºÞ´X´Áªº¡An¦Û¶O¥´³£¬O¥i¥Hªº¡C ¤p§ÌµLª¾ÃѲL¡A½Ð°Ý 822Y±oÃÄÃÒ¡AÃÄÃÒ·|«ü©ú¥Î©ó±ß´Á¨ÅÀù¯f¤H¶Ü¡H¦¤¤´Á¯f¤Hn¥ÎÃÄ¡A¥u¯à¡u¦Û¶O¡v¡]¥ß¤Áµ²®Ñ¡H¡^Âå°|©M«OÀI¤½¥q·|¤£·|¸ÑÄÀ¬°¦Û«_·ÀI¡A¦³¨Æ¤£²z½ß¡H ¤T´ÁÁ{§É¸ÕÅ窺µ²ªG¡AÃø¹D¤£¯à¤Þ¥Ó¬°¹ï¦¤¤´Á¨ÅÀù¦³®Ä¡H¤£¬O¦³¦¹¤@»¡¡A822¶V¦¬I¥´¡A¶V¦³¦¨®Ä¶Ü¡HÃø¹D©úª¾¿©±w¨ÅÀù¡]¯f¤H©M®aÄÝÅ宣¸Uª¬¡^¡A¥u¦]¦µo²{´N¤£¯à¥Î822¡An´c¤Æ¨ì±ß´Á¤~¯à¥Î822¡H³o¤ÓÂ÷ÃФF§a¡H ¯E¹©ªÑ»ùªñ¤é¶^¤£¥ð¡A¤p§Ì·í¬ÝÀ¸¡A¼@±¡°_¥ñ¡C°ß¥ÎÃÄ°ÝÃD¡AÅåÄߦÓÃø¥HÄÀÃh¡A½Ð¥xÁÞ¤j¼·¤¾¸Ñ´b¡A¸U¤À·P¿E¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/28 ¤U¤È 12:23:54²Ä 2574 ½g¦^À³
|
5 YK¸Ñª¼¥|ºØ±¡ªp¤¤ªº²Ä¤TºØ±¡ªp (±q¤½¥q¦^µªµo²{¤]¯à®³ÃÄÃÒ ) ¦pªGÁ{§É¼f®Ö¤£¦p¹w´Á¡A¦³¦ó³Æ®×¡H 2015/03/03¯E¹©¤WÂdªk»¡·|(3)Q&A Michael¡G¦pªG²£«~¨S¦³Àø®Ä¡A§Ú̦³«Ü¦hӳƮסA¦ý¬O¥Ø«e¨Ó¬Ý¡A¨S¦³¥²n¡C ¸U¤@¸Ñª¼®É¨S¦³²Îp¤Wªº·N¸q¡APȨS¦³¹F¨ì¹w´Á¼Ð·Ç0.05¡A«ç»ò¿ì¡H¤@¯ëFirst In Class Breakthrough Therapy´Nºâ¨S¦³¹F¨ì0.05¡A¦pªG¯f¤H¨S¦³¦w¥þÅU¼{¡A¦Ó¥BÀø®Ä¨ãSignificant¡AÁÙ¬O·|㤩Conditional Approval¡C³oÀ³¸Ó¬O³ÌÃaªºª¬ªp¡A¤]´N¬O»¡¸Ñª¼ªº®ÉÔPȤ£¨ì0.05¡A³o´N¬O³Æ®×¡C «e«h»P¥»«h¶K¤å¬ö¿ý¨Ó¦Û¬P±á¤j¬ö¿ýOBI Pharma Observe |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/28 ¤U¤È 12:12:04²Ä 2573 ½g¦^À³
|
Cliff¥S 1¹ï©ó³oºØªk³Wªº¹ê°È¤Wªº±¡ªp ¤p§Ì¯uªº¥´µ²¤F ÁÙ¦n¦³¦Ñ¥v¥S»PCliff¥Sªº°Q½×¤À¨É ·PÁ´±®¦ ¹ï©óÄY«¯e¯fÃĪ«¼f¬dpµeªº¥|Ó¾÷¨î¦p¦ó»PYK¸Ñª¼¥|ºØ±¡ªp°µÁpµ²¤~¬O¤j®aÃöª`ªºµJÂI, YK¸Ñª¼¥|ºØ±¡ªp¤¤ªº²Ä¤@ºØ±¡ªp §Ú¤ñ¸û¤£¾á¤ß¦]¬°¼fÃÄÃÒ·|«Ü§Ö YK:¦pªGpÈ<0.001¡A¥Nªí¿ù»~¾÷²v¤p©ó0.1%¡A·íµM¥i¥H§Ö³t³q¹D(Fast Track)©¹«e¨«¡A©Ò¥H½µP¤§«án¬Ý¨â²Õ¼Æ¾ÚªºpÈ¡C YK¡G¯E¹©¤T´Á¸ÕÅçÄYÂÔ¨ìÀt¤òªºµ{«×¡C¦b¬ü°êªº¸ÕÅçÄÝ©ó2b´Á¡A¬O¥H¤T´Áªº³W®æ¨Ó°µ¤G´Áªº¨Æ¡A¥xÆW¬O¤T´Á¡C¤@¯ë¼Ú¬ün¦³¨âÓ°ê®a¤T´Á¤~¯à¤W¥«¡A§Ú̧Ʊæ¤@Ó¥xÆWªº¤T´Á¼Æ¾Ú¡A¥H¤Îì¥ý¦b¬ü°êªº¤T´Á³W®æªº¤G´Á¼Æ¾Ú¡A¨âӼƾڦn´N¯à¥Ó½Ð·sÃĤW¥«¡C³o¼Ë¥i¥H¬Ù±¼²Ä¤T´Áªº¸g¶O»PÁ{§É®É¶¡¡C (³o¬q¸Ü´CÅé³ø¾Éªº¤º®e¤£¤@¼Ë) Michael¡G¦pªGÀø®Ä¦n¡A¤@©w·|¾¨§Ö¥Ó½ÐÃÄÃÒ¡A¤§«ePfizer¦³¤@Ó¬r©Ê«Ü±jªº¨ÅÀù·sÃĪº¤G´Á¸ÕÅç¡A¸ÕÅç¤H¼Æ¦³100¤H¥ª¥k¡A¤]´£¦¤G´Á¸Ñª¼¡A±o¨ìFDAªºConditional Approval¡C 2 YK¸Ñª¼¥|ºØ±¡ªp¤¤ªº²Ä¤GºØ±¡ªp pÈ<0.05 ¤p§Ì¯uªº¬O¥´µ²¤F ¬O¥Î¬ü°êµ¥¦P¤T´Áªº¤G´ÁÁ{§É »P¥xÆWªº¸Ø°ê¤T´Á ¦V¬ü°ê¥Ó½Ð¬ð¯}©ÊªvÀø®Öã«á ¦A°µ¤@Ó¤H¼Æ¤£¤@ªº¤T´Á( ¦p¤p¤T´Á ) »Ýn°µ¤TÓ¤T´ÁÁ{§É¶Ü ??? Ó¤H¥H¬ü°ê¥Ó½Ð¬ð¯}©ÊªvÀø®Ö㬰§C¼Ð ¦]¬°¥þ²y¤S¦³´XÁûÃįள¨ì³oÓºaÄ£! 3 Cliff¥S´£¨ì: Ãļt´£¥X¥Ó½ÐFast Track»{ÃÒ«á¡AFDA·|¦b60¤Ñ¤º¨M©w§å㦹¶µ»{ÃÒ»P§_¡A¦Ó«D¡u§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð¡v Cliff¥S ·|¤£·|»~¸Ñ¤F ? ¨Ì¾Ú±´°Q¬ü°êÄY«¯e¯f¥ÎÃÄ«P¶ipµe (¤U) .§Ö³t³q¹D¾÷¨îFast Track Fast TrackÃĪ«µo®i¾÷¨î¬O¬ü°êFDAªº¥[³t¸ÕÅ礤·sÃĨú±o¤W¥«®Ö㪺¤è¦¡¡C³oºØ¤è¦¡¬O§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð¡C³q±`¬Oµ¹¨º¨Ç¦³§Æ±æªvÀøÄY«¡B«Â¯Ù¥Í©Rªº¯e¯f¡A¦Ó¥B³o¨Ç¯e¯f¥Ø«e¨Ã¨S¦³¨ä¥LªºÃĪ«¥iªvªº¡C Cliff¥S ·|¤£·|§â¨âÓ60¤Ñ »~¸Ñ¤F( FDA¦^À³®É¶¡¤]¬O60¤Ñ) https://connectomeblog.wordpress.com/2014/08/25/epsc-2/ 4 YK:¦pªGpÈ <0.001¡A¥Nªí¿ù»~¾÷²v¤p©ó0.1%¡A·íµM¥i¥H§Ö³t³q¹D(Fast Track)©¹«e¨«, ¸Ñª¼¥X²{¥|ºØ±¡ªp¤¤ªº§Ú»{¬°²Ä¤@ºØ±¡ªp¼fÃÄÃÒ¤@©w«Ü§Ö pȶV¤p¼fÃÄÃÒ¶V§Ö¤~²Å¦X±`²z»PÅÞ¿è ¥H¤W´N±ÐCliff¥S ÁÂÁ |
|
|
·|û¡Gyfpeng10138988 µoªí®É¶¡:2016/1/28 ¤W¤È 10:34:39²Ä 2572 ½g¦^À³
|
D§b¤j¡G º¥ý·PÁ±z¦bª©¤Wªø´Áªº°^Äm¡A´£¨Ñ½Ñ¦h¸ê®Æ¡A ¥H¤Î¦³®Äªº°Q½×¡C§@¬°¤@¦ì¼ç¤ôªÌ¡A§l¨ú³o»ò¦hªº¾i¤À¡A ÂǾ÷·|¸ò±z»¡ÁnÁÂÁ¡I¹ï©ó±zªº EPS¹w¦ô¡A¤p§Ì·q¨Ø¡A ¨Ç·LªººÃ¸q¡A¥H¤U¸ò±z°Q½×°Q½×(¦p¤£¤è«K½Ð¤£¥²¦^À³)¡G 1. ¼Æ¦r³¡¤À¡A¨Ï¥Î"·s¼W®×¨Ò"§@¬°¦~«×pºâ°ò¦¡A ³oÓ¦b"·sÃÄ·s¦~«×"ªºÀ禬pºâ¬Û·íÁo©ú¡F¦ý¹ï©ó ®רҪºº¯³z¡A¥H¤Î·sÃĦ~«×ªº²Ö¶i¨Ï¥Î¡AÅãµM §C¦ô¡C ¥t¥~¡A¾P°â°ª®p¬O¥H¥|´Á¤H¼Æ*0.75¤Îº¯³z²v0.7pºâ¡A 0.7·|¤£·|¹L«×°ª¦ô¡H 2. ¤Á½R¤@¤U¡G¦pªG¥u¬ÝEPS¡A·Ó±zªº¦ôºâ¡A¶¶§Qªº¸Ü¡A 10¦~«á(¼Ú¬üÃÄÃÒºâ5¦~¡A°ª®p¦A5¦~)EPS¬ù30¤¸¡A ¤]´N¬O10¦~«á¦X²zªÑ»ù¬O900¡C¬Ý¨Ó§¹¥þ¨S¦³§l¤Þ¤O¡A ¨º»ò½Ð°ÝD¤j±z§ë¸ê¯E¹©ªº²z¥Ñ¬O¤°»ò¡HD¤jªº¥Î·N ¬O¤£·Q§ë¸ê¤H¹L«×¹w´ú¡A©Ò¥H¥¿Å³ø¾É¶Ü¡H D¤jªºpºâ¬Û·í¦³·N¸q¡A¹ï©ó¤½¥q±N¨ÓªºÀ禬¹w¦ô¡A ´£¨Ñ«Ü¦³»ùȪº°ò¦¡AÁÂÁ¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/1/28 ¤W¤È 09:26:02²Ä 2571 ½g¦^À³
|
¸É¥RCliff¤j ¨ì¥Ø«e¬°¤î¦@¦³¨âÓBTD³Q¨ú®ø ¨âÓ³£¬OC¨xªºÃÄ¡AMerck»PBMS |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/1/28 ¤W¤È 09:23:58²Ä 2570 ½g¦^À³
|
ÁÂÁÂCliff¤j¡A¦A°µ¤@¦¸²M·¡ªº´¦¥Ü¡A§ó¯à©ú¥Õ¢Ô¢Ò¢Ïµ¹¤©§Ö³t³q¹D¡A¬ð¯}©ÊªvÀø¡A¥[³t¼f¬d¡AÀu¥ý¼f¬dµ¥¤£¦P¾÷¨îªº»{ÃҼзǡC |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/1/28 ¤W¤È 12:22:41²Ä 2569 ½g¦^À³
|
¥xÁÞ¥S¡A»P±z¤Á½R¡C Ãö©óFast Track¡BPriority Review &Breakthrough Therapy¡A¤p§Ìı±o±z¦³¨Ç»~¸Ñ¤]¦³¨Ç¥´µ²ªº¦a¤è¡C Fast Track¡G Ó¤Hı±o³o¤@¶µ¬O³Ì®e©ö®³¡A¤]¬O³Ì¦¥i¥H®³ªº¤@¶µ¡A³Ì®e©ö®³ªº¦ÛµM¤]´N¤ñ¸û¤£µ}©_¡C¥¦¥²¶·¥ÑÃļt¦Û¤v´£¥X¥Ó½Ð¡A¦Ó¥B¥un¦³¡uªì¨B¸ê®Æ¡v¡]Á{§É«e©ÎÁ{§É¸ê®Æ¬Ò¥i¡^Åã¥ÜÀø®Ä¤ñ²{¦³ªvÀø§ó¦n©Î¬Æ¦Ü°Æ§@¥Î§ó§C¡A¥Î©ó¡uÂåÀø©|¥¼³Qº¡¨¬¡vªº¡u«¤j¯e¯f¡vªÌ¡A¬Ò¦³§Æ±æÀò¦¹»{ÃÒ¡A©Ò¥H¹³Àù¯g¡B·R´þ³£®e©öÀò¦¹»{ÃÒ¡C¬°¦ó»¡¥un¦³¡uªì¨B¸ê®Æ¡v§Y¥i´£¥X¥Ó½Ð¡H¦]¬°¥¦¥i¥H¦b·sÃĬãµo¹Lµ{ªº¥ô¦ó¶¥¬q³£¥i¥H´£¥X¥Ó½Ð¡A¥ØªºÅýFDA¯à¦´Á´N¯à¤¶¤JÃļt·sÃĪº¡u¬ãµo¡v¡]¤£¬OÃÄÃÒ¼f¬d¡^¡AÅý¾ãÓ·sÃĬãµo¹Lµ{¤¤¥i¥H¸g¥Ñ»PFDA¸û¦hªº¶}·|»P®Ñ±©¹¨Ó¡A¨Ó¾¨¶q¥¿½T¦a¨ó§UÃļt¾¨§Ö¦a¨ú±oÃĪ«¤W¥«©Ò»ÝÃĪººØºØ¸ê®Æ»P¼Æ¾Ú¡A¬Ù±¼¨«¤J©t¥ßµL´©¡AµL¤H«ü¾ÉªºÞªP¸ô¡A©Ò¥H¬Æ¦Ü¬Opreclinical stageªº¼Æ¾Ú¥ç¥i¡A´«¥y¸Ü»¡¡AÀò±o³o¶µ»{ÃÒªº·sÃĨ䣤@©w¦³¨º»ò°ªªº¾÷·|¯à®³¨ì³Ì«áªºÃÄÃÒ¡C Ãļt´£¥X¥Ó½ÐFast Track»{ÃÒ«á¡AFDA·|¦b60¤Ñ¤º¨M©w§å㦹¶µ»{ÃÒ»P§_¡A¦Ó«D¡u§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð¡v¡A³oÂI±z¦ü¥G¦³©Ò»~¸Ñ¡CnFDA¦b60¤Ñ¤º§¹¦¨·sÃļf¬d¡A³o¥sObama¨ÓÃö»¡¤]Ãø¥H¹F¨ì¡C¦]¬°Ãļt´£¥XFast Track¥Ó½Ðªº®É¶¡ÂI¥i¥H¬OIND®É©ÎIND«á¡A¦b³o»ò¦ªº®É¶¡ÂI¤W¡A®Ú¥»¶ZÂ÷ÃÄÃÒ¼f¬dÁÙ®t¤Q¸U¤K¤d¨½¡A©Òª`«ªº¬O¤W±©Ò´£¨ìªº¡A¯à»PFDA°µ¦´Áªº·¾³q¡AÁקK¡u¬ãµo¹Lµ{¡v¨«ÞªP¸ô¡A¦Ó«D¤w¨«¨ì¤F¡u·sÃļf¬d¹Lµ{¡v¡C¤£¹L¤@¥¹¶i¤J¸ÕÅç²×ÂIn¥Ó½ÐÃÄÃҮɡA¥i¨É¦³ºu°Ê¦¡¼f¬d¡]Rolling review¡^ªºÀu´f¡A¥i§â¤w§¹¦¨ªº³¡¤À¼Æ¾Ú¸ê®Æ³v¦¸°e©¹FDA¥ý¼f¡A¦Ó¤£¥²¹³¶Ç²Î¼f¬d·sÃĤ@¼Ë¡A¶·§â©Ò¦³¥Ó½Ð·sÃļf¬dªº¸ê®Æ²Î²Î³Æ»ô«á¤~¯à°e¥hFDA¡C§åã«áY¥¼¨Ó·íFDAµo²{¤£¦A¨ã³Æ/²Å¦Xªº±ø¥ó®É·|¥D°ÊºM¾P»{ÃÒ¡C³q±`Àò±oFast Track»{ÃÒªº·sÃÄ¡A¤]¥i¯à²Å¦XAccelerated Review¤ÎPriority Review¡C ÀHµÛÁ{§É¸ÕÅç¤@´Á¡B¤G´Á¡Kªº¶i®i¡A¦pªG¦³¡uªì¨BÁ{§É¸ê®Æ¡v¡]¦Ü¤Ö¬OPhase I¡F¤]´N¬O¤HÅ骺¡^±o¥HÅã¥Ü¤ñ²{¦³ÃĪ«¦bÁ{§É²×ÂI¡]clinical endpoint¡^¦³¹ê½è¤WªºÀu¶V©ÊªÌ¡A¥i¥H¥Ó½ÐBreakthrough Therapy»{ÃÒ¡C¡]¡Kindicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies¡^ Breakthrough Therapy¡G ¥Ó½Ð®É¾÷¡GIND®É©ÎIND«á¡C §åã®É¾÷¡GFDA·|¦b60¤Ñ¤º¨M©w§å㦹¶µ»{ÃÒ»P§_¡C ¦³¦ó¦n³B¡GFDA·|¦¨¥ß±MÄÝ©eû·|¨Ó¥[±j«ü¾É·sÃĪº¬ãµo¹Lµ{¡AÅý¬ãµo¹Lµ{§ó¦³®Ä²v¡A¦P®É¤]¨É¦³ºu°Ê¦¡¼f¬d¡]Rolling review¡^ªº«Ý¹J¡C ¦³¦ó¯ÊÂI¡G¥¼¨Ó·íFDA¥D°Ê©Î³Q°Êµo²{³Ì²×¼Æ¾Ú¦H©ó·íªìªì¨B¼Æ¾Ú¡A©Îµo²{¦³§ó·sªºÃÒ¾ÚÅã¥Ü¨ä¥¦·sÃÄÀø®Ä¶W¶V¦¹ÃĮɡA·|¥D°ÊºM¾P»{ÃÒ¡C¦L¶H¤¤Merck´¿¦³¤@ÓC¨x·sÃÄ´N³QºM¾P¹L¡C©Ò¥H³o¶µ»{ÃÒ¤£¤@©w¥Ã»·¤£ÅÜ¡A¤]¤£¥Nªí¤@©w¥i¥H®³¨ìÃÄÃÒ¡CºÝµø¼Æ¾Ú¦Ó©w¡C Accelerated Review¡G ³o¬O¤@ºØ¼f¬d¸ô®|¡]Approval pathway¡^¡A¦Ó«D»{ÃÒ¡]Designation¡^¡C ¦b¬ãµo¹Lµ{¤¤Ãļt»PÃÄÃÒ¼f¬d³æ¦ì´N´À¥N©ÊÁ{§É²×ÂI¡]Surrogate endpoint¡^°µ°Q½×¡AY´À¥N©ÊÁ{§É²×ÂI¼Æ¾Ú¥i¦X²z¦a¹w´ÁÀu©ó²{¦³«¤j¯e¯fÃĪ«ªÌ¡A¥i³Q§åã³o¶µ¸ô®|¡C¦³¥i¯à¥H¤G´Á¼Æ¾Ú°e¼f¥ý¨ú±oÃÄÃÒ¡A¥¼¨Ó¤W¥««á¦A¸É°µ/¸É°e¤T´Á½T¥ß©Ê¸ÕÅç¼Æ¾Ú¡C Priority Review¡G Á{§É¸ÕÅçµ²§ô¶i¦æ¨ì¥Ó½ÐÃÄÃҮɡAY¼Æ¾Ú/¸ê®ÆÅã¥ÜÀu©ó²{¦³«¤j¯e¯f¦³¾÷·|Àò¦¹»{ÃÒ¡CFDA¦bÃÄÃҥӽЪº2Ó¤ë«ØÀÉ´Á¶¡¤ºY»{¬°¦¹ÃIJŦX±ø¥ó¡A·|§â§¹¦¨ÃÄÃÒ¼f¬dªº¹w©w®É¶¡¡]PDUFA¡^¥Ñ¶Ç²Îªº10Ӥ뤺§¹¦¨ÁYµu¬°6Ӥ뤺§¹¦¨¡C ©Ò¥H°ò¥»¤W¡u¡K¦pªG®ÖãBTD¤]¾A¥Î¨ä¥L¨Ã¨É¦³¨ä¥L¤TºØºÞ¹D¡A±q®Öã¨ìÃÄÃÒ®Öµo¥§¡10Ó¤ë¡A³o»òµuªº®É¶¡¦p¦ó°µ¤T´ÁÁ{§É?¡K¡v³o¼Ëªº°ÝÃD¬O¤£¦s¦bªº¡A¦]¬°¦UÓ»{ÃÒªº¾A¥Î®É¾÷¬O¤£¬Û¦Pªº¡C ¥H¤W¸ê®Æ©Î³\²²¤¬Æ¦Ü¿ù»~¡A·L¨¥¤j¸q½Ð°Ñ¬Ý¡G ¡uGuidance for Industry¡GExpedited Programs for Serious Conditions¡VDrugs and Biologics.¡v ¡]http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf ¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤U¤È 11:34:32²Ä 2568 ½g¦^À³
|
4 ¥t¥~¥xÆW¬ãµoªº³Ð·sÃĪ« ,°·«OÀ³¤ä¥I¥H³yºÖ°ê¤H¤]µ¹¥Í§Þ¤½¥q¹ªÀy(¥Íµ¦·|¤W¦¸¦³«Ø¨¥) °ê¥~¬ãµoªº¶PÀù¥³£µ¹¥I¤F, °ê¤º¦Û¦æ¬ãµoªº¨ÅÀùOBI822 »P¥H«áªº¾AÀ³¯g¨S¦³²z¥Ñ¤£µ¹¥I¤j³¡¥÷ ¸É¥R ¬ü°êÂಾ©Ê¨ÅÀù¤H¼Æ¶W¹L155000¤H ¦ppºâ¤K¤j¤u·~°ê®a¦Ü¤Ö¶W¹L300000¤H |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/1/27 ¤U¤È 10:37:15²Ä 2567 ½g¦^À³
|
D§b¤j: §O°Ê®ð§r~ °ß±©¤jµ´¹ï¤£¬O¨º¼Ëªº¤H. ½ÐÄ~Äòµoªí±zªº°ª¨£,¦h·¾³q¦h¿EÀú.ÁÂÁ±z! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤U¤È 10:09:45²Ä 2566 ½g¦^À³
|
D§b¤j 1¬ü°êÂಾ©Ê¨ÅÀù¤H¼Æ¶W¹L155000¤H ¤£¬O15000¤H ®t¤Q¿³á (n§ä¬ü°êªº¸ê°T ¤£n§ä¹Å¸q°ò·þ±ÐÂå°|) http://mbcn.org/education/category/most-commonly-used-statistics-for-mbc LIVING WITH MBC The number of people living with metastatic breast cancer in the US is estimated to be over 155,000 2 ©w»ù¯dµ¹¤½¥q»P¬ü°êFDA ,À³´L«¤½¥q , §K¬ÌÀøªk¦³¨ä°ê»Ú¦æ±¡,¤£©yÀ°¤½¥q©w»ù 3 §ÚÅ¥¹L±i¸³ºtÁ¿¿ý¼v±a ¹ï©ó¬ü°ê³h§xªº¯f±w¤@¯ë·|±Ä¥Î°eÃĵ¹Âå°|ªº¤è¦¡ ¦ý¬OÃÄ»ù¤£¯à¬å ¥xÆW¤è±À³·|¦¨¥ß°òª÷·|¹ï®z¶Õ¯f±w´£¨ÑÂåÀø·ÓÅU |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2016/1/27 ¤U¤È 09:18:22²Ä 2565 ½g¦^À³
|
°ß¤j¡G§Ú¥u¬Oºâºâ¾P°âª÷ÃB¡A¦³«Ü¤j°ÝÃD¶Ü¡H¤p§ÌÁA¤F¡A³oª©±z¬OÀY¡A±z»¡¤Fºâ¡I |
|
|
·|û¡G°ß±©10140520 µoªí®É¶¡:2016/1/27 ¤U¤È 09:05:41²Ä 2564 ½g¦^À³
|
D§b¤j ¤p§Ì¦pªG»¡¡A§Ú®Ú¥»Ãi±o³¾®³¨ìÃÄÃÒ¡A¥i¥H¾a¾P°âÁȦh¤Ö¿ú¡H¦³EPS¤~¬O¯u¥¿ªºÀ禬¡A §Ú·Q¡AÀ³¸Ó¬O¨S¾÷Ó¤H·|ÃhºÃ¡A¤p§Ìµ´¹ï¤ñ±z§ó¦³¸ê®æ³o»ò»¡§a¡A©Ò¥H.......¥Nªí±z³o´X¤ÑÁ¿ªº³£¬O¼o¸Ü¡A¹ï¶Ü¡HÁÙ¬O¸Óµê¤ß¤@ÂI¡H |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2016/1/27 ¤U¤È 09:04:03²Ä 2563 ½g¦^À³
|
©êºp¡G¬ü°ê¦b¨ÅÀùÁ{§É¤À´Á¤ñ¨Ò ¡A¨Ó·½¥xÆW¡§¹Å¸q¡¨°ò·þ±ÐÂå°| |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2016/1/27 ¤U¤È 08:46:36²Ä 2562 ½g¦^À³
|
¥xÁÞ¤j: §Ú¨S¤º½u©Ò¥H¤£²q¸Ñª¼µ²ªG¡A¤]¨SªÅ²zɨé½æ¥Xªº¤H¦b·Q¤°»ò¡A§ó¤£·Qª¾¹D¥¨·à«ç»òײz¯T¸s¡C §Ú¥u·Qª¾¹D®³¨ìÃÄÃÒ«á¥i¥H¾a¾P°âÁȦh¤Ö¿ú¡A³oùØɥΥxÁÞ¤jPo¹Lªº¼Æ¾Ú¤è«Kpºâ¡G¶È ¯à´N¥Ø«e©Òª¾¦³ªº±¡ªp¤U°µ«Ü¦h°²³]¡A¦ý¤H¼Æ¬O³]¸ê®Æ¡C¦pªG¨º¦ì¤j¤j»{¬°«ç³o»ò ¤Ö¤H±o¨ÅÀù¡H³Â·Ð¥xÁÞ¤j¸ÑÄÀ¡I¡q¶}ª±¯º¡r A ´N¨ÅÀù»PªÍÀù¨C¦~¬ü°ê·s¼W»P¦º¤`¤H¼Æ(2014) -----------¹w¦ô·s¼W®×¨Ò ---¹w¦ô¦º¤`®×¨Ò ¨ÅÀù------- 235030 -------40430 ªÍ»P¤ä®ðºÞÀù 224210 -------159260 B´N¨ÅÀù»PªÍÀù¨C¦~¼Ú¬w·s¼W»P¦º¤`¤H¼Æ (2012) -----------¹w¦ô·s¼W®×¨Ò ---¹w¦ô¦º¤`®×¨Ò ¨ÅÀù------- 464000------- 131000 ªÍ»P¤ä®ðºÞÀù 224210 -------159260 ¬ü°ê¦b¨ÅÀùÁ{§É¤À´Á¤ñ¨Ò ¡A¨Ó·½¥xÆW°ò·þ±ÐÂå°| ¬ü°ê ²Ä¤@´Á 60% ²Ä¤G´Á 20% ²Ä¤T´Á 14% ²Ä¥|´Á 6% ¨ÅÀù4´Á¦û·s¼W®×¨Ò6%¡A´«ºâ¬ü°ê4´Á¤H¼Æ14000¤H¡A¼Ú¬w28000¤H¡C ¦³GH¦û75%¡A½Õ¾ã¾A¥Î¤H¼Æ¤À§O¬°10500©M21000¤H¡F§ì¡§5¦~¡¨«á¾P°â°ª®pº¯³z²v70%¬°7350¤H©M14700¤H¡C ¬ü°ê¥«³õÃÄ»ù30000¬ü¤¸*7350=2.2»õ¬ü¤¸*²b§Q40%¬°8800¸U¬ü¤¸ ¼Ú¬w¥«³õÃÄ»ù30000¬ü¤¸*14700=4.4»õ¬ü¤¸*Åv§Qª÷15%¬°6600¸U¬ü¤¸ ¤]´N¬O¬ü°ê¥[¼Ú¬w5¦~«á6.6»õ¬ü¤¸/¦~Åq®p¾PÈ¡A²b§Q1.54»õ¬ü¤¸¦X¥x¹ô50.82»õEPS29.77¤¸ pºâùؤ饻¥«³õÁÙ¥¼§t¡A¤¤°ê³sÁ{§É³£ÁÙ¨S¦³³q¹L©Ò¥H¤]¥¼p¤J °t¦X¤U±¥xÆW¥Í§Þ¾ã¦X¨|¦¨¤¤¤ß¾ã²zªº¼Æ¾Ú,±Æ¦W²Ä 2¦W´N¬Oªº Xeloda ¥e©Ò¦³¨ÅÀùÃÄ«~¾P°âÃB¤§ 10.0%¡A ¬° 15.9 »õ¬ü¤¸¡A¨Ã¥B¬O 2012 ¦~¥þ²y±Æ¦W²Ä 62 ¦WªººZ¾PÃĪ«¡C±Æ¦W²Ä 3 ¦W¤§¨ÅÀùÃĪ«¬° Zoladex¡A ¬O±Æ¦W²Ä 1 ªº¨ÅÀù²üº¸»X¥ÎÃÄ¡A2012 ¦~¾P°âÃB¦³ 10.9 »õ¬ü¤¸ ©Ò¥H³oÓ6.6»õ¼Ú¬w¥[¬ü°ê¾P°âÃB¦b4´ÁÀ³¸Ó¬O¦X²z¡C¡q§OªºÃĦb¸Ó´Á¤H¼Æ¥i¤ñ4´Á¦h³á¡r ·íµM¦U¦ì¥i¥H½Õ¾ãº¯³z²v¡BÃÄ»ù©ÎÅv§Qª÷¤Î²b§Q¤ñ¨Ò¡A¥X¨Óªº¼Æ¦r´N¤£¤@¼Ë¡C¦ý¦pªG¦³¤j¤j°í«ù»{¬°®³¨ì ÃÄÃҫᡧ°¨¤W¡¨¨C´Á³£¥i¥Î¡A«OÀI¤½¥q¤]µ¹¥I¡F©ÎªÌ¨ä¥L8ºØÀù¯g¤]¾A¥Î¡A§â³oÓEPS¼¥H5©Î30ÀH¤j®a¶}¤ß§Ú¨S ·N¨£¡C¦]¬°°²³]¤Ó¦hÃø§K¦³¿ù©Ò¥H¶È¨Ñ°Ñ¦Ò¡A¥Î·N¤]¥u¬O¤U¦¸¦pªG±z¬Ý¨ì¦³³ø§i¼g¾P°âÃB200»õ¬ü¤¸¡A¦Ü¤ÖÅý±z¦³Ó©³ ¤£n¨º»ò§Ö¬Û«H¥¦¡CÁÂÁ ªþµù¸ê®Æ¨Ó·½¡G¥xÆW¥Í§Þ¾ã¦X¨|¦¨¤¤¤ß »ùÈÃì½LÂI(¨ÅÀù) 2012 ¦~¥þ²y¨ÅÀùÃÄ«~É]³õ«e¤¤jÃĪ«¤À§O¬° Herceptin¡BXeloda¡BZoladex¡B Evista¡BAfinitor¡A«e¤¤jÃĪ«¥e©Ò¦³¤w¤WÉ]¨ÅÀùÃÄ«~¤§Á`¾P°âÃB 66.0%¡CHerceptin ©ó 2012 ¦~ªºÉ]³õ¾P°â¹F¨ì 64.2 »õ¬ü¤¸¡A¨Ã¥B¦¨¬°¥þ²yºZ¾P²Ä 9 ¦WÃĪ«±Æ¦W²Ä 2¦W´N¬O ªº Xeloda ¥e©Ò¦³¨ÅÀùÃÄ«~¾P°âÃB¤§ 10.0%¡A¬° 15.9 »õ¬ü¤¸¡A¨Ã¥B¬O 2012 ¦~¥þ ²y±Æ¦W²Ä 62 ¦WªººZ¾PÃĪ«¡C±Æ¦W²Ä 3 ¦W¤§¨ÅÀùÃĪ«¬° Zoladex¡A¬O±Æ¦W²Ä 1 ªº¨Å Àù²üº¸»X¥ÎÃÄ¡A2012 ¦~¾P°âÃB¦³ 10.9 »õ¬ü¤¸¡C ¡i¼¶¼g¤é´Á:2014/12¡A¹wp§ó·s¤é´Á:2015/12¡j 11 ¥xÆW¥Í§Þ¾ã¦X¨|¦¨¤¤¤ß»ùÈÃì½LÂI(¨ÅÀù) Perjeta ©ó 2012 ¦~¤WÉ]«áªºÉ]³õªí²{¤£«U¡A¦Ü 2013 ¦~¤w§Ö³t®Ê¤É¦Ü 3.4 »õ¬ü ¤¸ªº¾P°âÃB¡A¦¨ªø²v°ª¹F 151.6%¡C2014¡ã2017 ¦~¥þ²y¨ÅÀùÃÄ«~É]³õ¹w¦ô±N¦³´X ¶µ¬ãµo·sÃĶi¤JÄvª§¿E¯PªºÉ]³õ¡A±N±À¤É¨ÅÀùÉ]³õªº«ùÄò¦¨ªø¡C쥻©~«aªº Herceptin¡A¦]¬°¦P§@¥Î¼Ð¹v¤§ Perjeta ¤Î Kadcyla µ¥·sÃĶi¤JÄvª§ªº´À¥N¦Ó±N¨ü¨ì ¼vÅT¡A¦]¦¹¾P°âÃB±N§e²{¤U·ÆÁͶաAPerheta ¥i±æ¦Ü 2015 ¦~ÅE¤ÉºZ¾PÃĪ«¤§¦C¡A ¾P°âÃB¹w¦ô¥i¹F¨ì 13.5 »õ¬ü¤¸¡A2014¡ã17 ¦~¤§ CAGR ¬° 40.5%¡CKadcyla ¬° Herceptin ªº§ÜÅé½Æ¦XÃĪ«¡]antibody-drug conjugateated ¡AADC¡^¡A¦]¨ã³Æ Herceptin »P¤ÆÀøÃĪ«ªºÂù®Ä§@¥Î¡A±N§Ö³t·m§ðÉ]³õ¡A¹wp 2015 ¥ç¥i®Ê¤ÉºZ¾PÃĪ«¤§¦C¡A ¾P°âÃB¬ù¬° 10.6 »õ¬ü¤¸¡A2014¡ã17 ¤§ CAGR ¬° 50.0%¡CµM¦Ó 2016¡ã17 ¦~±N¦³ ¤@¨ÇÉ]³õ¤Wªº¥Dn²£«~±Á{±M§Q¨ì´Á¡A¾Ç¦WÃĪº«d»ùÄvª§¡A¨Ï±o¨ÅÀùÃĪ«É]³õ¦Ü 2017 ¦~±N·L´Tªº¤U¶^¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤U¤È 08:41:05²Ä 2561 ½g¦^À³
|
¦Ñ¥v¤j 1 »{¦P§Aªº¬Ýªk:Áú°êHanmi Pharmaceutical»P ÁÉ¿Õµá¯}¬ö¿ýªº39»õ¼Ú¤¸¦X§@±ÂÅvª÷ (¤@ÁûÁ{§É«e ¤@Áû¤@´Á ¤@Áû¤G´Á)»·»·¶W¶V2014¦~½÷·ç&¼w°êÀq§JPD-L1ªº28.5»õ¬üª÷¡A¦³¬°ªÌ¥çY¬O¡C ¤µ¦~¦³³oÓ¹Ú´N°÷²¢¤F 2¤ñ¸û¦b·N¶ùµ¹PD-1ÁÙ¬OPD-L1 ¦³¦ó®t§O? ¬d¨ìÁú°êHanmi Pharmaceutical ±ÂÅv¥X¥hªº²£«~ªºÁ{§É´Á§O:(¿}§¿¯fÃÄ) Efpeglenatide(HM11260C) Phase 2 Long-acting Exendin-4 analog Once a week~month admin.; T2DM Licensed out to Sanofi LAPSInsulin 115(HM12470) Phase l Long-acting insulin analogOnce a week admin.; T2DM Licensed out to Sanofi LAPSInsulin Combo Preclinica Long-acting Insulin 115/ Exendin-4 combination Once a week admin.; T2DM Licensed out to Sanofi ¥t¥~Áú°êHanmi Pharmaceutical»P§¨ÓÃļtñ¸pBTK inhibitor (¤G´ÁÁ{§ÉªºRAÃĪ«) ¦X§@±ÂÅv6.9»õ¬ü¤¸ HM71224 BTK inhibitor Licensed out to Eli ¤µ¤ÑÁú°êHanmi Pharmaceutical ªÑ»ù 709,000Áú¤¸ ´«ºâ¥x¹ô19821¤¸ ¬ü¤¸/¥x¹ô 33.601 ¬ü¤¸/ÁúéG1202.25 ¨ÅÀùOBI822 ¦bµ¥«Ý°ê»Ú¦æ®aªº¼z²´ÃÑ^¶¯(¤j®a²q¤@²q·|¤£·|¤]¤TÃĦP®É¦X§@±ÂÅv)( ¨ÅÀù §Z±_Àù ¯ØŦÀù) Àù¯g¥«³õ¤ñ¿}§¿¯f¥«³õ¤j, Á{§É´Á§O¤ñ Hanmi Pharmaceutical §ó«á´Á ,(¨ÅÀù¤w¸Ñª¼¶R®a§ó¦w¥þ¦³«O»Ù) ¦Ñ´¤j ½Í¨ìPȦѴ¤j¤j´N¯º¤f±`¶}, ¤µ¤ÑÁú°êHanmi Pharmaceutical ªÑ»ù 709,000Áú¤¸ ´«ºâ¥x¹ô19821¤¸ ¦pªG¦³¤@¤Ñ¨ÅÀùOBI822¤]¤TÃĦP®É¦X§@±ÂÅv ,·Q¹³¦Ñ´¤j¤j¥²·|¸ú¦b´Ö³Q¸Ì¯º ¯º¨ì¤Ñ«G |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2016/1/27 ¤U¤È 02:31:47²Ä 2560 ½g¦^À³
|
³oÓ¸ê®Æ§ó·shttp://www.dezedr.com/item_detail.php?lm=news&newsid=361 |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2016/1/27 ¤U¤È 02:26:25²Ä 2559 ½g¦^À³
|
¦Ñ¥v¤j¡G¦³¨º»ò¤jªºªÅ®ð¿ú¬O¦]¬°¦³¨º»ò¤j¥«³õ¡A¦ÓÁÉ¿Õµá¤S¬OÀsÀY«á±°l§L²³¦h¡A½Ð°Ñ¦Ò¡IÁÂÁ http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_and_hanmi_announce_lice_1964217_05-11-2015!07_00_00.aspx http://news.sina.com.tw/article/20140805/13043875.html |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/1/27 ¤U¤È 01:17:51²Ä 2558 ½g¦^À³
|
¥xÁÞ¥S ¾Ö¦³BTD¸ê®æ»Pn¤£n¶i¦æ¤T´ÁÁ{§ÉÀ³¤À¶}¨Ó¬Ý¡A¤§«e´£¨ì´XÓ§K¤T´ÁªºÃĪ«¡A¤]¥¼¥²¦³BTD¸ê®æ¡A ¦Ó¤ß®®¨ú±oBTD¤§«áªºÁ{§É³]p¬O2b/Phase3¦X¨ÖÁ{§É¡A¨Ã¨S¦³§K¥h¤T´Á¡A¦Ü©ó¤ß®®§¹¦¨2b¤§«á·| ¤£·|±o¨ì§K°£¤T´ÁÁ{§ÉªºÀu´f¡A³o¬OFDAªº¨Æ¡C©Ò¥H¯E¹©¦pªG¬O±¡ªp¤@¡A´N¤£¥ÎºÞBTD¦³µL¨ú±o¤F¡A BLA®É¶¡®t²§¬O¦bstandard review©Îpriority review¡C¦pªG¬O±¡ªp¤G¡A´N¨Ä¨Ä°µ¤H¼Æ¤£¤@ªº ¤T´Á§a¡A¥Ñ©ó¨C®a¥Ó½ÐBTD¸ê®æªº®É¶¡¤£¤@¡A©Ò¥H§Ú¤£·|¦b·N¡u¥§¡¤QÓ¤ë¡v³oӼƦr¡A¹³¤ß®® 2014¦~11¤ë´N¨ú±oBTD¡ASND13¨ì²{¦b¤w¸g¶W¹L13Ó¤ë¤F¡Aµ¥¨ì¨ú±oÃÄÃÒ®£©ÈÁÙn2¦~¡C ¦Ü©ó¬ü°ê¬O§_¥i¯à¤ñ¥xÆW§ó¦®ÖµoÃÄÃÒ¡A³o¥ó¨Æ§Ú¤£´±·Q¡A§Ú¤Ï¦Ó¤ñ¸û¦b·N¶ùµ¹PD-1ÁÙ¬OPD-L1¡A ¤Ï¥¿¨â®a³£¬O¦n³¥¤H¡CÁú¬üÃÄ·~°µ§¹2b´N¨ú±oÁÉ¿Õµá¯}¬ö¿ýªº39»õ¼Ú¤¸¦X§@±ÂÅvª÷¡A»·»·¶W¶V2014 ¦~½÷·ç&¼w°êÀq§JPD-L1ªº28.5»õ¬üª÷¡A¦³¬°ªÌ¥çY¬O¡C¤µ¦~¦³³oÓ¹Ú´N°÷²¢¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤W¤È 09:44:29²Ä 2557 ½g¦^À³
|
¦Ñ¥v¤j §Ú·Q°_¨Ó¤F °²¦p¸Ñª¼«á¬O²Ä¤@ºØ±¡ªp¤½¥q¥«·|¨«§Ö³t³q¹DFast Track ¨Ó¥Ó½ÐÃÄÃÒ °²¦p³Q¬ü°êFDA®Ö㠨̦ѥv¤j¬ã§P ·|¤£·|µo¥Í¤ñ¥xÆWTFDA§ó¦®ÖãÃÄÃÒ ¸É¥R A§Ö³t³q¹D¾÷¨îFast Track ³¡¤À«ÂI 1Fast TrackÃĪ«µo®i¾÷¨î¬O¬ü°êFDAªº¥[³t¸ÕÅ礤·sÃĨú±o¤W¥«®Ö㪺¤è¦¡¡C³oºØ¤è¦¡¬O§â·sÃļf¬dªº®É¶¡©w¦b¥H60¤Ñ¬°¥Ø¼Ð 2¬ü°êFDA¹ïFast Track¥Ó½Ðªºn¨D¬O¥²¶·±oº¡¨¬¤@Ó¥¼³Qº¡¨¬ªºÂåÃĻݨD¡A¥ô¦ó³Qµo®i°µ¬°ªvÀø©Î¹w¨¾¥Ø«e¨S¦³ªvÀø¤èªkªº¯e¯fªºÃĪ«³£¥i¥H³Qµø¬°º¡¨¬¤@Ó¥¼³Qº¡¨¬ªºÂåÃĻݨD¡C¦Ó¦pªG¬O¹ï©ó¥Ø«e¤w¸g¦³ªvÀø¤è¦¡ªº¯e¯f¡An·Q¦¨¬°Fast TrackªºÃĪ«¥²¶·®i¥Ü¨ä»P²{¦æªvÀø¡]available therapy¡^¬Û¤ñ®i²{¥XªºÀu¶Õ¡A¨Ò¦p¡G®i²{Àu©ó²{¦æªvÀøªºÀø®Ä¡B¯à°÷ÁקKµo¥Í²{¦æªvÀø¤è¦¡·|²£¥ÍªºÄY«°Æ§@¥Î¡B§ïµ½¤@¨Ç¦´Á¶EÂ_¯à°÷¦³¸û¨Î¹w«áªºÄY«¯e¯fªº¶EÂ_¯à¤O¡B»P¤w³Q±µ¨üªºªvÀø¬Û¤ñ¯à°÷¦bÅãµÛ´î¤ÖÁ{§É¤Wªº¬r©Ê¡C 3Fast Track¥²¶·¥ÑÃļt¥D°Ê´£¥X¥Ó½Ð¡C¦bÃĪ«ªº¶}µo¶¥¬qªº¥ô¦ó®ÉÂI³£¥i¥H´£¥X¥Ó½Ð¡CFDA±N¼f®Ö¸Ó¥Ó½Ð¨Ã¦b¦¬¥ó¤é°_60¤é¤º°ò©óÃĪ«¬O§_¹ï¤@ÓÄY«¯e¯fº¡¨¬¤F¥¼³Qº¡¨¬ªºÂåÃĻݨD¶i¦æ½T»{ B¬ð¯}©ÊªvÀø¡]Breakthrough Therapy¡^³¡¤À«ÂI ¬ð¯}©ÊªvÀø¬O¤@ºØ¥[³t¥Î©óªvÀøÄY«¯e¯f¥Bªì¨BªºÁ{§ÉÃÒ¾Ú¤w¸gÃÒ©ú³oÓÃĪ«¤w¦³»·¸û²{¦æªvÀø¬°ÀuªºÃĪ«¶}µo»P¼f®Öªºµ{§Ç¡Cn¨M©w¬O§_¤ñ²{¦æªvÀø¤è¦¡¦³©ÒÅãµÛ§ïµ½¬O°ò©óªvÀø®ÄªGªº±j«×¡A¥]§t®ÄªGªº´Á¶¡¡A¥H¤ÎÆ[¹î¨ìªºÁ{§Éµ²ªGªº«n©Ê¡CÁ`Åé¨Ó»¡¡AÁ{§ÉÃÒ¾ÚÀ³¸Ón¯à®i²{¥X©úÅãÀu©ó²{¦æªvÀøªºÀu¶Õ¡C ÃĪ«¨ú±o¬ð¯}©ÊªvÀø¤§«á¥i¥H±o¨ì¥H¤Uªº¼úÀy¡G ¥þ³¡fast trackªº¼úÀy¡C FDA·|©ó¬ð¯}©ÊªvÀø¥Ó½Ð¦¬¥ó«á60¤Ñ¤º°µ¥X¦^À³¡C https://connectomeblog.wordpress.com/2014/08/25/epsc-2/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤W¤È 08:17:11²Ä 2556 ½g¦^À³
|
5¨Ì¾Ú¬ü°êFDA¼fÃĪº¤è¦¡¦³fast track ,BTD,priority review,»Paccelerated review, ¨Ò¦p®³¨ìBTD¤]¯à¨É¦³priority review,®³¨ìfast review¤j³¡¥÷³£¯à®³¨ìpriority review¡A °²³]¸Ñª¼¬O¤j®a´Á±æªº²Ä¤GºØ±¡ªp¡A¤½¥q¦V¬ü°êFDA´£¨ìÃÄÃҥӽСA¨ÃÀò±oÃø¯à¥i¶QªºBTD®Öã¡A¨Ãµ¹¤©priority review,¨âӤ뤺»Ý¦^ÂСA¤»Ó¤ë¤º»Ý§¹¦¨ÃÄÃÒ¼f¬d¡A¦b³oºØ±¡ªp¤U ·|¦³®É¶¡¦b¬ü°ê°µ¤T´ÁÁ{§É¡A¥]¬A¤p«¬¤T´Á¡A 6 §Ú·Q¤F«Ü¤[¡A³o¨âºØ¸Ñª¼±¡ªp¦³¥i¯à±o¨ìªº³qÃö§¹J¬O¤@¼Ëªº¡A¤£ª¾¦Ñ¥v¤j¦³¦ó¬Ýªk? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/27 ¤W¤È 12:11:26²Ä 2555 ½g¦^À³
|
¦Ñ¥v¤j ÁÂÁ§A´£¨ÑASCO«n¸ê°T ¥t¥~·Q½Ð±Ð¦Ñ¥v¤j¦³ÃöFDAªk³W¤Wªº°ÝÃD 1¸Ñª¼¦pªG¬O²Ä¤@ºØ±¡ªp¡A¬ü°êFDA·|¥Î®³¤@ºØºÞ¹Dµ¹¨ÅÀùOBI822¡Afast track,priority review,©Î¨ä¥L 2¦pªG¬O²Ä¤GºØ±¡ªp·|¦V¬ü°êFDA¥Ó½ÐBTD®Öã 3³o¨âºØ±¡ªp»P®ÖãÃÄÃҮɶ¡ªº§ÖºC¦³¦ó®t§O 4¥H«e¥v¤j¦³´£¨Ñ¤@¨ÇÃĪ«¡A¦³BTD,¨S¦³BTD ¼fÃĮɶ¡¦n¹³®t²§¤£¤j¡A¥t¥~²Ä¤GºØ±¡ªp¤@©wn°µ¤T´ÁÁ{§É¶Ü? ¦]¬°¦pªG®ÖãBTD¤]¾A¥Î¨ä¥L¨Ã¨É¦³¨ä¥L¤TºØºÞ¹D¡A±q®Öã¨ìÃÄÃÒ®Öµo¥§¡10Ó¤ë¡A ³o»òµuªº®É¶¡¦p¦ó°µ¤T´ÁÁ{§É? |
|
|
·|û¡G°Î¦WªÌ10141057 µoªí®É¶¡:2016/1/26 ¤W¤È 10:57:42²Ä 2554 ½g¦^À³
|
¤p§Ìè¦n¬Ý¨ì¤@¥»®Ñ 2009/07/20.¥Í¤Æ»sÃļthuman genomeªÑ»ùötº¦¤@¤Ñ¤§¤ºº¦´T270%.¦ý³o¥u¬O¶}©l¦Ó¤w.®Ú¾Ú¸Ó¤½¥q´ú¸Õ³ø§iÅã¥Ü .³oºØÃĪ«¬Oªñ50¦~¨ÓªvÀø¬õ´³©Ê¯T½H.³Ì¥i¯à²£¥Í²©R©Ê®ÄªGªºµo©ú.7Ӥ뤧«áªÑ»ù¤Sº¦¤F165%.¦P¼Ë¦a.2009/4/14¤édendreon corp¤½¥q«Å¥¬¨ä«e¦C¸¢Àù¯g¬Ì]provenge¬Û¸û©ó¦w¼¢¾¯¥i¥HÅãµÛ©µªø¯f±w¦s¬¡²v.©ó¬OªÑ»ù¤@¤Ñº¦¤F200%¦Ó«á11Ó¤ëªÑ»ù¤SÄ~Äòº¦¤F117% |
|
|
·|û¡G¤½¥D©@°Ø10141343 µoªí®É¶¡:2016/1/26 ¤W¤È 10:49:30²Ä 2553 ½g¦^À³
|
¯uªº¦n¥Î¤ßÁÞ¤j¡A¦³ÁÞ¤j¯u¦n¡A¥V¤Ñ§Ö¹L¤O¡A¬K¤Ñ§Y±N¨ÓÁ{¡A¶ý¯ª¦Û¦³¦w±Æ¡A¦n¦n§â´¤¬K¤Ñò¡I |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/1/26 ¤W¤È 10:16:33²Ä 2552 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j¤Î¦Ñ´¤j ¦b´H¥V¤¤À°¤p¦ÏÌ¥[ªo¥´®ð,¬Û«H´H¥V±NºÉ,§Y±Nªï¨Ó¬K·xªá¶},·P®¦¨â¦ì¤j¤j¤j |
|
|
·|û¡GBenjamin10139027 µoªí®É¶¡:2016/1/26 ¤W¤È 09:55:02²Ä 2551 ½g¦^À³
|
¥xÁÞ¤j¡A¯u¬O¤ÓÁÂÁ±z¤F¡I Áö»¡¦Ñ¥v¤jÁ¿¹L¡A¸Ñª¼«e¦UºØ¥ú©Ç³°Â÷ªº²{¶H·|¤£Â_¥X²{¡A¦ý¬Q¤Ñ¬Ý¨ìª©¤W¥X²{EPS½×¯E¹©ªÑ»ù¡A¤´¤£¸T¦n®ð¤S¦n¯º¡G³oÓª©½Ö¤£ª¾¥Ø«e¯E¹©¨S¦³EPS©O¡H ³\¤[¨S¬Ý¹L21ÅT§¯¥¤F¡A¦³¤]¥u¬Ý¹L¤E¤T¤f®|ªº¡C§Æ±æ³o¦¸¯à¬Ý¨ì21ÅT¡B¤@¤@O¤f®|ªºÂ§¯¥¡AÁÙ¯E¹©¤@Ó¤½¹D¡I |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/1/26 ¤W¤È 06:14:39²Ä 2550 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j¡B¦Ñ´¤jªº´`´`µ½»¤ |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/1/26 ¤W¤È 01:09:28²Ä 2549 ½g¦^À³
|
¥xÁÞ¤j: §Ún§â±z³o½g¾Ç´ú°ò¥»Æ[©À½×©M¨º¤ä¶ý¯ªÅÒ³£CO°_¨Ó,¨C¤é«ôŪ. ·PÁ±z~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/25 ¤U¤È 11:02:59²Ä 2548 ½g¦^À³
|
¦Ñ´¤j¤j 1·PÁ¦Ѵ¤j¤j¥H«e´£¨ÑªºIBMªº²Îp¤ÀªR¹Bºâ¤u¨ã(SPSS ) ¦w©w¤H¤ß ¥\¼wµL¶q §Ú³£¥Î¯È»Pµ§¨Ó¤ÀªR(ppss) 2¹Å¸q¿¤±ö¤s¶mªº±öªá¶}¤F 3¤é«e©â¨ì¤@¤ä¶ý¯ªÅÒ (·íµM¬O°Ý¤þ¥Ó¦~¯E¹©) ¿ï¥X¨d¤¦²Ä¤@ªK¡AÄU§g§é¨ú²ö¿ðºÃ¡A¥@¶¡Y°Ý¬Ûª¾³B¡A¸U¨Æ³{¬K¥¿¤Î®É¡C ¯¬¦Ñ´¤j¤j ¤þ¥Ó¦~ ³{¬K¤j¦N °]·½¼s¶i |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/1/25 ¤U¤È 10:39:45²Ä 2547 ½g¦^À³
|
¥xÁÞ¤j¡Aµ¹±z¤@¸UÓÆg¡I±zÁ`¬O³o»ò¤¯·O¤SW¤f±C¤ß¦a¦b¤Þ¾ÉµÛ¤p¦Ï¸sÌ¡A³oÂIÅý¦Ñ´ºF·\§r¡I "E 6¤ëªÑªF·|YK¤w»¡©ú:¸Ñª¼¤£¬O¥u¬Ý¹êÅç²ÕªºPFS ¦Ó¬On¬Ý¨â²ÕªºPFS ,¤ñ¸û«á²£¥ÍªºPȬO§_¹F²Îp¾Ç¤WªºÅãµÛ®t²§" ¦Ñ´°½Ãi¡Aɱzªº¹§÷¥[ÂI®Æ¡÷ ¤p¦ÏÌ¡A²{¦bÀ³¸Ó³¬µÛ²´·ú¤]nª¾¹D¡A¨â²ÕªºPFS¡A¤ñ¸û«á²£¥ÍªºPȵ´¹ïÅãµÛ¨ì¬Ý¤£¨ì¼Æ¦r(P=0.000)¡I ¤Ñ¯«©M CyÂT¡÷¯à¤ñ¶Ü¡H¤Ñ±N©M½¼Âæ¡÷¯à¤ñ¶Ü¡H¤Ñ¾÷©MªÖ¼wÂû¡÷¯à¤ñ¶Ü¡H¤Ñ·N©M¥¢·N¡÷¯à¤ñ¶Ü¡H720¤Ñ©M180¤Ñ¡÷¯à¤ñ¶Ü¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/25 ¤U¤È 10:17:25²Ä 2546 ½g¦^À³
|
¦U¦ì¤j¤j °ò¥»Æ[©À»P¤j¾Ç¾Ç´ú °ò¥»Æ[©À¥ý«Ø¥ß¦n ¾Ç´ú¤~¯à¦Ò¦n »~§Pªº¾÷²v·|Åܤp A¼Ë¥»數»Pp ȪºÃö«Y:p ȬO®Ú¾Ú¥ÀÅé¯u¥¿®ÄªG¨S¦³®t異ªºµêµL°²說來pºâ¡A©Ò¥H¡G¦pªG¥À¸sÅé¯u¥¿®ÄªG¨S¦³®t異¡A¬ã¨sµ²ªGªºp ȸò¼Ë¥»數¤j¤p¨S¦³Ãö«Y¡C¥i¬O¥un¥À¸sÅ骺¯u¥¿®ÄªG¦³®t異¡A¬ã¨sµ²ªGªºp È´N·|ÀHµÛ¬ã¨s¼Ë¥»數¼W¥[¦Ó¶V來¶V¤p(¤@¦~¥b«eŪ¨ì¤U±¤å³¹, ²{¦b²×©ó¹y®©,Ó¤H»{¬°Åý¬ã¨s¼Ë¥»數¼W¥[³o¬O¯E¹©CR PD§ïLR PD³Ì«nªºì¦] ) Statistical Hypothesis Test ¡V Riddle of p Value p5 https://www.google.com.tw/#q=Statistical+Hypothesis+Test+%E2%80%93+Riddle+of+p+Value B CRPD §ïLRPD¹ïPFS ªº¼vÅT: ÁöµMCR PD»PLR PD ¦³30%ªº»~®tÈ ¦ý«ÂI¤£¬O»~®tÈ(¤£n¬Ý¨ì¼v¤l§Ñ±¼¥»½è) ,«ÂI¬OCR PD §ïLR PD¹ïPȦ³§Q ¦ý¹ïPFS¥u¦³¨Ç·L¼vÅT ³o¤~¬O«ÂI,¥h¦~6 7 ¤ë¤w¸g°Q½×¹L¤F (±qCliff¤j´£¨ìªº¤@½g¬ã¨s¤ÀªRµ²½×:³Ì²×¹ï©óPFSªº¼vÅT¡ALR»PCR¤§¶¡ªº®t²§©Ê¨Ã¤£¤j) C ¥h¦~3¤ëªk»¡·|©Ò¦³ªk¤H»PªÑªF¨S¦³¤H¤£ª¾¹D¸Ñª¼¥|ºØ¥i¯àªºµ²ªG(¥|ºØÃC¦âªº«HX¼u) ,¬°¤F¯à²Å¦X°ê»Ú´Á¥Zªºn¨D, 2¤ë¸Ñª¼«á¤½¥qÁÙ»Ýn´¦ÅS¸Ô²Ó¼Æ¾Ú¶Ü?¤½¥q¤w¦b6¤ëªÑªF·|¤w»¡©ú¤F¸Ñª¼«á·|¤½§i¤½¥q¥¼¨Ó»P¦U°êªk³W³æ¦ì°Ó°Qªº¤è¦V»P³W¹º,±q¥¼¨Óªº¤è¦V»P³W¹º´N¯à¤ß»â¯«·|. ¥t¥~¤G¤ë¸Ñª¼«á,°²³]´CÅ馳¤£¹ê³ø¾É,¦]ªÑªF¦b¥h¦~3¤ë¤w¦³¥´¬Ì],¦¤w²£¥Í§K¬Ì§ÜÅé,®ð©w¯«¶¢,¤£·|¨ü¼vÅT,°²³]¥¼¨Óªº¤è¦V»P³W¹º»á¬°¿n·¥¥¿±, ªÑªF¤Ï¦Ó·| ¤ßÃm¯««ï ,¤ßªá«ã©ñªï±µÁÞ¤k²{¨¨ÃÆ[½à³Ì´L¶Qªº1.1¤f®|ªºÂ§¬¶ D¤þ¥Ó¦~©°±G¤ë¸Ñª¼«ánÅ¥´CÅ骺,ÁÙ¬OnÅ¥¤½¶}¸ê°TÆ[´ú¯¸¤½¥q¹ï¸Ñª¼«áªº¤è¦V»P³W¹ºªº¤½§i? §Ú·|¿ï«áªÌ E 6¤ëªÑªF·|YK¤w»¡©ú:¸Ñª¼¤£¬O¥u¬Ý¹êÅç²ÕªºPFS ¦Ó¬On¬Ý¨â²ÕªºPFS ,¤ñ¸û«á²£¥ÍªºPȬO§_¹F²Îp¾Ç¤WªºÅãµÛ®t²§ ¥t¥~¤]n¬Ý¨ä¥¦¼Æ¾Ú ¤£¬O¥u¦³¬Ý³æ¤è±ªºPFS ¬O¥H¾ãÅ骺¼Æ¾Ú¨Ó¶i¦æµû¦ô (¶R¨®¤l¤]·| ¾ãÅéµû¦ô ¦p¥~§Î ¦w¥þ©Ê ªo¯Ó ÃC¦â «O¾i¤è«K©Ê »ù®æ.... ) F ªÑªF¬ù²¤¯àª¾¨ì¸Ñª¼®ÉÂI ,¬Û¤Ïªº¦X§@±ÂÅv®É¶¡»Pª÷ÃB´x´¤¦b¤½¥q¤â¤W, ¤G¤ë¤¤¶}©lÀH®Énª`·N¦X§@±ÂÅvªº¤½§i ¤£n¤µ¤Ñ½æ±¼¯E¹©©ú¤Ñ¤½§i¦X§@±ÂÅv(¥u¯à²´¸C¸C¬Ý§O¤H¦bÆ[½à§¬¶)(¥i¯à80% ªº¤H·|²q¿ù®É¶¡ÂI 20%ªº¤H·|²q¹ï) ¨ä¥L¸É¥R G ¬ü°ê¥ý®³ÃÄÃÒ©Î¥xÆW¥ý®³ÃÄÃÒ: ¨Ì¾Ú6¤ëªÑªF·|¿à³Õ¦^µª ,¬ã§PÀ³¸Ó¬O¥¼©w½× (¦pªG¬ü°ê¯f±wµ¹¬F©²À£¤O¤]·|¥[³t¨ÅÀù822¤W¥«±o®É¶¡)(Á{§É¼Æ¾Ú»PFDA ªº¼f®Ö¬O¥DnÃöÁä)(¥xÆW¬O2017¦~ªì) H ¬O§_n°µ¬ü°ê¤T´Á:¥Ø«e¬O¥¼©w½× ¤½¥q¬O³W¹º¨«²Ä¤@ºØ±¡ªp(Á{§É¼Æ¾Ú»PFDA ªº§P©w¬O¥DnÃöÁä) (§ÚÓ¤H¬ã§P¸Ñª¼¥|ºØ¥i¯àªºµ²ªG¤¤ªº²Ä¤TºØ±¡ªp¤~»Ýn°µ¸û¤j³W¼Òªº¼Ú¬ü¤T´Á) °ò¥»Æ[©À¥ý«Ø¥ß¦n ¾Ç´ú¤~¯à¦Ò¦n »~§Pªº¾÷²v·|Åܤp ¥H¤W¶È¨Ñ°Ñ¦Ò ¦³¿ù½Ð§ó¥¿ |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2016/1/25 ¤U¤È 08:05:22²Ä 2545 ½g¦^À³
|
±ø¤jÁ¤F¡A§Ú·|³o»ò°í«ù´N¬O¦]¬°¦¹ª©¦³§A¸ò¥x¿}¤j ¤Î¦U¦ìª©¤Wªº¤j¤jÌ¡AÁÂÁ§AÌ¡A¦ý¬O§ÚÓ¤H»{¬° ªÑ»ù¯u¥¿ªº¨M¾ÔÂI¸¨¦bASCO 6¤ë¥÷«á |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/1/25 ¤U¤È 04:54:26²Ä 2544 ½g¦^À³
|
©êºp¡A¬OBen¤j¤~¹ï |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/1/25 ¤U¤È 04:48:54²Ä 2543 ½g¦^À³
|
Å¥¨ìBan¤j¦b©I³ê§Ú¡A©Ò¥H¥X¨Ó³ÛÁn"¦³" §A§Ú¬Ò´¿°l°ª±þ§C«á®¬¹L¡A©Ò¥H¾Ç·|Åó±ø±ø »¡¯uªº¹j¾ÀªO»¡"¸Ñª¼¼Æ¾Ú¦n·|¶^¡A¸Ñª¼¼Æ¾Ú¤£¦n¶^¤£°±"...«e¥y¤£¤j»{¦P¡A«á¥y«o¬O¤Q¤À»{¦P ¸Ñª¼¼Æ¾Ú¦n·|¶^¬O«ü¨Ì¾Ú°ê¥~¸gÅç¦b¸Ñª¼«e·|º¦¨ì"¤w¸g¦³ÂI¤£¦X²zªº»ù¦ì"¡A ©Ò¥H¸Ñª¼¼Æ¾Ú¦n´N·|¦p¹w´Á¯ëªº"§Q¦h¥XºÉ"¡A¶}©l¤U¶^ ¯E¹©§Q¦h¤Ó¦h¥B¤Ó¤j¡A¥B¥¼¨Ó§Q¦h¥X¤£ºÉ¡A°Ï°Ï755®Ú¥»¤£·|¬O¤ÑªáªO¡A¤ñ¸û¹³¬O¦aªO °²³]822¤W¥«À禬Àò§Q¤@¯ë¯ë¡A¨S¦³¤ñ¶PÀù¥60e USDªº¤T¿¡A¤Ï¦Ó¬O1/4¥u¦³15e USD Àò§Q§ó¥u¦³10e USD¡AEPS 200¡A¤ñ¤j¤O¥ú¥h¦~EPS 180ÁÙ¦h¡AªÑ»ùÀ³¸Ó·|°ª©ó¤j¤O¥ú§a~~ ?? ¹³¤p¶§¤j´N¬O¨ü¤H·q«ªº¦nº~¡A¦]¬°¥uºÞ¶R´N¹ï¤F¡A ¤â¤¤¦³ªÑ²¼¡A¤ß¤¤µLªÑ»ù¡A¸Ó¨Óªº´N·|¨Ó¡A 755¨S½æ¨ì¨SÃö«Y¡A¥H«á¨Ó½æ1755, 2755.... |
|
|
·|û¡GBenjamin10139027 µoªí®É¶¡:2016/1/25 ¤U¤È 02:42:17²Ä 2542 ½g¦^À³
|
¥¤ß¦Ó½×¤j¤j¡G ¨ä¹ê§Ú³Q¬~±¼¹L¤G¦¸¡A¨C¦¸³£¥Î§ó°ªªº»ù¥h°l¦^¨Ó¡I(³oÂI§Ú¦³½Ð±Ð¹LÅó±ø±ø¤j¤j¡A¦p¦ó¤~¯à"©ê¨c¨c") ¤j¥ß¥ú»Pº~·L¬ìªº¹Ï§Ú¬Ý¹L³\¦h¦¸¡A·Q¹L³\¦h¦¸n«ç¼Ë¤~¤£·|¨ü¶Ë¡B¤S¥i¥H¦Y¨ì¤j³¡¤Àªºº¦´T¡CY¯}°±·l½æ¡B¬ð¯}¶R¦^¡A§Ú¯u¤£ª¾¯à¤£¯à¦b¤j¥ß¥ú»Pº~·L¬ì¤WÁȨì¤j³¡¤Àªºº¦´T¡Kµª®×«Ü¥i¯à¬O§Ú°µ¤£¨ì¡I ©Ò¥H²{¦b¤~·|§â¤p¯E¯Eµ¹"Åó±ø±ø" XDDD |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2016/1/23 ¤U¤È 06:50:54²Ä 2541 ½g¦^À³
|
¤p©_¤j ¦nªü ¥u¬O¤£ª¾¹D®É¶¡¦aÂI ¦A·Ð½Ð§iª¾ºO |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/1/23 ¤U¤È 05:53:51²Ä 2540 ½g¦^À³
|
§ó¥¿ ¡u¦b187©M229³o¨âÓ¤wª¾½T©wªº¼Æ¦r¤U¡v Faith¤j¡A «¢¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/1/23 ¤U¤È 05:47:29²Ä 2539 ½g¦^À³
|
¤p©_¤j ÁÂÁ±z §ÚÌ´NÀR«Ýµ²ªG¤½¥¬§a¡I ¦b¦¹¤§«e¡A¤p§Ìn¦V±z¬Ý»ô¡ã §Ñ¤FÁÙ¦³«OÀI½cÂêµÛ¯E¹©¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/1/23 ¤U¤È 05:43:06²Ä 2538 ½g¦^À³
|
¶Ù¡Aªü®¶¤j¡A ¬Ý¨ì§A¯u¦n¡I ¤Ñ®ð§NºÎı¯uµÎªA ¹L§¹¦~¸Ñª¼«á ¤]¤W¨Ó·nºX¼y¯¬¤@¤U ¦p¦ó¡I¡H Faith¤j¡A ¤p§Ì°O±o±z¥H«eªº¶K¤å ¦pªG¥H¹êÅç²Õ±wªÌPFS¤p©ó9Ӥ묰µL®Äªº¤À¬É µL®Äªº¤ñ¨Ò¥i¯à¤j¬ù20%~25%¬O¤W(¸Ñª¼ªºM PFS¦n¬Ý) ¦pªGµL®Äªº¤ñ¨Ò©¹30%¾aªñ ¨º´N¬O¦³®Äªº¤ñ¨Ò70%¤¤ªºÀø®Ä¸û®tªº¨º20%¨Ó¨M©wM PFS ¹A¾ä¦~«áªì¨B¸Ñª¼®É¤½¥¬ªº¼Æ¦r©È¬O¨S¨º»ò¦n¬Ý ¨º´N±oµ¥¨ì6¤ëªºASCO¤½¥q¦A°µ¸Ô²Óªº»¡©úÅo¡I ¦b187©M299³o¨âÓ¤wª¾½T©wªº¼Æ¦r¤U 822ªº¦n³B¬O°¾¦V«BÅS§¡ÀL(¦³®Ä¤ñ¨Ò°ª)ÁÙ¬O¦Ñ¤Ñ¯S§O²²ÅU¬Y¨Ç±Ú¸s ´Nµ¥¸Ô²Óªº¼Æ¾Ú¤ÀªR¤F ¯E¹©¥[ªo¡I |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2016/1/23 ¤W¤È 11:35:22²Ä 2537 ½g¦^À³
|
¥x¿}¤j:±z¤]¬O§Úªº®v¤÷¤§¤@..«¢ §Ú´X¦~«e¹ï¯E¹©ÁÙ¬O¤@¬¤£³qªº ÁÂÁ§A §Ú¤j³¡¤À³£¦b¦Û¤vªº¯E¹©¸s²ÕùØÀY±´°Q±´°Q¯E¹©±o¸û²`¤Jªº³¡¤À ¦]¬°¤½¶}ªº³õ©ÒµLªk½Í±o«Ü²`¤J ¤]·|ÅU§Ò¤@¨Ç°ÝÃD... ¥t¥~ ¥x¿}¤j ±z»¡ªº¨S¿ù ¯E¹©º¦¨ì600¤¸®É§Ú´N¥X°ê¦Û§U®È¦æ¤F¨â½ë ¤j«e¤Ñ¤~¦^°ê «¢«¢ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/23 ¤W¤È 11:10:00²Ä 2536 ½g¦^À³
|
ªü®¶¤j §A¬O¤£¬O¥X°ê¥h¦Ò¹î¥Í§Þ²£·~? ¦n¤[¤£¨£ ÁÂÁ¤À¨É¹Ú¹Ò |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/1/23 ¤W¤È 10:26:25²Ä 2535 ½g¦^À³
|
ªü®¶¤j «p¡ã³£Âæ.... °¸º¸¤]n·ÓÅU¤@¤U§Ú̹À⋯⋯ ¨£¨ì±z¯u¦n¡B¶}¤ß¡I |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2016/1/23 ¤W¤È 10:22:13²Ä 2534 ½g¦^À³
|
jm0423 Faith ¥xÁÞ Cliff ¤p©_ ¡K¡K.¦n¦hÀu¨qªº¦n¤H¦nªB¤Í°¸¹³Ì!! ±z̦nªü!!! §Ú¤@ª½³£¦³Ãö¦í¯E¹© ªÑ²¼¤]¨S½æ¹L¥b±iªü §Ú̪º¯E¹©FB¸s²Õ ¤]¨ÌµM¦³¦U»â°ì¤H¤~.¤À¤u¤ÀªR.§PÂ_¯E¹© ªü «¢«¢ ÀÆ¥úº¥«G¡K¡K¡K¡K °µ¹Ú¡K¡K¹Ú¨ì¤F¡K.833´N¦¨¥»¦Ò¶q¡K¥i¯à¸ò¥Lªºôô¦b¦P¤@Ó¦«¨à©Ò³Q·ÓÅU ¨ºÁû¥þ¥@¬É¥u¦³¤£¨ì10Áûªº¡¨¤j³J¡¨¦Û¤v¤]n¤W¥« ¨ºÓ¤@¤½§J¥i¥H¬r¦º¦n¦h¸U¤HªºªF¦è ¥i¯à´Nµ¹¤j³J¥h¼Å¤F~¦Û¤v¼Å¦Û¤vn½æ ¦ý~³£ÁÙ¦b¥¼©w¤§¤Ñ ¦]¬°~ ¦³ª§°õ! ¤£n¥þ«H ¤j¤jÌ~¤p¤p§Ì ¦A¥h¸É¯v¥h°Õ!!! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/1/23 ¤W¤È 10:17:19²Ä 2533 ½g¦^À³
|
¥xÁÞ¤j ÁÂÁ±z¡I ¤p©_¤j ¤p§Ì¤]¸ò±z¤À¨É¤@¤U¡A ¤p§Ì°O±o«Ü¤[¥H«e¤p§Ì´¿»¡¹L¡]Ãi±o¦^¥h§äpo¤å¤F¡^ ¡u²{¹ê¤W¡A§Ú̧ƱæµL®Äªº¶V¤Ö¶V¦n¡A ¦ý¦b¦¹Á{§É¹êÅ礤¡AYµL®Ä¤ñ¨Ò¯à¦b20%-30%¥ª¥k¡A ¤Ï¦Ó¹ï¼Æ¾Ú§ó¦³§Q¡I¡v¡]«e´£¤]¥²¶·¬O¡AµL®Äªº«D±`µL®Ä¡I¦n¶¤f³á¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/23 ¤W¤È 10:05:17²Ä 2532 ½g¦^À³
|
¥¤ß¤j ²Ä¤@³õ¬OÁÞ¤k¨«¨q°ê»ÚÆf¥Ø¡A§¯¥À³¸Ó¤£¤Öµo ²Ä¤G³õ¬OÁÞ¤kµ²±B¡A¦]·|¦³°ªÃB¸uª÷»P¬ù©w¦nªº¨½xª÷¡A¨C¦~¥¨ÃB¥Í¬¡¶Oµ¥¹ê¹ê¦b¦bªº¾Ö¦³¡A²q´ú§¯¥·|¤ñ¨«¨q¦h«Ü¦h ¸É¥R»¡©ú 833¦b¥xÁ{§É®ÖãªÍÀù»P¨ÅÀù¡A¬ü°ê·|¥H¤j¸zÀù¡AGÀù¨Ó¶i¦æÁ{§É |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2016/1/23 ¤W¤È 02:39:22²Ä 2531 ½g¦^À³
|
¥xÁÞ¤j¡A ±z»¡±o¯u¦n¡A§Ú»{¬°¸Ñª¼«á¡A¦Ü¤Ö¨C¤Ñ1ºÞ¡A³sÄò10ºÞ 1.1x§¬¶Åwªï¡A³oÓ§¬¶¥u¦³¸Ñª¼«e¤â¤W¦³ªÑ²¼ªº¤H¤~¯à°ª¿³ªºªY½à¡A¨ä¥L¤H¥u¯à§ª§Ò¡AµL©`»P®¬«ë§a Banjamin¤j¦b¹j¾Àª©»¡¤j¥ß¥ú¸òº~·L¬ìªº¬G¨Æ´N¬O»¡ ¥un¥¼¨ÓÁͶլO¤j¦hÀY¡A¹ê¦bµL¶·¤Ó¦b¥Gµu´Áªi°Ê °ß±©¤j¡A¯u¬O§Úªº¤ßÆF¾É®v¡A¾Ç´I¤¨®¤~°ª¤K¤æªº°ª¤H¡A¤p§Ì²`·P¨ØªA¡A§Ú̳£¬OºÆ¤l ¤p©_¤jªº¤ÀªR¤Q¤À¦X²z¡A¯uª¾¨`¨£ ¼w°ê»P¤é¥»³£¬O¤G¾Ô¾Ô±Ñ°ê¡A²{¦b¦U¦Û¦³§Þ³N»PÄvª§¤O¾Õ³õ¡A¼w°ê¿ï¾Ü±¹ï¾ú¥v±O±þµS¤Ó¤Hªº¿ù¡A¤é¥»°kÁ×¼¢¦w°ü»P«n¨Ê¤j±O±þ¡A¥Á±Ú©Ê¤£¦P©ÒP ¦P¼Ë¶R¯E¹©ªº¤H¦³¤H¥u·QÁȤF´N¶]¡A¦³¤H«o·Qnªø©êÁȨú³Ì¤j§Q¼í¡A¤]¬Oөʤ£¦P»P¨Mµ¦®t²§¡A½Ö³£·Q®³¤@¤â¦nµP¡A¦ý¨Ã«D§â§â³£¦n¡A¨C§½³£ÁÈ¡A¥un³Ì«áÁȦh¤Ö¤~¯à½×¿éĹ¡AŤ@®É¬O¤£¿ù¡A¤£¹L¦U¦ì¤j¤j¤w¸g«Ü©ú¥Õªí¥Ün¸ò§Ú¤@¼Ë·Ç³ÆŤd¬î |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤U¤È 10:10:20²Ä 2530 ½g¦^À³
|
ªÑ¥«¦W®·¤j ©e©}ªºÀ£¨î¥²¦³Ãzµoªº¼u¤É 1¥xÆW¯E¹©²Ä¤GÓÀù¯g§K¬ÌÀøªk¨t¦COBI833¦¤w¶i¤J¤@´ÁÁ{§É,§Ú¤]¬O³Ìªñ¯E¤Í¤À¨É¤~ª¾¹D,¥«³õ¨Ã¥¼¤ÏÀ³¦¹¤@§Q¦h ³oÓ§ó§ï¸üÅé³J¥ÕªºOBI-833¬O¯E¹©§ÞÂà¦Û¤¤¬ã°|ªº·s«¬¥D°Ê¦¡§K¬ÌÀøªk¡A´ÁÂÇ´£°ª¦Û¨§K¬Ì¨t²Î¹ïÀù ²ÓMªº¯}Ãa¤O¡A¹F¨ì§ó¦nªº§ÜÀù®ÄªG¡CÁ{§É¤@´Á¸ÕÅç¥Øªº¦b½T»{ÃÄ«~¥Î©ó¤HÅéªvÀøªº¦w¥þ©Ê ,¦ôp¸ÕÅçp µe¬°´Á¤@¦~¦¬®×26¤H,±À´ú2016¦~9¤ë§¹¦¨Á{§É¤@´Á¸ÕÅç ,©¹«á833¥ô¦ó¾AÀ³¯g¬ãµo¤@«ßª½±µ±q¤G´Á¶}©l 2¸Ñª¼«e³QÀ£À£¦^227¤¸¤w¤ÏÀ³¤F¥¼¨Ó¤£½T©w¦]¯À»P«H¤ß¤£¨¬»P°§C«ùªÑ³WÁ×·ÀIªº½æÀ£,¤µ¤Ñ¤wº¡¨¬§Þ³N©Ê¶^´T 3¯E¹©¸Ñª¼«e³QÀ£¦^,°²¦p¥¼¨Ó¤½§i¸Ñª¼¼Æ¾Ú¥¿±,¨«¶Õ²zÀ³»P¸Ñª¼«e©Ô¨ì³Ì°ª¦ý¸Ñª¼¼Æ¾Út±§e²{¬Û¤Ï¨«¶Õ 4ÁÞ¤k·|¨ü¨ì´XÅT¤f®| ¤@ÂI¤@ (X 1.1)ªºÂ§¯¥Åwªï,¥«³õ¤W¦Û·|ÁÙµ¹¤©¦w±Æ 5XXªÑ¸Ñª¼«e©Ô¨ì³Ì°ª¦ý¸Ñª¼¼Æ¾Út±,¦L¶H¦n¹³¬O18ÅT¤f®| ¹sÂI¤E¤T ªº¸Á¯¥ (X 0.93) ¥H¤W¬OÓ¤H²L¨£ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡GªÑ¥«¦W®·10141659 µoªí®É¶¡:2016/1/22 ¤U¤È 08:44:39²Ä 2529 ½g¦^À³
|
¥xÁÞ¤j ¤p§Ì¤µ¤Ñ¥t¤@ª©¤Í»¡¤µ¤Ñ·|À~¯}Áx¦æ±¡ ªGµMÀ~¤F¤£¤Ö¤H ¤µ¤Ñ¦¬¤F¤U¤Þ½u¬O¦n¨Æ ì«h¤W¦]¬°¤w¸g¦³µ´¤j³¡¦ì¦b¯E¹©¨¤W ©Ò¥H¦b«á¸êª÷¥²¶·µ¥¥´©³º}«G¨Ç¦A¶R¤F ¦]¬°²q§C¶V²q¶V§C ¶R§C¤]¥u¬O¹B®ð ¤£¦pµ¥¤îäF¦A¥[½X ¤U¶^«H¤ß¶V¨Ó¶V¯Ü®z ¥«³õÁÁ¨¥¤]·|Åܦh ¤j®a¦hª`·N»Ý¦³©w¨£¤~¯à¾Ô³Ó °ò¨È·Q·íªì¤@¸ô©Ô¨ì¸Ñª¼³Ì°ª¸Ñª¼ ¥«³õ¬£¤@¹M¬Ý¦h µ²ªG?³Ì°ªÂI´N¬O¸Ñª¼«e ¦³¤F°ò¨È¸gÅç¯E¹©ªñ´Á¥«³õ¬£±ó¦u ¸Ñª¼«á?·|«ç¼Ë... |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/1/22 ¤U¤È 07:47:55²Ä 2528 ½g¦^À³
|
ªü®¶¤j ±zÁ`ºâ¯B¥X¤ô± ·Q¦º¤p§Ì¤F ½Ð¦h¦h¬°¯E¤Í̵oÁn |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/1/22 ¤U¤È 07:07:12²Ä 2527 ½g¦^À³
|
ªü®¶¤j ²×©ó¬ß¨ì±z¤F¡I¦n·Q©À±z¡I ¨S§@¹Ú¨SÃö«Y¡AªB¤Í¤ñ¸û«n¡A¤@°_¥[ªo¡I ¤p§Ì¤]¦n·Q©À»¹«¤j¡BD§b¤j.... ´Á¬ß¤j®a¯à¤Wª© ¥xÁÞ¤j Æg¡IÁÂÁ±z¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/1/22 ¤U¤È 07:00:45²Ä 2526 ½g¦^À³
|
¥xÁÞ¤j: ÁÂÁ±zªº´£¿ô. §Úªº¦Ï̳o¬q®É¶¡¦³¼WµL´î, ±zªºÀç¾i¾¯°t¤è¤Ñ¤Ñ¦b³Ü, ¦Ñ¤â¦Ï°V½m·s¶i¦Ï, ²{¦bÓÓ¨±jÅé°·. ¤j®a«§«§¥sÁÂÁ±z. |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2016/1/22 ¤U¤È 06:14:37²Ä 2525 ½g¦^À³
|
hi ¨}¥S ¦p¦óª¾¹D¯E¹©³o¤½¥q¸ò°ò¨È¤£¦P¡H.... "¨â®a¤½¥qªº¦W¦r¤£¦P"~¦pªG±z¥uª¾¹D³o¼Ë.....¯E¹©±Nn¦p¦ó³ø±o¦í©O? |
|
|
·|û¡G´²¤á10141269 µoªí®É¶¡:2016/1/22 ¤U¤È 05:17:04²Ä 2524 ½g¦^À³
|
¨}¤j!!!§A¥un©âªÅ§â³o¥|ª©¥J¥J²Ó²Ó¥þ³¡¬Ý§¹!!!¤ß¤¤¥²µM¦³·sªºÅ鮩!!!! |
|
|
·|û¡G¨}¥S10141661 µoªí®É¶¡:2016/1/22 ¤U¤È 05:10:34²Ä 2523 ½g¦^À³
|
¨ä¹ê¤p§Ìªº°ÝÃD´N¦b¦p¦óª¾¹D¯E¹©³o¤½¥q¸ò°ò¨È¤£¦P¡H ·íªì°ò¨È¨Æ¥ó©|¥¼¤ÞÃz«e¡A¤S¦³½ÖÃhºÃ¹L°ò¨È©O¡H ¤p§Ì¤£¬O¨D¾Ô¡A½Ð§O»~·| |
|
|
·|û¡G´²¤á10141269 µoªí®É¶¡:2016/1/22 ¤U¤È 04:56:38²Ä 2522 ½g¦^À³
|
¨}¤j!!ªO¤Wªº¦U¦ì¤j¤j,³£¬Onªø´Á«ù¦³...©Ò¥H¤ñ¸û¤£¾á¤ß¤j½Lº¦¶^....¤Ï¦Ó¤ñ¸û¦b¥G¤½¥q¥»¨ªºÀç¹B....¥¿©Ò¿×¶RªÌ¤£©È..©ÈªÌ¤£¶R!!!§ë¸ê¬O¥i¥H«ÜÀu¶®ªº!!!!°²¦p¾ã¤Ñ·|´£¤ß¦QÁx¨º¼Ëªº·Pı«Ü²Ö!!¨Ñ±z°Ñ¦Ò!!! |
|
|
·|û¡G¨}¥S10141661 µoªí®É¶¡:2016/1/22 ¤U¤È 04:18:10²Ä 2521 ½g¦^À³
|
¦U¦ì¤j¤j¡ã ¤p§Ì¸ÛÀµ°T°Ý ¤j®a¬°¦ó£¸ÂI¤]¤£¾á¤ß°ò¨È¨Æ¥óagain ´Nºâ¯E¹©¸Ñª¼perfect ¦ý¤j½L¤£¦n¡A¬O§_¤]·|¶¶«K©ì¦í¯E¹©°_¸©O¡H ¤µ¤Ñ±þ¦¨³o¼Ë¡A¤p§ÌµÛ¹ê¤ß·W¤F¤@¤U Àµ½Ð¦^µª¡G¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤U¤È 01:58:12²Ä 2520 ½g¦^À³
|
QQ¤j ¯E¹©¦pªG¦~«á´£«e¤½§i¸Ñª¼°T®§ ¦Ó¤£¬Oµ¥¨ì¤G¤ë©³²q´ú¥¿±µ²ªG©~¦h ÁÞ¤k¤þ¥Ó¦~©°±G¤ën²{¨°_¸¤F µ¥ÁÞ¤k°_¸¤F ¥u¦³·¥¤Ö¼Æ©¯¹BªÌ¯à§ì±o¨ì¦o ¤â¸}ºCªº´Nºâ¤ñ¦o§Ö10%ªº³t«×¤]§ì¤£¨ì¦o |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/1/22 ¤U¤È 01:27:29²Ä 2519 ½g¦^À³
|
¥xÁÞ¤j: ÁÂÁ±z¶O·s¾ã²z¤Î´£¨Ñªº¸ê°T, ¹ê¦b¤Ó°·±d¤F. Æg! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤U¤È 01:15:15²Ä 2518 ½g¦^À³
|
ªÑ¥«¦W®·¤j ©¼¦¹¤Á½R¨D¶i¨B ¤µ¤Ñ¦³¸É¨ì¦Ï¶Ü? Åó±ø±ø¤j ¯E¹©ªºÀ£¦^227¤¸¤w¤ÏÀ³¤F¥¼¨Ó¤£½T©w¦]¯À»P«H¤ß¤£¨¬ªº½æÀ£ ³o¼Ë¤jªºªÅ¶¡À³¸Ó¬O±ø¤j´£¨ìªº¦~«á³ø´_©Ê¦^¤Éªº»ºk¤j¹D |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/1/22 ¤U¤È 12:50:12²Ä 2517 ½g¦^À³
|
¤p©_¤j: ÁÂÁ±zªº¤ÀªR. Æg! ³Ìªñ¥h·s¶}ªº¤û¦×ÄÑ©±¬ã¨s¦n¤[, ¬Ý¬Ýµæ³æ, µæ¦â, ³f·½, ¼p®v, ÁöµM¹ï°t¤è¦³¨Ç¦n©_, ¦ý¤ñ¨Ó¤ñ¥h, ¶â, ÁÙ¬O¦Ï¦×ÄlÆg. Àç¾i, ¬ü¨ý, ²{¦bÁÙ¦b¥´§é¡K ÁÙ¬O¨Ä¨Ä¦Y¦Ï¦×¸û°·±d. £«¬Â¤j: ·PÁ±zªø¤[¥H¨Ó¹ï¦Ï̪ºÃöª`! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/1/22 ¤U¤È 12:02:15²Ä 2516 ½g¦^À³
|
¦A¦¸·PÁ£«¬Â¤j¡I Æ[¹î¨ì2¦ìPFS¤w¸g¤j©óµ¥©ó29Ӥ몺¨Ò¤l¡A¥H187©M229³o¨âӼƦr¨Ó»¡¡APFS=29Ó¤ëÄÝ©óªøªø§À¡A¤@Óªøªø§Àªº¾÷²v¬O10%¡A¨âÓªøªø§Àªº¨Ò¤l´N¬O1%¡A¦pªG¹ê»Úªº¾÷²v¤£¬O³o»ò§C¡A¦ý¦b187©M229¨âӼƦr¤w¸g¬O¨Æ¹êªº±¡ªp¤U¡A¦³¨âºØ¥i¯à¡A¤@Ó¥i¯à¬O¸~½F¤¤§tGH¨t¦CªºÀù²ÓM¤ñ¨Ò¤Ó¤Ö©ÎªÌ±wªÌ²£¥Í§ÜÅé¶q¤£¨¬ªº822µL®Ä±wªÌ¥i¯à¤ñ¹w´Á¦h(쥻¦ô10%~15%)¡A¹ê»Ú±¡§Î¬O822µL®Ä±wªÌªº¤ñ¨Òn©¹20%¾aÃ÷¡F¥t¤@Ó¬O2014¦~±ß¦¬®×ªº¹êÅç²Õªº±wªÌªºÀø®Ä¤ñ¤¤¦´Á¦¬®×ªº±wªÌªºÀø®Ä®t(³oÓ¥i¯à©Ê¤ñ¸û§C)¡C Y822µL®Ä±wªÌªº¤ñ¨Ò¦³¹F¨ì20%°ª¡A¨º»ò¦b2014/12ªº187¤HPD¤¤¡A°£¤F¹êÅç²Õªº¥i¯à¤j¬ù90¤HPD¥~¡A¨ä¾l¦b¹êÅç²Õªº¤j¬ù97¤HPD¥Dn¦³¤j¬ù¤@¥b¬O¨Ó¦Û822µL®Äªº±wªÌ¡A¤]´N¬Oªí¥Ü¡A¤@¦ìÄÝ©ó822¦³®Äªº¹êÅç²Õ±wªÌ¡A¥L̪ºPFS±¡ªp·|¤ñ¤¤©Ê°²³]ªºPFS ±¡ªp¨Ó±o¦n¡A¦]¦¹³Ì«á´¦ÅSªºM PFS¼Æ¦r·|¤ñ¤¤©Ê°²³]¨Ó±o¨Î¡C ¦b187©M229ªº¤wª¾¨Æ¹ê¤U¡AY822µL®Äªº¤ñ¨Ò¸û°ª(822¾A¥Î¤H¤f½d³ò¸û¤Ö)¡A«h822¦³®Äªº±wªÌ¨äPFS´N·|¤ñ¤¤©Ê°²³]ªº¹w´Á¨Ó±o°ª¡A¤]´N¬O¡AÆ[¹î¨ìªº187©M229ªº¦n³B°¾¦b822¦³®Äªº±wªÌ¨¤W¤ñ¸û¦h¡C ¥un822µL®Äªº¤ñ¨Ò¤£¬O¤Ó°ª(20%©Î25%³£¬O¥i±µ¨üªº½d³ò)¡A¹ï©óPȪº¼vÅT´N¤£¤j¡A¦ý·|ÅýÆ[¹î¨ìªº¹êÅç²ÕM PFS¼W¥[¡A¥u¬O³o20%~25%ªº822µL®Ä±wªÌ´Nnµ¥«Ý888©Î¨ä¥¦ªºªvÀø¤F¡C ¥H¤W¯ÂÄݱÀ´ú¡A¹ê»Ú±¡ªp¥H¸Ñª¼«á¤½§i¬°·Ç¡C |
|
|
·|û¡GªÑ¥«¦W®·10141659 µoªí®É¶¡:2016/1/22 ¤W¤È 10:41:39²Ä 2515 ½g¦^À³
|
¹Ç§AÅó±ø±ø¤j ³o2~3¦~¬Ý±zµo¨¥ ±z¤@ª½¬O§Ú³Ì¦nªºº]¼Ë ¬Ý¨ì§A¼ÊºÙ³£Åܦ¨¡¦¤@©w¹Ç§AÅó±ø±ø¡¦´Nª¾¹D±z¦³¦h¤j«H¤ß ¥xÁÞ¤j ¤]¬O§Ú¤@ª½«Ü´º¥õ ·PÁ±z¤@¸ô¬Û³! ¯E¹©¯à§_¦¨¬°¶Ç®aÄ_¶Ç¤U¥h §ÚÌ´Á«Ý«ùÄò¬Ý¤U¥h¨þ¨þ ¤p§Ì³Ìªñ¤]¦b¬ã¨s¤ß®®Y¦U¦ì°ª¤â¦³¤ß±o!¦nÃa³£Åwªï¶û³f¤H¤~¬OÃѳf¤H ½Ð¦b¤ß®®ª©«ü±ÐÁÂ°Õ |
|
|
·|û¡G¤@©w¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/1/22 ¤W¤È 10:30:56²Ä 2514 ½g¦^À³
|
£«¬Â¤j¡A ÁÂÁ¤À¨É ¼Ú¤ñ®Jªº2¦ì¨½¥Á¥Ø«e¬JµMÀ³¸Ó¦í¤F28Ó¤ë¡A·Q¥²¤w¸g«D±`¾AÀ³¨ºùتºÀô¹Ò ³o¼Ë¬Ý¨ÓÀ³¸Ó·|¦A¦íÓ¤T¤¦~¥H¤W ¨£·Lª¾µÛ¡A¨ä¥L¾F©~À³¸Ó¤]³£·|«Ü°ª¿³»P¾AÀ³¨}¦n ¯E¹©¸Ñª¼¡A±q³ÌªñªºªÑ»ù¡A¥~¸ê»Pªk¤H°Ê¦Vµ¥µo²{¥«³õ©~µM±N¤§µø¬°§QªÅ? ¥u¦³ª©¤W§A§Ú½Ñ¦ì¤j¤j¤@¸ô®¼¶i¡A¶R¦Ï¶R¨ì¤â³n¡A¬Æ¦Ü¤º¤ß¤£¸T¶}©l²£¥ÍÃhºÃ.... ÁÙ°O±o¤£¤[«e¶^¯}310©Ó¾P»ùªº¨º¬q®É¥ú¡A¤]¬O«sÂE¹M³¥¡Aª©¤W§N§N²M²M ¤£¤[«á¶}©l³ø´_©Êªº¨göt¡Aº¦¤F300%¤~¥ð®§... ´Nºâ¥ý«e455¶^¨ì250³Q®M¨cªºªª¦Ï¤H¡A¦b755,¬Æ¦Ü¥Ø«eªº570¤]¬OÃÃÀò§Q ®ïŲ¤£»·¡A¬Û«H´Nºâ755³Q®M¨cªº·sªª¦Ï¤H¡A·í¸Ñª¼«á³ø´_©Ê¤Wº¦®É¡A ötº¦ªº¯Eô¤]·|»·»·§â755¥Ï¦b¸£«á¡A¥u¬O¥Ø«eÁÙ¥¼¨£¨ì¦Ó¤w ¤j®a±`»¡º¦®É«¶Õ¡A¶^®É«½è¡C¥Ø«e¥»½è§¹¥þ¨S¦³§ïÅÜ ´N¹³¹qµø¼@·ã°Hº]¤@¼Ë¡AĬõ(Jô)³Ì«á¤j®a¤~ª¾ì¨Ó¬O¦bÀ°¹t¤ý¡A¥ý«eÅA¤ýÁÙ¤@ª½¥H¬°ÄQÅï¤~¤l¬°¨ä©Ò¥Î ¯E¹©³oºØ822¥@¬É¯Åªº¤jÃÄ¡A¥xÆW±q¨Ó¨S¦³¥X²{¹L¡A©Ò¥HÃhºÃªº¤H©Î³\¤ñ¬Û«Hªº¤H¦h ¦ýµ¥¨ì¼Æ¾Ú¥X¨Ó¡A¦ÛµM¤j®a´N³£¶}©l¬Û«H¤F¡A¯E¹©822´N¬O¹t¤ý·|µn¤WÄ_®y¡A¦Ó«DÄm¤ýÅA¤ý(ÂûÀnÃZµ¥) |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/1/22 ¤W¤È 10:09:02²Ä 2513 ½g¦^À³
|
5619¤j¡A ¤°¦ÃU¤j©MFaith¤j¤w¸g°µ¤F¸Ñ¾A ·Q¥²±z¤w¤ß»â¯«·| ¤p§Ì´N¤£¦A«ÂФF |
|
|
·|û¡GBenjamin10139027 µoªí®É¶¡:2016/1/22 ¤W¤È 10:04:38²Ä 2512 ½g¦^À³
|
¥xÁÞ¤j¡G §Ú¦Û¤w¬O¬Ý¤F¤j¥ß¥ú±q400º¦¨ì3700ªº½u¹Ï¡C¹Ï¤¤1005¨ì46X³o¤@¬qªº¨«¶Õ¡A§Ú¤@ª½¦b·Q¦p¦ó¯àÁ×¹L¡B©ÎªÌ»¡¡A¦p¦ó¯à«ù¦³¨ì3700 (¨ä¹ê3500¤]¦æ^^) µª®×´N¬O°ò¥»±¨SÅÜ«e¡A¥~¦bªº¥ô¦ó··«B«B³£·í¨S¬Ý¨ì¡B¨SÅ¥¨ì¡Aªø½u«ù¦³¡C ³ÌªñµL¥©¤£¥©¦a¦b¬ÝFisherªº"Common stocks and uncommon profits"¡C¤Ú·Ý·Ý¤ñ§Ú¦¬Ý¤F´X¤Q¦~¡A«¢¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤W¤È 09:52:28²Ä 2511 ½g¦^À³
|
¯E§J¤j Benjamin¤j Á|¤â¤§³Ò ¥H«e³£¬O§l¦¬ª©¤W«e½ú¾i¤Àªø¤jªº ·ç¤hÃļt¾a§ÜÀùÃĪ«¥´±Ñ¥þ°êÄÁ¿ö²£È http://fund.udn.com/fund/story/5862/1029885 |
|
|
·|û¡GBenjamin10139027 µoªí®É¶¡:2016/1/22 ¤W¤È 09:48:31²Ä 2510 ½g¦^À³
|
¥xÁÞ¤j¡G ±z¦C±o¯u¬O¤Ó¸Ô²Ó¤F¡I§Ú¦Û¤w¤]°µ¹LÃþ¦üªº¨Æ¡A¦ý¥u¦C¥X¤F¬ù10±ø¥ª¥k... ¦ý»¡¹ê¦b¡A¾ß¤]¾ß±o¤â³n¤F...«¢ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/1/22 ¤W¤È 09:14:52²Ä 2509 ½g¦^À³
|
¥xÁÞ¤j ·P®¦±zªº°^Äm ¦³±z²`¤Jªº¨£¸Ñ»P¾ã²z ¤j¹Ù§ó¦w¤ßªø©ê |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤W¤È 09:02:02²Ä 2508 ½g¦^À³
|
¦U¦ì¤j¤j http://finance.yahoo.com/q?s=BMY ½Ð«öMax ©ñ¤j¬ÝBMYªº¤@¥Í ¥²ªv§´¬I¶QÄ_¬O¬ü°ê¤@®aÂåÃÄ¡BÀç¾i¤Î«O°·²£«~©M¤Æ§©«~¤½¥q¡C ¥²ªv§´¬I¶QÄ_¤½¥q¦b1989¦~¥Ñ¬ü°ê¨â¤j»sÃļt¥²ªv§´©M¬I¶QÄ_¦X¨Ö¦Ó¦¨ Bristol-Myers Squibb Company (BMY)ªÑ»ù1999¦~¤@«×¹F70¬ü¤¸,2005¦~°_¿n·¥¨ÖÁʨðµ¹ïªº¨Æ>>> ¬ãµoÀù¯g§K¬ÌÀøªk ³ÌªñÁö¹J¤¤¬üªÑ¥«¶×¥« ¥Ûªo 쪫®Æ¤U¶^ ªÑ»ùÂ÷³Ì°ª»ù¤w¤£»· (¤£ª¾ªÑ²¼¤À³Î¦h¤Ö¦¸ Á`¥«È¹F1060»õ¬ü¤¸) ªø©êÀò§QÅå¤H ¯E¹©ªºÁÞ¤À¤l·sÃÄ 822 833 888 ¾A¥Î14ºØÀù¯g ¯E¹©ªºÁÞ¤À¤l·sÃĤñ³o¨ÇCTLA-4 PD-1 PD-L1³æ®è§ÜÅéÃĩΤp¤À¤lÃħó¨ãÀu¶Õ §ó¦w¥þ §ó±M¤@ Bristol-Myers Squibb acquired Medarex Inc., a biotech company and a partner since 2005. This acquisition was the largest String of Pearls transaction to date, and significantly expanded Bristol-Myers Squibb¡¦s oncology and immunology pipeline, positioned the company for long-term leadership in biologics and allowed it to gain full rights for ipilimumab. §ë¤J CTLA-4 PD-1 PD-L1 Àù¯g§K¬ÌÀøªk¶i¤J¤G¤T´Áªº¤jÃļt Bristol-Myers Squibb (¶Â¦â¯À½F¤w¤W¥«,¤T´ÁÁ{§É¦³«D¤p²ÓMªÍÀù ¤p²ÓMªÍÀù ÄáÅ@¸¢Àù µÇŦÀù ÀYÀVÀù ¤G´ÁÁ{§É¦³²O¤ÚÀù GÀù ¤j¸zÀù §Z±_Àù) Merck&Co.¡B(¶Â¦â¯À½F¤w¤W¥« ¦b¤T´ÁÁ{§É¦³«D¤p²ÓMªÍÀù ÀYÀVÀù ÁxÅnÀù ) AstraZeneca (¤T´ÁÁ{§É¦³«D¤p²ÓMªÍÀù ¤G´ÁÁ{§É¦³ÀYÀVÀù ) Roche/Genetech (¤T´ÁÁ{§É¦³ ÁxÅnÀù «D¤p²ÓMªÍÀù ¤G´Á¦³µÇŦÀù ) pfizr (¤T´ÁÁ{§É¦³«D¤p²ÓMªÍÀù) ¥Ø«e¤w®Öã¤W¥«ªºÃĪ«: anti-CTLA4 1 Ipilimumab (Yervoy) late-stage melanoma PD-1 inhibitors :nivolumab (Opdivo) 3melanoma ( metastatic) ¶Â¦â¯À½F 4 non-small cell lung cancer(metastatic) «D¤p²ÓMªÍÀù 5 renal cell carcinoma (metastatic) µÇŦÀù PD-1 inhibitors : pembrolizumab (Keytruda) 6 melanoma (metastatic) ¶Â¦â¯À½F 7 non-small cell lung cancer (metastatic) «D¤p²ÓMªÍÀù Áp¦X¥ÎÃÄ 8 Opdivo plus Yervoy (previously untreated advanced melanoma) Âಾ©Ê¶Â¦â¯À½F FDA¹w©w 01/23/2016 §P©w¬O§_®Öã |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/1/22 ¤W¤È 08:55:03²Ä 2507 ½g¦^À³
|
¤½¥D¤j ¦U¦ì¤j¤j ¥Í§Þ²£·~ÄÝ©ó°ª·ÀI°ª³ø¹S²£·~,, ¥Í§Þ¤½¥q¨ã¦³¤Q¦~¿i¼C ¥XÀT¾U§Qªº¯S¦â, (¤Q¦~´Hµ¡µL¤H°Ý ¤@Á|¦¨¦W¤Ñ¤Uª¾),¸Ñª¼«e»Ý°µ¦n·ÀIºÞ²z«á ¦Aµû¦ô¤U±20ÃD ·í¦U¦ì¤j¤j¦^µª¬Oªº¤ñ²v¶V°ª®É¶V¦³§ë¸ê»ùÈ ¬ãµo¦¨¥\¾÷²v¶V¤j ¥i©ñ¤ß³¯E¹©¦b¤G¤ë¤@°_¨£ÃÒ¥þ²y²Ä¤@Áû¨ÅÀù§K¬ÌÀøªkªº¸Ñª¼ (¦^µª¬Oªº¤ñ²v¤£°ª®É «Øij¤£n°Ñ»P¸Ñª¼) ¥H¤U¬O2014¦~10¤ë¶K¤å(×¥¿ª©)¶È´£¨Ñ°Ñ¦Ò ½Ðª`·N·ÀIºÞ²z ¬O ¤f ¤f§_ («ü¨ÅÀù 822 ) 1 ®Ö¤ß¤Hû¨ã¦³¸Û«H»P»ùÈÆ[ ¦³Ä@´º¦¨¬°¥þ²yÀù¯g§K¬ÌÀøªkªº»â¾É«~µP 2 ±M§Q§G§½¶g©µ°÷ªø ±M§Q¬O¥i¨¾¿mªº ¯àµn¦b¾ï¬õ¦â¤p¥U¤l 3 ¦³ÂåÀø»P¾Ç³N³æ¦ì´£¨ÑÁ{§É¬ã¨s©Î¬ì¾Ç¬ã¨s¬ÛÃö¤ä´© 4 ²£«~¥«³õ¨ã¦³¥þ²y¥«³õ,¥¼¨Ó±w¯f·|¤£Â_¼W¥[ ¾A¥Î¤H¤f°÷¤j 5 »PÄvª§²£«~¤ñ¸û¤½¥q¬ãµoªº²£«~¨ã¦³¿W¯SÄvª§Àu¶Õ ·|»P¼ç¦b±ÂÅv¹ï¶H¶i¦æµ¦²¤Áp·ù(¦pÁp¦X¥ÎÃÄ) 6 ¤w§¹¦¨¼ç¦b¶R®aªºÂ²³ø,²£«~¨ã¦³°ª±ÂÅvª÷¼ç¤O(¤w¦³¤£¤ÖÀù¯g§K¬ÌÀøªk±ÂÅv®×¥ó¤½¶}±ÂÅvª÷) 7 ¬ãµo¹Î¶¤¸gÅçÂ×´I,¦b¬ü°ê¦³¬ãµoÃĪ«¦¨¥\ªº¸gÅç 8 ©Ò¬ãµoªº²£«~ÁÞ¤À¤l·sÃĬO(first in class ,best in class, only in class) 9 ©Ò¬ãµoªº²£«~¯à´x´¤Á{§É«eÃIJz¬r²z »P´x´¤Á{§É®É¤§ÃĪ«°Ê¤O¾Ç §C°Æ§@¥Î °ª¦w¥þ©Ê(¤w³q¹L9¦¸DSMB ÄY®æ¦ÒÅç ) 10²£«~½uÂ×´I¦h¤¸¥H°§C¬ãµo¥¢±Ñ¹ï¤½¥qªº¨RÀ» ( 822 833 834 888 868 858) 11¬ãµoªº²£«~¨ã¦³¼Ð¹v©Ê,¤£¶Ë¤Î¥¿±`²ÓM ¬ì¾Çµo²{¦³Äè·ÀÀù¯g·F²ÓM¼ç¤O 11¦b§ÜÀù¾÷¨î¤W¥i¯à¦P®É±a¦³§ÜÅé§K¬Ì»P²ÓM§K¬Ì, 12´x´¤ÃöÁä§Þ³N: ²£«~¥i¥H¤j¶q¥Í²£,°§C¥Í²£¦¨¥»,²£«~»sµ{³W®æ«~½èéw 13«n¤Hª«±M³X¹ï¨ÅÀù¬Ì]ªº«H¤ß»P´Á«Ý¬Û·í¥¿± 14¤w³Q¯Ç¤JMSCI ¦¨¥÷ªÑ (¤w³q¹L¬ü°ê¥Í§Þ±M®a±M·~µû¦ô) 15¦³¨â¿´¸Éµ¹Ä¥(¦×¬r±ìµß¯À ÁÞ´¹¤ù±ÂÅvª÷) ¤ä´©¥D¤O²£«~822 833 888 16©Ò¬ãµoªºÃĪ«Àò±o¬ì¾Ç®a»P¥Í§Þ±M®a ªÑªF ªk¤H §ë«H§ëÅUªºªÖ©w»P´Á«Ý 17©Ò¬ãµo²£«~¥¼¨Ó¯à¥Ñ¥½´Á ¤¤´Á ªì´Á¤Î¹w¨¾¥«³õ±À¶i¥HÂX¤j¥«¦û²v 18²£«~¬OÄÝ©ó«æ¢©Ê±Ï©RÃÄ,¯àº¡¨¬¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D unmet medical need 19 822¯à¸Ñ°£ Global H Ceramide¹ïT²ÓMB²ÓMªº§K¬Ì§í¨î,¨Ã¯à§í¨îÀù²ÓM¦åºÞ¼W¥Í 20 ¬ãµo¸êª÷¥R¸Î ¥¼¨Ó¨ã¦³¨ÖÁʨä¥L¥Í§Þ¤½¥qªº¼ç¤O |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/1/21 ¤U¤È 10:03:12²Ä 2506 ½g¦^À³
|
·PÁ¤°¦ÃU¤j©MFaith¤jªº«üÂI¡C¤p§Ì²q·Q¹L¬O¨ºÓ°ÇÂÈ¡A¥u¬O´îÁ~»¡ªk¤Ó¥È§®¡C §Æ±æ¦b½å©úªº¨½ªø±a»â¤U¡A§ó¦hªº¨½¥Á¯àµLÁ~¤@¨»´¡C |
|
|
·|û¡G¤°¦ÃU10141261 µoªí®É¶¡:2016/1/21 ¤U¤È 08:48:49²Ä 2505 ½g¦^À³
|
£«¬Â¤j ¦hÁ§iª¾¨½¥Áªº°Á~´T«×¡A¥LÌÀ³¸ÓÆZ´Á«ÝµLÁ~°² 5619¤j «Øij±z¦h¬Ý´X¦¸¦U¤j¤jªº¯d¨¥¡A¥²¯à¤ß»â¯«·|¡A¦³¨Ç¨Æ¤£¾A¦X¤Óª½¥Õ©O¡I |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/1/21 ¤U¤È 07:56:31²Ä 2504 ½g¦^À³
|
¤p©_¤j¡A¤p§Ì·M¾|µLª¾¡AÅ¥¤£À´±z©M£«¬Â¤j©Ò»¡ªºÁ~¸ê¤ô·Ç¡C¦ü¥G´îÁ~¦b¸Ó¨½¦¨¬°¦n¨Æ¡C ¯à§_½Ð¤p©_¤j¸ÑÄÀÁ~¸ê¤ô·Ç©M°·±dªºÃö«Y¡H«D±`ÁÂÁ¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/1/21 ¤U¤È 05:41:45²Ä 2503 ½g¦^À³
|
£«¬Â¤j¡A «D±`·PÁ±z¸ò¨½ªø¥´Å¥ ¤p§Ì¹ï¼Ú¤ñ®J¨½¥ÁªºÁ~¸ê¤ô·Ç©M°·±d±¡§Î§ó¤F¸Ñ¤F ÁÂÁ±z¡I |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2016/1/21 ¤U¤È 01:34:45²Ä 2502 ½g¦^À³
|
¤p©_¤j:°Ý¤F¨½ªø,³o¾Fªº¨â¦ì©~¥Á¦Û±q·h¶i¨Ó´N¶}©l´îÁ~¦@´î¤F¦Ê¤À¤§¤¤Q¥ª¥k,¨ì¥Ø«e¬°¤î¨S¤°»òÅܤÆ,§O¾F¦³¨S¦³¦p¦¹´N¤£±o¦Óª¾. |
|
|
·|û¡GªÑ¥«¦W®·10141659 µoªí®É¶¡:2016/1/20 ¤U¤È 11:43:23²Ä 2501 ½g¦^À³
|
¡u§K¬ÌÀøªk¡v¬O·í«e¥þ²yÀù¯gªvÀøªº«ÂIÁͶաA¨ä¤¤¤@¶µ¼öªùµ¦²¤´N¬O§Q¥Î¸~½F¯S©w¯fìÅX°Ê¤HÅé§K¬Ì¨t²Î¡A¥H¨D³Ì²×²M°£¸~½F²ÓM¡CµM¦Ó¡A³o¶µµ¦²¤¦Ü¤Ö¥²¶·§JªA¨â¤j§xÃøÂI¡G1¡B§Üì¶i¤J§Üì§e²{²ÓMªº®ÄªG¡A2. ¥²¶·¤Þµo¡u²ÓM§K¬Ì¡v¤ÏÀ³¡C ¡@§K¬ÌÀøªk¥i°Ï¤À¬°¤À¤l§K¬ÌÀøªk¤Î²ÓM§K¬ÌÀøªk¡C¤À¤l§K¬ÌÀøªk¥]¬A¤p¤À¤lÃĪ«¡B¨ú¦Û°Êª«ªº³æ®è§ÜÅéÃĪ«¡AÂÇÃĪ«»¤µo§K¬Ì¤ÏÀ³¡AÀù±w¨Ï¥Î«á¥iªýÂ_Àù²ÓM°T®§¶Ç»¼¡A¹F¨ìªýÂ_ÂX´²¡B§ðÀ»Àù²ÓM®ÄªG¡C²ÓM§K¬ÌÀøªk¥i¨ú¥XÀù±w¦å²G¤¤ªº§K¬Ì²ÓM¡A¸g¹êÅç«Ç°ö¾i§ï³y¦¨¹ïÀù²ÓM¿ëÃѫק󰪡B§ðÀ»¤O§ó±j¡A¼W±j¨ä§ÜÀù¯à¤O¡A¦Aª`¤JÀù±wÅ餺¡A¹F¨ìªýÂ_Àù²ÓMÂX´²¡B§ðÀ»Àù²ÓM¥\®Ä¡A¥B¸ûµL¤ÆÀø²£¥Íªºäú¤ß¹Ã¦Rµ¥°Æ§@¥Î¡A¥i´£°ªÀù¤Í¥Í¬¡«~½è¡C |
|
|
|